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ABSTRACT 
KRISTAL L. CHICHLOWSKA: Short-Term and Long-Term Changes of Select 
Electrocardiogram Variables Preceding Heart Failure 
(Under the direction of Dr. Gerardo Heiss) 
 
 Background: The association between long-term changes in electrocardiograph 
(ECG) abnormalities and incident heart failure in healthy populations is unclear.  
Furthermore, there is a paucity of data on the short-term repeatability of and the long-
term changes of ECG abnormalities.   
 Methods: This study examined the short-term repeatability of ECG measures 
(QRS/T angle, Cornell voltage, Cornell product, left ventricular mass (LVM), T wave 
amplitudes in lead V5 and V1, and ST depression) in the ECG Repeatability Study using 
nested random effects models.  In the Atherosclerosis Risk in Communities (ARIC) 
Study, we described the long-term changes of ECG variables (QRS/T angle, QT interval, 
Cornell voltage, Cornell product, LVM, T wave amplitudes in leads V5 and V1 and ST 
depression) over repeat ARIC visits and additionally examined their association with 
incident heart failure.  ECG variables were dichotomized (0 or 1, with “1” indicating 
increased risk for heart failure) and long-term change was defined as moving from “0” at 
baseline (1987 – 1989) to “1” over any ARIC visit.  Continuous long-term change 
variables for ECG measures were created using the number of ECGs available over 
ARIC visits and time from baseline.  Logistic and linear regression models were used to 
describe the long-term changes of ECG variables by coronary heart disease (CHD), 
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diabetes and hypertension status.  Cox regression models were used to assess the 
associations between long-term changes of ECG variables and incident heart failure.   
 Results: Short-term repeatability of the ECG measures was excellent.  Mean 
values of the annual rate of change in ECG measures differed by CHD, diabetes and 
hypertension status and a higher proportion of ECG change was present in persons with 
these conditions.  Finally, continuous and categorical ECG measures were associated 
with incident heart failure, however stronger associations were observed among the latter. 
 Conclusions: The long-term changes in select ECG measures may be useful for 
continuous monitoring of heart failure in the clinical setting.  Further research to ascertain 
whether these select ECGs predict incident heart failure above and beyond traditional risk 
factors for heart failure is warranted and may provide insight into avenues for the 
prevention of heart failure.   
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CHAPTER 1: INTRODUCTION 
 
1.1 Heart failure 
Heart failure results from impaired left ventricular systolic function or ventricular 
diastolic function and other abnormalities that interfere with ventricular filling or 
emptying (1).  Systolic dysfunction is often associated with abnormal contractility and 
low ejection fraction, while diastolic dysfunction is generally associated with abnormal 
relaxation of the heart ventricle and normal ejection fraction (1).   
Many individuals with heart failure remain asymptomatic for extended periods of 
time either because the impairment is mild (2) or because of the compensatory 
mechanisms in heart failure that help to maintain cardiac output and blood pressure 
including augmented stroke volume, ventricular hypertrophy and activation of 
neurohormonal systems (3).  However, when the compensatory mechanisms fail, the 
symptoms of heart failure are numerous and non-specific, and while the clinical signs 
tend to have good specificity, they also tend to have poor sensitivity (4).  As a result, mild 
forms of heart failure may be undiagnosed in the clinical encounter.   
In conjunction with the various signs and physical symptoms of heart failure, 
there exist numerous scoring systems to classify heart failure for use in research: 
Minnesota Heart Health Study (5), Framingham (6), Rotterdam (7), Gothenburg (8), 
Gheorghiade (9), Boston (10), Walma (11), National Health and Nutrition Examination 
Survey (12), and European Society for Cardiology (13) criteria.  Some studies (14-16) 
have attempted to validate these classification systems.  Although there is no gold 
standard classification system for heart failure, the prognosis tends to be poor regardless 
of the criteria used (17). 
Some of the items included in the above case classification schema are non-
specific, such as fatigue and edema, and thus more objective criteria are needed to validly 
diagnose persons with heart failure.  Heart failure is commonly diagnosed by an 
echocardiogram but is also assessed via radionuclide ventriculograms, cardiac magnetic 
resonance imaging and/or chest radiographs (18), although chest radiographs tend to have 
low specificity and sensitivity (18-20).  Both B-type brain natriuretic peptide (BNP) and 
N-terminus proBNP have been used to identify persons with heart failure (21-23) and 
BNP levels have been shown to correlate well with the New York Heart Association 
(NYHA) classification (23).   
There are two main systematizations of heart failure, the NYHA and the 
American College of Cardiology-American Heart Association (ACC/AHA) classification 
for heart failure (18).  Four classes encompass the NYHA classification: 1) no limitation 
of physical activity; 2) slight limitation of physical activity and dyspnea and fatigue with 
moderate physical activity; 3) marked limitation of activity and dyspnea with minimal 
activity; and 4) severe limitation of activity and symptoms are present even at rest.  The 
ACC/AHA staging system acknowledges the progression from asymptomatic to 
symptomatic heart failure and includes the following: 1) at high risk for heart failure but 
without structural heart disease or symptoms of heart failure; 2) with structural heart 
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disease but without symptoms; 3) with structural heart disease but with prior or current 
symptoms; and 4) refractory heart failure and requiring specialized interventions. 
Early identification and treatment of risk factors may be the most important step 
in eliminating the public health burden of heart failure (24).  If persons at high risk for 
heart failure are not treated, then many develop structural heart disease and go on to 
develop overt heart failure.  The prognosis of heart failure is poor after diagnosis, with a 
1-year case fatality ranging from 22 to 43 percent (25-27) and a 5-year case fatality 
ranging from 42 to 75 percent (25-28).   
The treatment for heart failure depends on its stage.  At Stage A, early 
modification of factors and behaviors associated with increased risk of heart failure has 
been shown to be beneficial in reducing risk (29) and treatment often involves 
modification of the neurohormonal axis with the use of angiotensin-converting enzyme 
inhibitors and angiotensin II receptor blockers (29).  Treatment may also involve dietary 
sodium restriction and moderation of alcohol intake or exercise (30), however there is no 
direct evidence that these measures can prevent the development of heart failure.  At 
Stages B, C and D, Stage A treatment recommendations also apply.  In addition, therapy 
with β−blockers, digoxin, diuretics and the use of more invasive procedures such as valve 
replacement, implantable cardioverter defribillator placement and coronary 
revascularization may be necessary (29).  Most of the evidenced-based care for heart 
failure is based on treatment for systolic heart failure, and although there is no proven 
therapy for heart failure with preserved systolic function, treatment is similar to that for 
systolic dysfunction (31).   
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1.2 Epidemiology of heart failure 
The burden of heart failure has increased over the past decades.  From 1979 to 
2005, hospital discharges for heart failure increased 171% (32, 33).  In 2009, 
estimated heart failure healthcare costs are $37.2 billion, and in 2003 $4.4 billion was 
paid to Medicare beneficiaries for congestive heart failure (34).  As of 2006, there 
were 5.7 million adults diagnosed with heart failure, and 670,000 incident cases (34).  
Although incidence remains relatively stable over the past decades (35-37), 
prevalence has been increasing (38).  There is also evidence that the proportion of 
persons with heart failure with preserved systolic function has increased over time 
(31).  Registry data indicate that half of persons presenting to hospitals with heart 
failure have preserved systolic function (39, 40).   
The trend of increasing incidence of heart failure may be due to decreased 
case fatality of coronary heart disease (CHD) (41), use of effective medical therapy 
(42), improved outcomes of surgical intervention (43), or increases in the burden of 
risk factors for heart failure (44, 45).  However, the increasing trend in heart failure 
may also be an artifact due to more sensitive diagnostic tests, detection of milder 
cases, greater awareness of heart failure or rehospitalizations (46) of persons with 
heart failure.  Heart failure prevalence is expected to increase with the aging of the 
population (41, 47) and because of improved survival after myocardial infarction 
(MI).  
An abundance of risk factors for heart failure have been identified: age (48), 
cigarette smoking (49), low physical activity (49), overweight (49), hypertension (49-
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51), diabetes (49-52), obesity (49, 52, 53), CHD (49-52), elevated pulse pressure (52, 
54), valvular heart disease (49-51), reduced kidney function (55) and left ventricular 
hypertrophy (LVH) (50, 51).  Other important risk factors are race and sex.  In each 
of the past three decades, black patients had a higher prevalence of heart failure 
compared with white or Latino patients in the United States (US) (56).  While an 
increase in prevalence of heart failure in men aged 70 years and younger has been 
observed, women have a higher prevalence of heart failure at age 70 years and older.  
However, this difference may be due to the increased average life expectancy in 
women (56). 
Heart failure is a burgeoning public health problem, and the prevalence has 
increased over the past two decades (57).  Furthermore, the prognosis of heart failure 
is grim (25-28).  Although, therapy (42, 43, 58) exists that could reduce the mortality 
rate, the need for hospitalization and delay the progression of heart failure, there is a 
clear need to focus on primary prevention of heart failure, especially since the 
majority of heart failure cases are attributable to hypertension, coronary artery disease 
and diabetes (24, 41), all of which are treatable or preventable conditions.  
Furthermore, AHA guidelines emphasize the importance of risk factor modification 
and early detection in addition to the implementation of proven treatments to reduce 
morbidity and mortality (18).  For these reasons, risk stratification of persons is 
imperative to enable identification of persons who will benefit from further 
examination, preventive measures and if necessary more aggressive use of 
pharmacologic and interventional strategies.   
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1.3 ECG abnormalities and incident heart failure 
The results of four (59-62) fairly recent population-based studies have implicated 
select electrocardiogram (ECG) variables as predictive of incident heart failure in 
relatively healthy populations (Table 1).   
Both Dhingra and colleagues (59) and Okin and colleagues (60) examined the 
effect of one selected ECG abnormality on incident heart failure, and both QRS duration 
and ST depression were found to be associated with incident heart failure in their 
respective studies.  Adjusting for age, sex and body mass index (BMI), systolic blood 
pressure, anti-hypertensive treatment, total high-density lipoprotein cholesterol, diabetes 
mellitus, smoking status, interim MI and valve disease, a QRS duration between 100 – 
119 milliseconds (ms) and a QRS duration ≥ 120 ms were associated with incident heart 
failure in the Framingham Heart Study (FHS) (59) compared with a QRS duration < 100 
ms: hazard ratios (HR) = 1.43 (95% confidence interval (CI) = 1.05, 1.96) and 1.74 (95% 
CI = 1.28, 2.35), respectively.  In analyses with QRS duration in its continuous form, 
heart failure incidence increased with longer QRS durations in age- and sex-specific 
models (HR = 1.27, 95% CI = 1.14, 1.41).  Although the Strong Heart Study (SHS) was 
limited by a small number of heart failure events (N = 77), continuous (HR per 10 µV = 
1.22, 95% CI = 1.13, 1.32) and categorical (10-24 µV HR = 1.79, 95% CI = 0.56, 5.71; -
4-9 µV HR = 2.76, 95% CI = 0.91, 8.34; ≤ -5 µV HR = 5.55, 95% CI = 1.96, 15.74; 
versus ≥ 25 µV) measures of ST depression in leads V5 and V6 were shown to be 
associated with incident heart failure, adjusting for sex, age, diabetes, CHD and 
albuminuria (60).  Although the categorical measure of ST depression showed a stepwise 
increasing risk for heart failure as ST depression values decreased, the confidence 
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intervals were imprecise and should be interpreted with caution.  Dhingra and colleagues 
(59) and Okin and colleagues (60) did not adjust for other ECG variables in the SHS and 
the FHS, and thus it is difficult to assert that either QRS duration or ST depression 
predict, independently of other ECG variables, new-onset heart failure.  Although, Okin 
and colleagues recognized the need to control for left ventricular mass (LVM), they did 
not adjust for Cornell voltage, since it was not found to be a significant predictor of new-
onset heart failure in the SHS (60).  
Results from the Women’s Health Initiative (WHI) Study by Rautaharju and 
colleagues (61) corroborated the association found between ST depression and new-onset 
heart failure in the SHS (60).  Rautaharju and colleagues (61) found that ST depression in 
lead V5 was associated with incident heart failure when the lowest decile (≤ 0 µV) was  
compared with all other deciles (>0 µV) (HR = 2.11, 95% CI =1.62, 2.52), adjusting for 
age, ethnicity, systolic blood pressure, BMI, smoking status, hormone therapy use, 
cholesterol-lowering drugs, diabetes status, use of cardioactive drugs.  This association 
remained, although attenuated (HR = 1.49, 95% CI = 1.17, 1.89), when multiple ECG 
variables were added to the model, including QRS/T angle, T net amplitude in lead V1, 
QRSnon-dipolar voltage (ndpv), QT interval and heart rate variability.  All ECG variables under 
study, QRS/T angle, MI, ST depression, T net amplitude, QRSndpv, T net amplitude in 
lead V5, ST gradient in lead V5, QT interval, Cornell voltage, T wave roundness index, 
heart rate variability and Tndpv, were associated with incident heart failure in the WHI 
(61).  It is important to note that only the lowest decile, and not the highest, for T net 
amplitude in lead V5, and the highest decile, not the lowest, for T net amplitude in lead 
V1, were significantly associated with new-onset heart failure when compared with the 
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middle deciles collectively.  Strengths of this study conducted by Rautaharju and 
colleagues in the WHI (61) include the evaluation of multiple ECG variables, the 
additional evaluation of multivariable-adjusted multiple ECG variable models and the use 
of a large, population-based study.  However, this study was limited to women.   
Comparable to Dhingra and colleagues (59) and Okin and colleagues (60) in the 
FHS and the SHS, Rautaharju and colleagues (62) evaluated ST depression and QRS 
interval in the Atherosclerosis Risk in Communities (ARIC) Study.  Similar to results 
found in the SHS (60) and the WHI (61), Rautaharju and colleagues (62) found that ST 
depression in lead V5 in men (HR = 2.11, 95% CI = 1.58, 2.82) and in women (HR = 
1.38, 95% CI = 1.01, 1.88), was associated with incident heart failure when the lowest 
decile (≤ 5 µV in men and ≤ -7 µV in women) was the inference group, adjusting for age, 
ethnicity, systolic blood pressure, BMI, smoking status, hormone therapy use, 
cholesterol-lowering drugs, diabetes status, use of cardioactive drugs.  With the 
additional adjustment of multiple ECGs, MI, LVM, QRS/T angle, ST amplitude in lead 
V5, QT interval, heart rate, QRSndpv and T net amplitude in lead V1, the association 
remained in men (HR = 1.57, 95% CI = 1.16, 2.06) but not in women (HR = 1.05, 95% 
CI = 0.77, 1.44).  In contrast to Dhingra and colleagues (59), Rautaharju and colleagues 
(62) were unable to observe a significant association between QRS interval and incident 
heart failure in additional analyses conducted in the ARIC Study (results not presented).   
Many of the ECG variables analyzed in the ARIC Study and the WHI by 
Rautaharju and colleagues were comparable (61, 63).  In multivariable-adjusted single-
ECG models, QRS/T angle, ST depression, QRSndpv, T net amplitude in lead V1, and 
Cornell voltage were significantly associated with incident heart failure in the WHI 
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participants and in women in the ARIC Study (61, 62).  Conversely, MI, QT interval and 
T net amplitude in lead V5 were not associated with new-onset heart failure in women in 
the ARIC Study (62), whereas associations were observed between these ECG variables 
and incident heart failure in women in the WHI (61).  In addition to the ECG variables 
listed above, heart rate and Cornell product were also associated with new-onset heart 
failure in women in the ARIC Study (62).  With the exception of QRSndpv, all ECG 
variables entered into multivariable-adjusted single ECG models, MI, LVM, QRS/T 
angle, ST depression, QT interval, heart rate, T net amplitude in lead V1, Cornell product, 
Cornell voltage and T net amplitude in lead V5, were associated with incident heart 
failure in men in the ARIC Study (62). 
There were notable differences between ECG abnormality and incident heart 
failure associations observed in the WHI and the ARIC Study when multivariable-
adjusted multiple ECG models were used.  T amplitude in lead V1 was significantly 
associated with incident heart failure in the WHI Study (HR = 1.56, 95% CI = 1.19, 2.05) 
(61), however, it was not associated with new-onset heart failure in the ARIC Study in 
both men (HR = 1.21, 95% CI = 0.89, 1.67) and in women (HR = 1.12, 95% CI = 0.89, 
1.51) (62).  Although QRSndpv and QRS/T angle were associated with incident heart 
failure in both the WHI (61) and in women in the ARIC Study (62), MI, ST depression, 
and QT interval were associated with new-onset heart failure in the WHI and not in the 
ARIC Study.  In addition to the ECG variables listed above, heart rate was also 
associated with new-onset heart failure in women in the ARIC Study (62).  In men in the 
ARIC Study, all ECG variables, MI, LVM, QRS/T angle, ST depression, QT interval, 
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and heart rate, with the exception of QRSndpv, were additionally associated with incident 
heart failure (62). 
The analysis of the effect of ECG abnormalities on the incidence of heart failure 
in the ARIC Study (62) extends previous studies (59-61) by examining multiple ECG 
variables by sex.  However, varying cut points for ECG measures made comparisons 
problematic between the studies.  For example, in the WHI Study for both T net 
amplitude in lead V5 and T net amplitude in lead V1, the highest and the lowest deciles 
were inference groups and the remaining deciles were collectively the referent group, 
whereas in the ARIC Study the lowest decile (≤ 122 µV for men and ≤ 107 µV for 
women) and the highest decile (≥ 307 µV for men and ≥ 151 µV for women) for T net 
amplitude in lead V1 was the inference group, and “other deciles” was the comparison 
group. 
 While these previous studies (59-62) contribute to our understanding of the 
effects of ECG variables, based on a single measurement, on the incidence of heart 
failure, these studies use different populations, definitions of heart failure (see Table 1), 
cut points and inference groups for ECG variables (detailed in the next section).  
Furthermore, the accuracy of the ECG measures is not well documented in these studies.  
Sources of error in measurements of ECG variables within a person include within-
person biological and methodological variability, which includes variability in placement 
of electrodes and the precision of the ECG record readings (64).  If measurement 
variability is high (low repeatability), then the ECG variable is likely to have bias 
associated with its estimate of effect on incident heart failure (65).  Despite these 
limitations, the relationship between select ECG variables and incident heart failure has 
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been demonstrated in persons with and without cardiovascular disease (CVD) (59, 61, 62, 
66), and remains relatively robust after adjustment of clinical and demographic factors 
and other ECG measures, leading to the hypothesis that there is an independent 
association between ECG variables and incident heart failure.  The mechanisms linking 
these ECG variables with incident heart failure are unclear.  It has been posited that the 
ECG measures studied may be markers of ventricular remodeling and evolving CHD (59-
62), an interpretation that would benefit from consideration of repeat measures of these 
ECG parameters.   
 
 Table 1. Summary of 4 prospective studies examining the relationship between ECG abnormalities and incident heart failure 
Author 
(year) Study 
Study 
population 
Mean 
follow-up 
(years) 
Incident 
heart 
failure 
Measure of 
incident heart 
failure ECG variables, estimate (95% confidence interval) 
Dhingra 
(2006)(59) 
FHS Men and 
women, 
aged 28-62 
years 
12.7 324 Framingham criteria 
and a review of 
medical records by 3 
experienced 
investigators 
QRS duration vs. <100 ms; 100-119 ms: 1.4 (1.1, 2.0); ≥ 120 ms: 1.7 (1.3, 2.4) 
Okin 
(2007)(60) 
SHS American 
Indian men 
and women 
aged 35-74 
years 
5.7 77 Framingham criteria, 
a review of medical 
records 
ST depression (per 10 µV): 1.31 (1.24, 1.39) 
ST amplitude vs. ≥25µV; 
10-24 µV: 1.79 (0.56, 5.71); 
 -4-9 µV: 2.76 (0.91, 8.34); 
≤-5 µV: 5.55 (1.96, 15.74) 
Rautaharju 
(2006)(61) 
WHI Women, 
aged 50-79 
years 
6.2 375 Active follow-up for 
hospitalized heart 
failure requiring 
medical treatment, 
and a review of 
medical records 
Old MI (Novacode 5.1-5.4) vs. no; yes: 2.0 (1.5, 2.6) 
QRS/T angle vs. 0-56°; 57-96°: 1.9 (1.4, 2.5); ≥97°: 2.7 (2.1, 3.6) 
ST depression vs. > 0µV; ≤ 0µV: 2.1 (1.6, 2.5) 
TV1 amplitude vs. -41-80µV; <-41µV: 1.1 (0.8,1.5); >80µV: 2.2 (1.7,2.8) 
QRSndpv vs. < 65µV; ≥ 65µV: 2.0 (1.5, 2.7) 
TV5 amplitude vs. 73-235 µV; <73µV: 1.9 (1.5, 2.4); >235µV: 0.9 (0.5, 1.4) 
STV5 gradient vs. ≥3 µV; <3µV: 1.7 (1.3, 2.3) 
QT interval vs. <437 ms; ≥ 437 ms: 1.8 (1.4, 2.3) 
Cornell voltage vs. <1800 µV; ≥ 1800 µV: 1.6 (1.3, 2.1) 
T wave roundness index vs <31%; 31-57%: 1.3 (1.1, 1.7); >57%: 1.6 (1.2, 2.2) 
Heart rate variability vs. 8-44ms; <8ms:1.3 (1.0, 1.7); >44ms: 1.5 (1.2, 2.0) 
Tndpv vs. <13µV; ≥13µV: 1.3 (1.0, 1.8) 
Rautaharju 
(2007)(62) 
ARIC Men and 
women, 
aged 45-64  
14.0 951 ICD-9-CM code 428 
or death certificate 
with ICD-9 code 428 
or ICD-10 code 150 
Note: reference groups are ‘no MI’ or ‘other deciles’ collectively 
Old MI (Novacode 5.1-5.4); M: 3.1 (1.9, 5.0); W: 1.8 (0.9, 3.7) 
LVM (M: ≥ 204 g; W: ≥ 162 g); M: 2.4 (1.7, 3.3); W: 1.3 (1.0, 1.9) 
QRS/Tsimple angle (M: ≥ 107°; W: ≥ 89°); M: 1.7 (1.2, 2.3); W: 1.9 (1.4, 2.5) 
QRS/Txyz angle (M: ≥ 110°; W: ≥ 94°); M: 2.0 (1.5, 2.7); W: 2.3 (1.6, 2.8) 
ST depression (M: <5µV; W: <-7µV); M: 2.1 (1.6, 2.8; W: 1.4 (1.0, 1.9) 
QT interval (M: > 436ms; W: > 442ms); M: 2.1 (1.6, 2.8); W: 1.1 (0.8, 1.5) 
Heart rate (M: > 77 cnts/min; W: 79 cnts/min); M: 1.9 (1.4, 2.6); W:1.7 (1.3, 
2.3) 
QRSndpv (M: ≥ 81µV; W: ≥ 63µV); M: 1.4 (0.9, 2.0); W: 2.1 (1.6, 2.9) 
TV1 amplitude (M: ≥ 307µV; W: ≥ 151µV); M: 1.8 (1.3, 2.4); W: 1.6 (1.2, 2.1) 
Cornell product (M: ≥ 207µV/s; W: ≥ 152µV/s); M: 1.7(1.2,2.3); W:1.6(1.2, 
2.2) 
Cornell voltage (M: ≥ 2650µV; W: ≥ 1673µV); 1.6 (1.1, 2.2); W: 1.5 (1.1, 2.0) 
TV5 amplitude (M: < 122µV; W: <107µV); M: 1.8 (1.3, 2.4);W: 1.3 (1.0, 1.8) 
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Abbreviations: ECG, electrocardiogram; FHS, the Framingham Heart Study; ms, milli-seconds; WHI, Women's Health Initiative; MI, myocardial infarction; µV, microvolts;  
ndpv, non-dipolar voltage; SHS, Strong Heart Study; ARIC, the Atherosclerosis Risk in Communities Study; ICD, International Classification of Disease;  LVM, left ventricular 
mass; g, gram; M, men; W, women; cnts/min, counts per minute; µV/s, microvolts per second. 
 1.4 ECG variables 
ECG variables shown to be associated with incident heart failure in multivariable-
adjusted single ECG models include (59-62) QRS/T angle, MI, ST depression, T net 
amplitudes in lead V1 and V5, QRSndpv, QT interval, Cornell voltage, QRS duration, 
LVM, Cornell product and heart rate.  In addition, the following were found to be 
associated with incident heart failure in multivariable-adjusted multiple ECG models (61, 
62): QRS/T angle, ST depression, T net amplitude in lead V1, QRSndpv, QT interval, MI, 
LVM and heart rate. The following section provides a brief background of these ECG 
variables and details how they were defined in their respective studies.  
In the analysis conducted by Rautaharju and colleagues in both the WHI and the 
ARIC Study (61, 62), the QRS/Txyz angle was derived from the X, Y, and Z leads 
generated from a matrix transformation method.  The X, Y, and Z leads refer to one 
system of spatial vectorcardiography, where the X, Y and Z leads are combined to form 
three loops: frontal, sagittal and horizontal (67).  Vectorcardiography accounts for 
configuration of the loops in addition to measurement of amplitude and duration.  Since 
the orthogonal X, Y and Z leads are not routinely recorded, they can be obtained from the 
matrix transformational method, where the mean X, Y and Z values in the QRS and T 
windows are calculated to obtain QRS and T vectors (68).  The QRS/T angle is the 
spatial angle between the directions of ventricular depolarization and repolarization; 
greater angles reflect greater abnormalities in repolarization (69).  The QRS/T angle has 
been shown to be positively associated with blood pressure, indicating that it may be a 
sensitive and early marker of the repolarization alterations in systemic hypertension (70).  
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 Wide QRS/T angles have also been shown to be associated with LVH, bundle-branch 
block and ischemia (69).   
The QRS/Tsimple angle has been previously shown to detect a QRS/Txyz angle with 
88% sensitivity and 91% specificity, and thus may act as an appropriate substitute for the 
QRS/Txyz angle (63).  Rautaharju and colleagues developed a method for estimation of 
the QRS/T angle using the net QRS and T amplitudes in three standard leads for each 
(63).  The QRS/Tsimple angle is calculated as the inverse cosine between the mean QRS 
and T vectors, approximated by the three QRS and T net amplitudes for each vector (61).  
In the ARIC Study, net T wave amplitudes were calculated by adding signed T' from 
signed T in leads V5, aVF and V2, and net QRS amplitudes were calculated by subtracting 
the absolute value of S- or QS-waves in leads V6, aVF and V2 from the R wave (62).   
In the WHI Study, Rautaharju and colleagues obtained T net amplitude by 
calculating mean and peak T wave values in lead V5, whereas for T wave amplitude in V1 
only the mean value was used (61), however in the ARIC Study mean values for both T 
amplitude in leads V5 and V1 were used (62).  The T wave represents the uncanceled 
potential differences of ventricular repolarization, and is slightly lower in women than in 
men (67).  Conditions associated with tall T waves are hyperkalemia and intracranial 
hemorrhage (67). 
Cornell voltage, Cornell product, and LVM, are measures of LVH.  In both the 
WHI (61) and the ARIC Study (62), the Cornell voltage was determined by summing the 
R wave amplitude in the aVL lead, and the Q- or QS-wave amplitude in the V3 lead (71).  
The Cornell product has a reported specificity of 95% and a sensitivity of 51% (72).  
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 Although the sensitivity appears to be low, the sensitivity is still higher than for either 
QRS duration or Cornell voltage alone (72, 73).  In the ARIC Study (62), the Cornell 
product was created by multiplying the Cornell voltage and the QRS duration.  The ECG 
measures for LVM were derived in the ARIC Study using race- and sex-specific 
calculations (74).  LVM is then regressed on Cornell voltage and body weight.  An 
increase in LVM generates leftward and posterior QRS forces which are believed to 
result from an increase in the size or number of muscle fibers (67).  Hypertension often 
leads to LVH through changes in heart structure (75), and as a result ventricular 
repolarization and depolarization abnormalities often occur.  In fact, repolarization and 
depolarization abnormalities often precede overt LVH and may be evident on the ECG by 
changes in QRS/T angle (76).  The mechanisms linking LVH to disease are not fully 
understood.  However, hypertrophy results in increased demand for oxygen to the 
myocardial tissue, which can be decreased in the presence of atherosclerosis and lead to 
ischemia (77).   
Measures of LVM have been shown to differ by sex, race and body mass.  
Important differences have been observed by sex (78, 79), with men having higher QRS 
voltages and longer QRS durations than women, and by race (71, 79-82), with blacks 
having higher QRS voltages than whites and whites having longer QRS durations than 
blacks.  Furthermore, QRS amplitude is reduced in persons with a large body mass, and is 
believed to result from the increased distance between the precordial electrode and the 
heart (83).  Consequently, persons with low body weight may be over-diagnosed and 
overweight persons may be under-diagnosed with LVH (83).   
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 Rautaharju and colleagues in the ARIC Study (62), and similarly in the WHI 
Study (61), calculated the QT interval as sex- and race-specific and adjusted for heart rate 
as a linear function of the RR interval (84).  QT as a linear function of the RR interval 
was calculated as QT interval – 0.185 x (RR interval – 1) + 0.06 for men and as QT 
interval – 0.185 x (RR interval – 1) for women (85).  The QT interval represents the sum 
differences in ventricular repolarization and depolarization (67).  In relatively healthy 
individuals, QT varies by sex, race and heart rate.  Women tend to have longer QT 
intervals compared to men and higher heart rates (82, 86), and blacks tend to have shorter 
QT intervals than whites (82).  It is believed that sex hormones play a role in cardiac 
repolarization, and thus prolong the QT interval in women (87).  In addition, the QT 
interval varies over 24 hours and tends to be longer at night (88, 89).  Marked QT 
lengthening (non-corrected QT interval > 125% of the average normal value) can be 
attributed to congenital or neurogenic causes, severe hypokalemia, fad diets, 
antiarrhythmic drugs, myocardial ischemia (67) and may be a marker of subclinical 
atherosclerosis (90).  The causes for prolonged QT intervals are unknown, however 
cardiac ion channels (91) and autonomic neuropathy (92) involvement have been 
suggested.   
The QRSndpv variable was also obtained in both the WHI and the ARIC Study (61, 
62).  Singular value decomposition was used to obtain the QRSndpv and represents the 
square root of the sum of the residual variance of the higher order components that are 
not contained in the X, Y, and Z components of the twelve-lead ECG signal (62).  The 
higher order components (N = 8) are obtained from the matrix report of the Marquette-
GE 12SL ECG.  The Marquette GE contains 2 ms simultaneous samples of all twelve 
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 ECG leads for one complete cycle per individual.  Within the report, the window between 
the beginning and the end of the QRS complex and the voltage is used to obtain the 
square root of the total variance of the non-dipolar components.  The first three terms are 
similar to the dipolar X, Y and Z components of an orthogonal lead system obtained from 
vectorcardiography.  The total variance is the summation of the non-dipolar components 
4 – 8 and the dipolar components 1 – 3.   
A widely used set of criteria for ECG recognition of prior MI, the Novacode (93), 
provides cut points for separating normal from pathological Q waves.  An MI, defined by 
Novacode criteria (5.1-5.4), was used in both the WHI and the ARIC Study (61, 62), 
however the prevalence is low in the ARIC Study (2.2% and 0.9% in men and women, 
respectively).  The reasons why some persons have atypical or no symptoms are 
unknown.  Various theories about possible mechanisms have been discussed (94).  
However, the process is likely to be similar to the processes involved with recognized 
MI, where an atherosclerotic plaque ruptures and occludes a thrombotic coronary artery.  
The difference between recognized and unrecognized MI is believed to lie in the 
interpretation of symptoms.  A blunted perception of MI may result from a dysfunction 
with receptor and afferent neurons, cancellation of multiple stimuli in the thalamus and 
the dorsal horn of the spinal chord, a defect in the central nervous system and depression 
may play a role (94).  Persons of older age (95), and female sex (96, 97) are at greater 
risk for undiagnosed MI.   
In the FHS, Dhingra and colleagues recorded a twelve-lead configuration and X, 
Y, and Z orthogonal leads to measure QRS duration (59).  QRS duration was defined 
using World Health Organization criteria for bundle branch block (98): left bundle branch 
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 block was defined as a QRS duration of ≥ 120 ms; absent Q waves; wide-notched R 
waves in leads V5 and V6 present; presence of monophasic QS in leads V1 and V2; and 
absence of secondary R waves in lead V1.  Right bundle branch block was defined as 
QRS duration ≥ 120 ms; broad, notched R waves in leads V1 and V2; and wide, deep and 
notched S waves in V5 and V6.  QRS segments that were ≥ 120 ms and did not meet the 
criteria for either left or right bundle branch block were categorized as indeterminate.  
Although the normal QRS interval is equal to or less than 0.10 seconds on a twelve-lead 
ECG, a QRS interval > 100 ms has been associated with reduced left ventricular ejection 
fraction (99).  An increased QRS interval indicates a ventricular ectopic beat, toxic drug 
effects or severe hypokalemia in addition to bundle branch blocks (3).  Lastly, the QRS 
duration is slightly longer in tall, large persons rather than short, small persons and in 
males than in females (67).  
In the SHS, absolute ST segment deviation was measured at the midpoint of the 
ST segment on median complexes in leads V5 and V6 and the quartiles were based on the 
maximal magnitude of ST deviation in those leads (60), whereas in the ARIC Study, ST 
depression was measured using ST amplitude in lead V5 at 60 ms past the end of the QRS 
interval (J-point) (62).  Lead V5 was chosen, since it has been shown to be sensitive to the 
detection of myocardial ischemia, particularly in exercise tests.  In the WHI Study, 
Rautaharju and colleagues (61) defined ST depression as the ST segment (the interval 
from 20 ms past the J-point to the J-point plus 80 ms or the beginning of the T wave, 
whichever occurred later) mean value in lead V5 negative or 0 μV.  Eighty ms past the J-
point is conventionally used in the clinical encounter (67).  However, since this definition 
of the ST segment originated from exercise testing as a diagnostic test for myocardial 
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 ischemia secondary to CHD, 60 ms was used by Rhautaharju and colleagues to obtain 
resting ECGs in large population-based studies (62, 100).  Although some ST segment 
elevation has been observed in approximately 90% of normal individuals, any ST 
segment depression is considered abnormal (67).  Ventricular action potentials overlap 
along the ST segment, as the beginning of the ST segment represents ventricular 
depolarization and the end involves rapid repolarization of the ventricles (67).  Common 
causes of ST depression are tachycardia, delayed repolarization following slow 
depolarization resulting from bundle branch block or LVH among other entities, and 
myocardial ischemia (67). 
Heart rate is measured by the twelve-lead ECG via RR intervals (62), and has 
been known to decrease with age.  However, Spodnick and colleagues found that while 
heart rate decreased with age in men, it increased in women over a 30 year span (101).  
There are a multitude of factors responsible for variations in heart rate, including physical 
fitness, sex, temperature and altitude (67).  The normal heart rate in adults ranges from 50 
to 90 beats per minute (102).  Bradycardia is attributed to increased vagal tone and 
hypothyroidism, hypothermia, hyperkalemia, myocardial ischemia and common drugs 
(e.g., β – blockers, digitalis and clonidine) have been implicated as potential causes (67).  
Precipitating conditions for tachycardia include hypotension, heart failure, anemia, 
hyperthyroidism and myocarditis and result from increased sympathetic activity (67).  
Sympathetic activity can also be increased with the use of β-adrenergic agonists and 
anticholinergenic agents, in addition to caffeinated beverages (67). 
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 1.4.1 Coding ECG abnormalities 
Many cardiac disorders alter the morphology of the ECG recording in a 
diagnostically useful way, and these abnormalities can be interpreted by classification 
systems such as the Minnesota (103) and Novacode (93).  Both the Minnesota code and 
Novacode were developed to standardize the interpretation of ECGs and enhance 
repeatability, and both provide a clear advantage over visual reading because they are less 
prone to error (93, 104).  As a result, the use of computer processed ECGs has become 
more frequent and is now the preferred methodology of ECG classification for large 
prospective studies.  The Minnesota Code is a classification system for the ECG that 
utilizes a defined set of measurement rules to assign specific numerical codes according 
to the severity of the ECG findings.  However, evaluation of serial changes of ECGs 
becomes much more complex, as the Minnesota Code requires side-by-side comparison 
of a referent and follow-up ECGs.  Data from the Multiple Risk Factor Intervention Trial 
indicate that misclassification occurs up to 40 to 50% when new abnormalities are coded 
(105).  The Novacode criteria were formulated to include ECG abnormalities not covered 
by Minnesota Code criteria and were designed to meet the needs of clinical trials (93).  
The Novacode coding sequence follows the traditional order of interpretation of ECGs in 
clinical settings (arrhythmic codes followed by antrio-ventricular conduction, ventricular 
conduction, prolonged repolarization codes and MI codes) (93).  Moreover, the Novacode 
criteria were developed to ease the determination of serial ECG changes associated with 
pathology (93).   
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 1.5 Short-term changes of ECG variables 
 Many epidemiologic studies have demonstrated that abnormalities in various 
resting, standard twelve-lead ECG measures and their changes over time are associated 
with subsequent cardiovascular morbidity and mortality (59-62, 69, 100, 106-109).  
However, the accuracy of the ECG measures is often not well documented in those 
studies.  Sources of error in measurements of ECG variables within a person include 
within-person biological and methodological variability, which includes variability in 
placement of electrodes and the precision of the ECG record readings (64).  If 
measurement variability is high (low repeatability), then the ECG variable is likely to 
have bias associated with its estimate of effect on cardiovascular outcomes (65).   
The ECG Repeatability Study was conducted in 2001 to estimate the 2-minute 
and 1-week repeatability of ECG measures in 63 participants, ages 45-64 years (85, 110).  
Two previous reports (85, 110) from the ECG Repeatability Study quantified the short-
term repeatability of T wave axis, QT interval, heart rate and heart rate variability using 
the standard twelve-lead ECG (Table 2).  Vaidean and colleagues (85) investigated 
spatial T wave axis and QT interval.  The intraclass correlation (ICC) coefficients for the 
T wave axis and heart rate were 0.87 (95% CI: 0.81, 0.93) and 0.82 (95% CI: 0.75, 0.90), 
respectively, and for QT interval-based indices, ICC coefficients were greater than 0.60.  
Schroeder and colleagues (110) found that for 10-second recordings, ICC coefficients for 
mean heart rate and RR interval were greater than 0.80, whereas ICC coefficients for 
standard deviation of all RR intervals (SDNN) and root mean square of differences in RR 
intervals (rMSSD), ranged from 0.41 to 0.57. 
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To our knowledge, the short-term measurement variability of spatial QRS/T 
angle, Cornell voltage, Cornell product, LVM, T net amplitudes in leads V1 and V5, and 
ST depression as derived from the twelve-lead ECG has yet to be investigated in the ECG 
Repeatability Study.  Past and future studies can benefit from the estimation of short-term 
repeatability of these ECG measures, since this would enable consideration in 
measurement protocols and statistical adjustment for variability (111). 
  
Table 2. Summary of 2 studies examining the short-term repeatability of ECG variables in the ECG Repeatability Study 
Author (year) Study Study population ECG variables, intraclass correlation coefficient (95% confidence interval) 
Schroeder 
(2004)(110) 
ECGRS Men and women, 
aged 45-64 years  10-second 2-minute 6-minute 
HR 
RR 
SDNN 
rMSSD 
HF 
LF 
Hfnu 
Lfnu 
ln HR 
ln RR 
ln SDNN 
ln rMSSD 
ln HF 
ln LF 
ln HFnu 
ln LFnu 
0.80 (0.72-0.88) 
0.85 (0.78-0.91) 
0.41 (0.22-0.59) 
0.47 (0.30-0.63) 
. 
. 
. 
. 
0.82 (0.75-0.90) 
0.82 (0.75-0.90) 
0.46 (0.31-0.62) 
0.57 (0.43-0.70) 
. 
. 
. 
. 
0.89 (0.85-0.94) 
0.92 (0.89-0.96) 
0.86 (0.80-0.91) 
0.91 (0.87-0.95) 
0.89 (0.86-0.93) 
0.72 (0.65-0.80) 
0.60 (0.48-0.73) 
0.60 (0.48-0.73) 
0.91 (0.87-0.95) 
0.91 (0.87-0.95) 
0.70 (0.59-0.80) 
0.82 (0.75-0.89) 
0.69 (0.59-0.79) 
0.55 (0.42-0.68) 
0.50 (0.35-0.64) 
0.68 (0.58-0.78) 
0.90 (0.85-0.94) 
0.93 (0.90-0.96) 
0.87 (0.81-0.92) 
0.91 (0.87-0.95) 
0.85 (0.79-0.91) 
0.83 (0.77-0.89) 
0.76 (0.68-0.85) 
0.76 (0.68-0.85) 
0.92 (0.88-0.95) 
0.92 (0.88-0.95) 
0.73 (0.63-0.83) 
0.84 (0.78-0.91) 
0.82 (0.75-0.89) 
0.78 (0.70-0.86) 
0.76 (0.68-0.84) 
0.73 (0.63-0.83) 
Vaidean  
(2005)(85) 
ECGRS Men and women, 
aged 45-64 years 
T wave axis: 0.87 (0.81, 0.93) 
QT interval: 0.86 (0.81, 0.92) 
Bazett heart rate-corrected QT interval: 0.69 (0.59,0.80) 
Fridericia heart rate-corrected QT interval: 0.73 (0.63, 0.83) 
QT prolongation index: 0.74 (0.65, 0.83) 
QT as a linear function of the RR interval: M: 0.92 (0.88, 0.97); W: 0.62 (0.41, 0.83) 
Heart rate: 0.82 (0.75, 0.90) 
24 
Abbreviations: ECG, electrocardiogram; ECGRS, the Electrocardiogram Repeatability Study; HF, high frequency power; HFnu, normalized high frequency power; HR,mean heart 
rate; LF, low frequency power; LFnu, normalized low frequency power; rMSSD, root mean square of successive differences in normal-to-normal RR intervals; RR, mean RR 
interval; SDNN, standard deviation of all normal-to-normal RR intervals. 
 
  
  
1.6 Long-term changes of ECG variables 
Epidemiologic studies have demonstrated that the changes of abnormalities in 
various resting, standard twelve-lead ECG measures are associated with subsequent 
cardiovascular morbidity and mortality (112-115).  However, little is known about the 
long-term changes in ECG measures in groups defined by demographic characteristics, 
cardiovascular risk or morbidity.  This information may aid risk stratification in clinical 
encounters and assist researchers in characterizing the role of ECG measurements on 
incident cardiovascular morbidity and mortality.   
 
Despite the important role of the temporal evolution in ECG variables in the 
context of clinical and demographic risk factors for cardiovascular morbidity and 
mortality, little prospective research has addressed these associations (113, 116-121) 
(Table 3).  A previous study conducted by Levy and colleagues presented categorical 
changes of R wave and S wave voltages and repolarization abnormalities by sex in 
participants with LVH in the FHS (113).  Although it would appear that there were no 
sex-differences in ECG voltages and repolarization abnormalities, no statistical test was 
performed.  An additional limitation of this study was the selection of participants with 
LVH.  Thus results can only be generalized to comparable high-risk populations.  In this 
study, change was defined categorically in two different ways: 1) Participants were 
classified into one of four quartiles at baseline according to the sum of the R wave in aVL 
and the S wave in lead V3.  Change (decreased, increased or no change) was defined as 
moving from one quartile to another during follow-up. 2) At baseline a blinded reviewer 
of ECGs categorized repolarization as normal, mildly abnormal (ST-T flattening, isolated 
ST depression, or T wave inversion) or severely abnormal (ST depression in association 
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with inverted or biphasic T waves).  Change (improved, worsened or no change) was 
defined as moving from one classification to another over follow-up.   
Okin and colleagues showed in patients in the Losartan Intervention For Endpoint 
(LIFE) Reduction in Hypertension Study, that Cornell product and Sokolow-Lyon 
voltage decreased to a greater degree in men than in women (117, 118), in non-diabetics 
than in diabetics (116, 117), and in participants < 65 years compared to those ≥ 65 years 
of age (117).  However, patients in the LIFE Study were selected based on moderate-to-
severe hypertension and elevated Cornell product and Sokolow-Lyon voltages, and some 
patients were receiving anti-hypertensive medication, and therefore results cannot be 
generalized to healthier populations.  Change was defined as the difference in baseline 
values of Cornell product and Sokolow-Lyon voltages and subsequent visits (116-118).  
 
To the authors’ knowledge, only three studies have evaluated the long-term 
changes of ECG measures in relatively healthy persons (119-121).  Tasaki and colleagues 
showed that heart rate in 15 elderly Japanese persons increased over a time span of 15 
years, while some measures of heart rate variability decreased with age (121).  However, 
this study was limited by small numbers.  Change was defined as the difference between 
baseline and the follow-up visit 15 years later.  Lastly, Schroeder and colleagues 
evaluated measures of heart rate variability by diabetes (119) and hypertension (120) 
status in the ARIC Study over a mean of 9 years and concluded that there were no 
differences in the rate of change in heart rate variability by these conditions.  Change was 
defined as heart rate variability at follow-up minus heart rate variability at baseline 
divided by the number of years between baseline and follow-up. 
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Previous studies have several strengths.  First, Okin and colleagues described the 
long term changes of ECG measures of LVH (Cornell product and Sokolow-Lyon 
voltage) in the LIFE Study, by various CVD risk factors, including age, sex, and diabetes 
status (116-118).  Tasaki and colleagues’(121) results of increasing heart rate and 
decreasing heart rate variability over a time span of 15 years corroborated cross-sectional 
results of age-related differences in heart rate and heart rate variability reported in 
previous studies (122, 123).  Although Levy and colleagues primary objective was to 
examine the effect of changes of ECG measures on CVD, we appreciate their 
presentation of descriptive results of the long-term changes of ECG measures by sex in 
the FHS (113).  Schroeder and colleagues (119, 120) described the longitudinal changes 
of heart rate variability in a large population-based cohort by diabetes, fasting glucose, 
insulin resistance, treated and untreated hypertension status, while controlling for 
multiple covariates, such as age, sex, race, study center, hypertension or diabetes status, 
smoking, education, BMI, and baseline heart rate variability and correcting for 
measurement error in continuous baseline measurements.   
 
The descriptive epidemiology of the ECG measures in these studies has several 
limitations: Okin and colleagues (116-118) and Levy and colleagues (113) described the 
changes of ECG measures in participants with LVH at baseline; additionally, persons in 
the LIFE Study were treated for hypertension during the course of the clinical trial; and 
results are limited to ECG measures of LVH and heart rate variability.  As a result of 
these limitations, it is difficult to make definite conclusions about the long-term changes 
of various ECG measures in a relatively healthy population, and to our knowledge, no 
work has focused on the descriptive epidemiology of the long-term changes of a wide 
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array of ECG variables in relatively healthy population-based studies, taking into account 
clinical risk factors for CVD morbidity and mortality.  
 Table 3. Summary of 7 prospective studies examining the long-term changes of ECG variables by clinical and demographic risk factors 
for heart failure  
Author 
(year) Study Study population ECG variable 
ECG change variable, clinical/demographic factor(s), means (SD if available or 
confidence interval), N (%) odds ratio (95% confidence interval) 
Levy 
(1994) (113) 
FHS Men and women, aged 
28-62 years 
R wave and S wave 
voltage, R wave 
amplitude in lead aVL, 
S wave amplitude in 
lead V3 
Change to another quartile: 
Decreased: Men (M), 242 (21%); women (W), 193 (21%) 
No change: M, 638 (56%); W, 537 (59%) 
Increased: M, 258 (23%); W, 184 (20%) 
 
Change in repolarization status: 
Improved (severely abnormal to mildly abnormal or mildly abnormal to normal): M 104 (10%); 
W, 90 (11%) 
No change: M 850 (77%), W, 638 (75%) 
Worsened (normal to mildly abnormal or mildly abnormal to severely abnormal): M 143 
(13%); W,125 (14%) 
 
Okin 
(2008) (118) 
LIFE Men and women, aged 
55-80 years with 
hypertension and left 
ventricular hypertrophy 
Cornell product, 
Sokolow-Lyon voltage 
Reduction in Cornell product ≥ 236mm/ms: 
Month 6: M, -146 (631); W,-101 (613) 
Year 1: M, -202 (690); W,-140 (677) 
Year 2: M, -266 (731); W,-205 (706) 
Year 3: M, -282 (756); W,-190 (726) 
Year 4: M, -281 (815); W,-175 (753) 
Year 5: M, -305 (814); W,-182 (771) 
Last: M, -251 (890); W,-149 (823) 
 
Reduction in Sokolow-Lyon voltage ≥3.5mm: 
Month 6: M, -1.8; W,-1.3 
Year 1: M, -2.5; W,-1.8  
Year 2: M, -3.5; W,-2.4 
Year 3: M, -4.0; W,-2.8  
Year 4: M, -4.6; W,-3.2  
Year 5: M, -5.1; W,-3.4  
Last: M, -4.8; W,-3.0  
 
Crude odds ratio (women vs. men): 
Odds that Cornell product decrease is - 236mm/ms or more: 0.76 (0.70, 0.83) 
Odds that Sokolow-Lyon voltage decrease is -3.5mm or more: 0.69 (0.64, 0.75) 
 
Adjusted odds ratio (women vs. men): 
Odds that Cornell product decrease is - 236mm/ms or more: 0.68 (0.61, 0.76) 
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 Odds that Sokolow-Lyon voltage decrease is -3.5mm or more: 0.85 (0.77, 0.95) 
Okin 
(2006) (116) 
LIFE Men and women, aged 
55-80 years with 
hypertension and left 
ventricular hypertrophy 
Cornell product  Change in Cornell product vs. baseline (mm/ms), diabetes: 
Month 6: -100 (580) 
Year 1: -126 (687) 
Year 2: -183 (658) 
Year 3: -156 (759) 
Year 4: -162 (820) 
Year 5: -174 (764) 
Last: -138 (866) 
 
Change in Cornell product vs. baseline (mm/ms), no diabetes: 
Month 6: -125 (628) 
Year 1: -174 (683) 
Year 2: -240 (726) 
Year 3: -242 (737) 
Year 4: -231 (778) 
Year 5: -245 (797) 
Last: -205 (866) 
Okin 
(2003) (117) 
LIFE Men and women, aged 
55-80 years with 
hypertension and left 
ventricular hypertrophy 
Cornell product, 
Sokolow-Lyon voltage 
Change in Cornell product (difference between last and baseline visit): 
Female: Losartan group, -249; Atenolol group-66 
Male: Losartan group, -338; Atenolol group -192 
Diabetes: Losartan group, -245; Atenolol group -17 
No diabetes: Losartan group, -296; Atenolol group -140 
< 65 years: Losartan group, -313; Atenolol group -195 
≥ 65 years: Losartan group, -275; Atenolol group -78 
White: Losartan group, -296; Atenolol group -126 
Other ethnicity: Losartan group, -213; Atenolol group -82 
 
Change in Sokolow-Lyon voltage (difference between last and baseline visit): 
Female: Losartan group, -3.8; Atenolol group -2.1 
Male: Losartan group, -5.5; Atenolol group -3.5 
Diabetes: Losartan group, -3.9; Atenolol group -1.6 
No diabetes: Losartan group, -4.7; Atenolol group -2.9 
< 65 years: Losartan group, -4.9; Atenolol group -3.4 
≥ 65 years: Losartan group, -4.4; Atenolol group -2.3 
White: Losartan group, -4.5; Atenolol group -2.7 
Other ethnicity: Losartan group, -5.7; Atenolol group -3.7 
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 Schroeder 
(2003) (120) 
ARIC Men and women, aged 
45-64 
Heart rate and heart 
rate variability 
Normotensives, mean annual decrease (ms/y): 
SDNN: 0.71 (0.66, 0.77) 
rMSSD: 0.42 (0.36, 0.48) 
RR interval: 5.92 (5.53, 6.31) 
 
Hypertensives, mean annual decrease (ms/y): 
SDNN: 0.63 (0.54, 0.72) 
rMSSD: 0.33 (0.23, 0.43) 
RR interval: 6.65 (6.01, 7.28) 
 
Treated hypertensives, mean annual decrease (ms/y): 
SDNN: 0.60 (0.50, 0.71) 
rMSSD: 0.39 (0.27, 0.50) 
RR interval: 5.93 (5.19, 6.67) 
 
Untreated hypertensives, mean annual decrease (ms/y): 
SDNN: 0.68 (0.52, 0.85) 
rMSSD: 0.19 (0.01, 0.37) 
RR interval: 8.53 (7.36, 9.70) 
 
Normotensives, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: 0.67 (0.62, 0.71) 
rMSSD: 0.39 (0.34, 0.44) 
RR interval: 5.97 (5.62, 6.33) 
 
Hypertensives, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: 0.74 (0.67, 0.81) 
rMSSD: 0.40 (0.33, 0.48) 
RR interval: 6.52 (5.94, 7.10) 
 
Treated hypertensives, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: 0.73 (0.65, 0.80) 
rMSSD: 0.40 (0.31, 0.49) 
RR interval: 6.37 (5.70, 7.05) 
 
Untreated hypertensives, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: 0.78 (0.66, 0.91) 
rMSSD: 0.42 (0.27, 0.56) 
RR interval: 6.91 (5.83, 8.00) Note: significantly different than normotensives at the 0.05 p-
level 
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 Schroeder 
(2005) (119) 
ARIC Men and women, aged 
45-64 
Heart rate and heart 
rate variability 
NFG, mean annual decrease (ms/y): 
SDNN: -0.69 (-0.75, -0.62) 
rMSSD: -0.39 (-0.46, -0.32) 
RR interval: 6.24 (5.79, 6.68) 
 
IFG, mean annual decrease (ms/y): 
SDNN: -0.67 (-0.75, -0.58) 
rMSSD: -0.32 (-0.41, -0.24) 
RR interval: 7.09 (6.52, 7.65) Note: significantly different than NFG group at the 0.05 p-level 
 
Diabetes, mean annual decrease (ms/y): 
SDNN: -0.74 (-0.92, -0.56) 
rMSSD: -0.46 (-0.65, -0.26) 
RR interval: 5.49 (4.24, 6.74) 
 
NFG, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: -0.66 (-0.71, -0.61) 
rMSSD: -0.36 (-0.41, -0.30) 
RR interval: 6.74 (6.33, 7.16) 
 
IFG, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: -0.66 (-0.72, -0.60) 
rMSSD: -0.34 (-0.41, -0.27) 
RR interval: 6.61 (6.09, 7.13) 
 
Diabetes, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: -0.95 (-1.08, -0.81) 
rMSSD: -0.66 (-0.82, -0.50) Note: significantly different than NFG group at the 0.05 p-level 
RR interval: 3.88 (2.72, 5.04) Note: significantly different than NFG group at the 0.05 p-level 
 
Hyperinsulinemia absent, mean annual decrease (ms/y): 
SDNN: -0.72 (-0.78, -0.67)  
rMSSD: -0.42 (-0.47, -0.36) 
RR interval: 6.35 (5.97, 6.73) 
 
Hyperinsulinemia present, mean annual decrease (ms/y): 
SDNN: -0.44 (-0.58, -0.30) Note: significantly different than the hyperinsulinemia present 
group at the 0.05 p-level 
rMSSD: -0.11 (-0.26, -0.04) Note: significantly different than the hyperinsulinemia present 
group at the 0.05 p-level 
RR interval: 8.12 (7.15, 9.10) Note: significantly different than the hyperinsulinemia present 
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 group at the 0.05 p-level 
 
Hyperinsulinemia absent,, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: -0.69 (-0.73, -0.65) 
rMSSD:-0.39 (-0.43, -0.34) 
RR interval: 6.58 (6.23, 6.93) 
 
Hyperinsulinemia present, mean annual decrease, adjusted for baseline (ms/y): 
SDNN: -0.62 (-0.73, -0.52) 
rMSSD: -0.28 (-0.40, -0.16) 
RR interval: 6.78 (5.87, 7.69) 
 
Tasaki 
(2000) (121) 
N=15 Healthy, elderly men 
and women aged 79-95 
years 
Heart rate and heart 
rate variability 
Heart rate: 
Mean values of minimal heart rate (bpm) at baseline and 15 years later (follow-up): 
Nighttime: baseline 49.2 (5.4); follow-up 55.3 (8.2) (p=0.0018) 
Daytime: baseline 59.6 (9.1); follow-up 64.1 (9.1) (p=0.0048) 
 
Mean values of maximal heart rate (bpm) at baseline and 15 years later: 
Nighttime: baseline 67.7 (6.6); follow-up 73.8 (11.7) (p=0.0099) 
Daytime: baseline 86.0 (11.3); follow-up 92.4 (15.6) (p=0.0114) 
 
Mean values of average heart rate (bpm) at baseline and 15 years later: 
Nighttime: baseline 53.6 (5.6); follow-up 59.5 (9.7) (p=0.0054) 
Daytime: baseline 67.8 (9.8); follow-up 72.5 (9.9) (p=0.0119) 
 
Heart rate variability: 
Mean values of SDNN index (ms) at baseline and 15 years later: 
Nighttime: baseline 53 (16); follow-up 45 (13) (p=0.0086) 
Daytime: baseline 53 (19); follow-up 44 (14) (p=0.0574) 
 
Mean values of NN50 index (per hour) at baseline and 15 years later: 
Nighttime: baseline 39.7 (35.1); follow-up 50.1 (55.9) (p=0.2393) 
Daytime: baseline 22.9 (17.0); follow-up 44.5 (41.7) (p=0.0425) 
 
Mean values of the low frequency component (ms2) at baseline and 15 years later: 
Nighttime: baseline 339.26 (290.63); follow-up 222.49 (213.52) (p=0.0151) 
Daytime: baseline 246.76 (170.54); follow-up 145.19 (112.10) (p=0.0032) 
 
Mean values of the high frequency component (ms2) at baseline and 15 years later: 
Nighttime: baseline 296.76 (229.95); follow-up 407.15 (467.04) (p=0.1932) 
Daytime: baseline 171.63 (153.81); follow-up 196.33 (194.72) (p=0.3398) 
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Mean values of the low frequency/high frequency component ratio at baseline and 15 years 
later: 
Nighttime: baseline 1.295 (0.665); follow-up 0.818 (0.531) (p=0.0270) 
Daytime: baseline 1.923 (0.910); follow-up 1.281 (0.951) (p=0.0371) 
Abbreviations: ECG, electrocardiogram; FHS, Framingham Heart Study; M, men; W, women; SBP, systolic blood pressure; DBP, diastolic blood pressure; LIFE, Losartan 
Intervention For Endpoint reduction in hypertension study; mm, millimeters; RR interval, the mean normal-to-normal RR interval length; SDNN, the standard deviation of all 
normal-to-normal RR intervals; rMSSD, the root mean square of successive differences in normal-to-normal RR intervals; NFG, normal fasting glucose; IFG, impaired fasting 
glucose; ms, milliseconds; bpm, beats per minute; NN50, number of instances where the difference between adjacent normal RR intervals exceeds 50 ms. 
 1.7 Changes in ECG variables and incident heart failure 
It has been demonstrated in large-population based studies that select ECG 
variables, either measured at one point in time (60-62) or entered in a model as a time-
varying variable (59), are associated with incident heart failure.  Although ECG variables 
have been known to vary over time due to biological and methodological variability 
(124), little work has focused on the effect of the long-term changes in these parameters 
on new-onset heart failure.   
To the best of our knowledge, there are only two studies that have examined the 
association between changes in ECG variables and new-onset heart failure (Table 4), and 
the results are conflicting (66, 112).  In the LIFE Study, Okin and colleagues found that 
both categorical and continuous measures of reduction of ECG-LVH, were associated 
with lower likelihood of new-onset heart failure over an average of 4.7 years of follow-up 
(66).  Categorical and continuous measures of reduction in LVH were defined as a 
Cornell product LVH reduction ≥ 236 mm per ms compared with lesser reductions, and 
as an 817 mm per ms (1 standard deviation of the mean) lower Cornell product, 
respectively.  In contrast, Fagard and colleagues  found that change (ECG variable at last 
visit minus the baseline value), defined as a continuous measure of LVM (sum of 3 
voltages, RaVL, SV1 and RV5), was not associated with incident heart failure in 4507 
elderly patients (112).   
Outcome assessment differed between the two studies: Okin and colleagues (66) 
defined heart failure as hospitalization based on clinical and diagnostic findings and 
requiring verification by a blinded committee, whereas Fagard and colleagues (112) 
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 defined heart failure as fatal and non-fatal, regardless of hospitalization, and requiring 
verification by a blinded review committee.  Adjustment covariates were diverse and 
varied by study: Okin and colleagues (66) adjusted for losartan versus atenolol treatment, 
age, sex, race/ethnicity, diabetes, history of ischemic heart disease, MI, stroke, peripheral 
artery disease, atrial fibrillation, smoking, albumin-creatinine ratio, serum glucose and 
creatinine levels, total and high-density lipoprotein cholesterol levels, BMI, Cornell 
product; baseline and in-treatment systolic and diastolic blood pressures; and baseline 
and changes of Sokolow-Lyon voltages, while Fagard and colleagues (112) adjusted for 
age, sex, BMI, smoking, systolic blood pressure, pulse rate, diabetes, previous 
antihypertensive treatment, cardiovascular complications at baseline and baseline ECG 
voltage.  
Previous studies have several strengths.  First, these studies were prospective, 
based on fairly large clinical trials, and patients had yearly updated ECGs.  Second, it is 
important to note that while Fagard and colleagues (112) used a continuous variable for 
ECG change, Okin and colleagues (66) focused on change in ECG measures of LVH 
using both continuous and categorical variables.  The use of continuous measures is 
important, since clinically meaningful changes can still occur within pre-specified 
categories.  There are limitations to these two studies for the readers to consider.  First, 
selection of patients in the LIFE Study was based on LVH, a Cornell product value 
greater than 2440 mm/msec or a Sokolow-Lyon voltage value of > 38 mm on a screening 
ECG before baseline, patients were hypertensive and some were receiving anti-
hypertension medications, and thus results from this study can only be applied to 
comparable high-risk populations.  Second, these studies did not document whether 
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measurement error in the ECG variables were accounted for when evaluating their 
association with incident heart failure.  Failure to take intra-individual variation in ECG 
measures into account may result in substantial bias associated with its estimate of effect 
on heart failure incidence (65).   
Although a few studies have assessed the impact of changes in ECG variables and 
incident heart failure in clinical trials consisting of high-risk populations (66, 112), there 
is no current information on whether the effect of changes in ECG variables are 
associated with incident heart failure in a relatively healthy, population-based cohort.   
 
 Table 4. Summary of 2 prospective studies examining the relationship between changes in ECG variables and incident heart failure 
Author 
(year) Study 
Study 
population 
Mean follow-
up (years) 
Incident heart 
failure 
Measure of incident 
heart failure 
Change in ECG variables, estimate (95% confidence 
interval) 
Fagard 
(2004) (112) SHE  
Men and 
women, 
aged 60  
years and 
older with 
systolic 
hypertension  
5.1 209 
Fatal and non-fatal 
requiring dyspnea, clinical 
signs and treatment 
Change in left ventricular mass, a 1-mV higher value: 
Crude: 1.32 (1.16, 1.47) 
Adjusted: 1.26 (1.11, 1.43) 
 
Okin 
(2007) (66) LIFE  
Men and 
women, 
aged 55-80 
years with 
hypertension 
and left 
ventricular 
hypertrophy 
4.7 214 
Clinical and diagnostic 
findings, a review by 
blinded Endpoint 
Committee 
Change in Cornell product: 
Crude, continuous, per 817 mm/msec decrease: 0.76 (0.68, 0.85) 
Adjusted, continuous, per 817 mm/msec decrease: 0.81 (0.74, 
0.89) 
Crude, categorical, ≥ 236 mm/msec decrease: 0.57 (0.44, 0.76) 
Adjusted, categorical, ≥ 236 mm/msec decrease: 0.64 (0.47, 0.89) 
Abbreviations: ECG, electrocardiogram; SHE, the Systolic Hypertension in Europe trial; LIFE, Losartan Intervention for Endpoint reduction in hypertension study.   38 
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CHAPTER 2: SPECIFIC AIMS 
 
The goals of this doctoral work were to determine the short-term repeatability of 
select twelve-lead electrocardiogram (ECG) variables in the ECG Repeatability Study, to 
describe the long-term changes of the ECG variables and to assess the association 
between the long-term changes of ECG variables and incident heart failure in the 
Atherosclerosis Risk in Communities (ARIC) Study.  Manuscripts I (Chapter 4), II 
(Chapter 5) and III (Chapter 6) correspond to Aims 1, 2 and 3, respectively. 
1) Estimate the short-term (2-minute and 1-week) repeatability of ECG variables 
(QRS/T angle, Cornell voltage, Cornell product, left ventricular mass (LVM), T wave 
amplitude in lead V5, T wave amplitude in lead V1, and ST depression in lead V5).   
Research question: Are the ECG variables highly repeatable in the short-term? 
2) Describe the long-term changes of ECG variables (QRS/T angle, QT interval, 
Cornell voltage, Cornell product, LVM, T wave amplitude in lead V5, T wave amplitude 
in lead V1, and ST depression in lead V5) by coronary heart disease, diabetes and 
hypertension status.   
Research question: Do the long-term changes of ECG variables differ by coronary 
heart disease, diabetes and hypertension status? 
  
3) Estimate the association between the long-term changes of ECG variables and 
incident heart failure, while considering their short-term repeatability. 
Research question: Are the long-term changes of ECG variables associated with 
incident heart failure, while considering their short-term repeatability? 
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CHAPTER 3: STUDY POPULATIONS AND METHODS 
 
3.1 Study populations 
The aims of this doctoral work were addressed in two separate studies.  The first, 
the electrocardiogram (ECG) Repeatability Study was used to investigate Aim 1.  The 
second study, the Atherosclerosis Risk in Communities (ARIC) Study was used to 
investigate Aims 2 and 3. 
 
3.1.1 The ECG Repeatability Study  
This ECG Repeatability Study included 63 volunteers, aged 45 to 64 years, 
recruited from the Chapel Hill, NC area between July and October, 2001 (1, 2).  
Participants were invited to attend two examination visits, separated on average by 10 
days, with a standard deviation of 4 days.  At each visit, participants had two ECG 
recordings.  Recruitment was limited to those without reported use of type Ia anti-
arrhythmics (quinidine, procainamide, disopyramide or moricizine), an artificial 
pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or 
pregnancy.  Furthermore, participants were excluded if they smoked, ate or drank 
anything but water less than ten hours prior to the visit(s).  Age, race/ethnicity and sex 
were self-reported and body mass index (BMI) was calculated as weight (kg) divided by 
height (m) squared.   
The race/ethnicity, sex, BMI and age of those who participated in the ECG 
Repeatability Study are listed in Table 5; for comparison, the characteristics of the 
original ARIC Study participants are listed as well. 
Table 5. Characteristics of the ECG Repeatability Study and the Atherosclerosis Risk in 
Communities (ARIC) Study participants 
 N (%) or mean (standard deviation) 
Characteristic 
ECG Repeatability Study 
(N = 63) 
ARIC Study 
(N = 15792) 
Race/ethnicity   
Black 19 (31.8%) 4266 (25.4%) 
White 43 (68.3%) 11478 (74.6%) 
Asian 1 (1.6%) 34 (0.2%) 
American Indian . 14 (0.1%) 
Sex   
Men 32 (50.8%) 7082 (44.9%) 
Women 31 (49.2%) 8710 (55.2%) 
Body mass index (kg/m2) 26.9 (5.3) 27.7 (5.4) 
Age (years) 52.0 (5.0) 54.2 (5.8) 
 
3.1.2 The ARIC Study  
The ARIC Study combines epidemiologic surveillance of four communities and a 
community-based prospective cohort designed to investigate the etiology and natural 
history of atherosclerosis and its sequelae.  From1987 to 1989, the ARIC Study cohort of 
15,792 black and white participants aged 45 to 64 years was drawn from four 
communities in North Carolina (NC), Mississippi (MS), Minnesota (MN), and Maryland 
(MD).  Two of the population samples (Washington County, MD and Minneapolis, MN 
suburbs) were mostly white.  Blacks were over-sampled in Forsyth County, NC (12% 
black) and were exclusively sampled in Jackson, MS to provide statistical power to 
investigate findings by race/ethnicity.  The overall recruitment response proportion at 
53 
 
baseline was 60%: black men (42%), black women (49%), women (67%) and white 
women (68%).  A comparison of study participants to non-respondents has been 
described (3). 
After a home interview which established a baseline socio-demographic and 
cardiovascular (CVD) profile of all enumerated residents in each study community who 
were willing to have an interview, age-eligible residents were invited to participate in a 
baseline, and three subsequent clinical examinations, scheduled at three year intervals.  
The baseline examination (Visit 1) was conducted between 1987 and 1989; Visit 2 was 
held between 1990 and 1992; Visit 3 between 1993 and 1995; and the last clinic visit 
(Visit 4) was conducted between 1996 and 1998.  Each clinical examination consisted of 
standardized interviews pertaining to CVD risk factors, medical history and obtainment 
of extensive clinical data and a twelve-lead standard ECG.  After Visit 1, the ARIC Study 
participants were followed annually via telephone interviews to establish vital status and 
assess indices of CVD, and surveillance of hospitalizations and ongoing record 
abstraction for hospitalized events and deaths.  Annual follow-up interviews and 
surveillance have continued after Visit 4, and those data will be available to the 
investigators in this study on a continuing basis.   
 
Construction of the cohort samples used to address Aim 2  
We excluded participants with fewer than two ECGs (n = 1340), with a QRS 
interval greater than or equal to 120 ms (n = 574), with a race/ethnicity other than black 
or white (n = 48), and black participants in Minneapolis, MN or Washington County, MD 
54 
 
(n = 55).  The final sample size for a cohort so defined (cohort 1) was 13,901.  Analyses 
evaluating the continuous change of ECG variables utilized cohort 1 data, whereas 
analyses evaluating categorical ECG change variables required the exclusion of 
participants with missing ECGs at baseline (n range = 228 – 287) and whose 
measurements parameters at baseline exceeded the established cut points detailed in 
Section 3.4 (cohorts 2 – 9; n range = 1287 – 4148).  Cohorts 2 through 9 excluded those 
whose ECG measures at baseline exceeded the established cut point because they already 
had a higher risk for incident heart failure at baseline.  The final sample sizes for cohorts 
2, 3, 4, 5, 6, 7, 8 and 9 were 10239, 12870, 12735, 12230, 12142, 12033, 12126 and 
12004, respectively.  Cohorts 1 through 9 were used to address Aim 2. 
 
Construction of the cohort samples used to address Aim 3  
We excluded participants with fewer than two ECGs (n = 1340), with a QRS 
interval greater than or equal to 120 ms (n = 574), with a race/ethnicity other than black 
or white (n = 48), black participants in Minneapolis, MN or Washington County, MD (n 
= 55), those with prevalent heart failure at baseline (n = 752), with missing information 
on heart failure at the baseline examination (n = 287) and those who were censored prior 
to ARIC Visit 4 (n = 4486).  The final sample size for a cohort so defined (cohort 10) was 
10,313.  Analyses evaluating the continuous change of ECG variables utilized cohort 10 
data, whereas analyses evaluating categorical ECG change variables required the 
exclusion of participants with missing ECGs at baseline (n range = 228 – 287) and whose 
measurements parameters at baseline exceeded the established cut points detailed in 
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Section 3.4 (cohorts 11 – 18; n range = 1287 – 4148).  The final sample sizes for cohorts 
2, 3, 4, 5, 6, 7, 8 and 9 were 7812, 9637, 9554, 9205, 9152, 9110, 9086 and 9044, 
respectively.  Cohorts 10 through 18 were used to address Aim 3. 
 
3.2 ECG methods 
3.2.1 The ECG Repeatability Study ECG methods 
The ECG Repeatability Study followed the standardized protocol used in the 
ARIC Study for placing electrodes, room condition and data collection (4).  All ECG 
recordings were carried out in a quiet, temperature-controlled room.  Participants 
reported for the visits between 7:30 and 11:30 am.  After participants rested in the supine 
position for fifteen minutes, one of four trained and certified ECG technicians recorded 
ten-second, twelve-lead ECGs using Kendall Q-Trace 5400 Ag/AgCl electrodes (Ludlow 
Co, Chicopee, Mass).  The E-V6 Halfpoint method (5) was used when recording the first 
of two ECGs using a MAC Personal Cardiographer (Marquette Electronics, Inc, 
Milwaukee, WI).  The E-V6 Halfpoint method improves the precision and the 
repeatability of chest electrode positioning by placing the V4 electrode at the horizontal 
level of the fifth intercostal space at the half-way point between the midsternal line and 
the left midaxillary line (V6 location).  Without removal of the electrodes, the recording 
was repeated after 1 to 2 minutes.  ECGs were digitized and sent via modem after each 
recording session to the Epidemiological Cardiology Research (EPICARE) Center at the 
Wake Forest University School of Medicine.  The EPICARE Center, blinded to 
participant identity and previous ECG readings, processed the ECGs using the most 
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recent version of the Marquette GE program, version 12SL.  Following an identical 
protocol, a second set of ECGs from the same participants were obtained on the second 
visit.   
 
3.2.2 The ARIC Study ECG methods 
The ARIC Study used standardized protocol for the acquisition of and processing 
of ECGs (4).  All ECG recordings were carried out in a quiet, temperature-controlled 
room.  After participants rested in the supine position for fifteen minutes, trained and 
certified ECG technicians recorded ten-second, twelve-lead ECGs using Kendall Q-Trace 
5400 Ag/AgCl electrodes (Ludlow Co, Chicopee, Mass).  The E-V6 Halfpoint method 
(5) was used when recording ECGs using a MAC Personal Cardiographer (Marquette 
Electronics, Inc, Milwaukee, WI).  The E-V6 Halfpoint method improves the precision 
and the repeatability of chest electrode positioning by placing the V4 electrode at the 
horizontal level of the fifth intercostal space at the half-way point between the midsternal 
line and the left midaxillary line (V6 location).  ECGs were digitized and sent via modem 
after each recording session to the EPICARE Center (Wake Forest University, Winston-
Salem, NC).  The EPICARE Center, blinded to participant identity processed the ECGs 
using the 12SL version of the Marquette GE program.   
 
The ARIC Study standardized procedure for data collection of ECGs  
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The ARIC Study standardized procedure for data collection of ECGs and quality 
control are briefly described below (6). 
Each participant, chest exposed, was instructed to lie on the recording bed with 
arms relaxed at the sides.  The individual was asked to avoid movements which might 
cause errors in marking the electrode locations.  A felt tip pin was used to mark the six 
chest electrode positions.  In order to increase the electrode/skin interface, the electrodes 
were placed on the skin for at least 2 to 3 minutes before taking the ECG.  The 10 
electrode sites (6 chest and four limb sites) were wiped with sterile alcohol in order to 
remove skin oil and perspiration. The four limb leads were placed on the medial side of 
the left ankle, right ankle, the left wrist and the right wrist.  The six chest leads were 
placed as follows: Electrode V2 was placed in the intercostals space immediately to the 
left of the sternal border.  Electrode V1 was placed in the fourth intercostal space 
immediately to the right of the sternal border.  The E point was defined as the space 
horizontally to the midsternal line and parallel with the fifth intercostal space.  Electrode 
6 was the same location as the E point in the midaxillary line (straight down from the 
center of the armpit).  Electrode V4 was located using the E-V6 halfpoint method.  A 
measuring tape was placed over the skin between the E point and the V6 marking.  V4 was 
midway between the E and V6.  Likewise, V3 was midway between V2 and V4.  V5 was 
midway between the location between V4 and V6.  If technical problems were observed 
due to poor electrode contact then it was necessary to do further preparation: 1) remove 
excess hair with a razor; or 2) brush sandpaper over the skin three times using light 
pressure.  When placing each electrode, it was massaged in a circular motion to maximize 
the contact with the skin.   
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After placing the electrodes on the skin, the ‘record’ key was pressed.  The 
machine read, ‘acquiring data.’  The machine automatically printed the ECG after it 
acquired 10 seconds of good data.  The ECG was torn off the machine and filed at the 
field center, and read locally by clinical physicians for notification and referral.  The 
records were then placed in participants’ local data files.  
Additionally, the ECGs were transmitted to the EPICARE Center.  If there was a 
problem transmitting to the EPICARE Center, ECGs were transmitted to the MAC 12 at 
the Minneapolis ECG Coding Center.  Every morning, the EPICARE Center notified 
each ARIC field center of the identification numbers (IDs) received.  After successful 
confirmation that EPICARE received the transmission, and it was of good quality, the 
ECG was deleted from the Mac PC Storage Directory.  Every other week EPICARE sent 
these data to the Coordinating Center (CC).  All resting twelve-lead ECG records with 
computer generated ECG findings listed below, which qualified for serial change coding 
at follow-up visits, and at least a 10% random sample of the remaining ECGs were 
visually coded at the Minnesota Coding Center by the Minnesota Code: 1) any 1-code; 2) 
and 4-1, 4-2, 5-1 or 5-2 code; 3) any 9-2, 6-4, 7-1-1, 7-2-1 or 7-4 code; and 4) any 6-1, 6-
8 or heart rate ≥ 140.  The visual Minnesota Codes were sent to the CC for data 
comparison with the computer generated codes.  Adjudication of computer codes was 
made only on ECGs that had a discrepancy involving any Q-code, ST, or T wave changes 
from Visit 1 to Visit 2.  The CC determined the IDs that had any of these discrepancies 
and sent a report form to the Minnesota Coding Center.  These ECGs were examined and 
the adjudicated record was sent to the CC.  The CC added the adjudicated codes to the 
database as the definitive Minnesota codes for the IDs involved. 
59 
 
The computer assigned codes were used in the Study Data in all cases except 
when adjudication resulted in a code different from the original EPICARE code.  If the 
two centers disagreed on ‘minor’ codes (codes other than Q waves, ST depression, T 
waves, ST-elevation, bundle branch block, Wolf-Parkinson-White, complete atrio-
ventricular block, heart rate ≥ 140), the EPICARE reading prevailed.  For major codes, 
the adjudicated reading prevailed.  
Baseline and follow-up ECGs were compared.  When two (adjudicated) ECGs 
were available from two separate visits, a determination was made at the CC as to 
whether the Minnesota code change criteria were met.  Determination was made by a 
computer algorithm and not by Minnesota Coders.  IDs that fit the change in criteria were 
examined side by side for serial ECG change at the Minnesota ECG Reading Center.  
Objective rules for side-by-side ECG evaluation were used to determine whether a 
Minnesota code change between ECG pairs was significant between visits, using the first 
clinic visit ECG as the referent. 
All ECG technicians were certified and were required to take an average of 3 
ECGs per week over a two-month period in order to remain familiar with the procedures 
and equipment.  Each technician was observed quarterly by senior technicians while 
taking a participant’s ECG, and performance was documented.  EPICARE checked the 
quality of the data.   
 
3.3 ECG Repeatability Study variables 
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The following ECG measures were generated at the EPICARE Center using 
methods previously described (7): QRS/T angle, Cornell voltage, Cornell product, left 
ventricular mass (LVM), net T wave amplitude in lead V5, net T wave amplitude in lead 
V1, and ST depression.  The QRS/T angle was defined as the angle between the net QRS 
and T wave vectors (8).  QRS/T angle was calculated using a simplified method from the 
net QRS amplitudes (R – absolute value of S or QS, whichever was larger, in leads V6, 
aVF and V2) and the net T wave amplitudes (signed T +signed T prime) in leads V5, aVF 
and V2.  T waves were obtained by calculating mean and peak T wave values in lead V5, 
whereas for T wave amplitude in lead V1, only the mean value was used.  ST depression 
was evaluated using ST amplitude in lead V5 at 60 ms past the end of the QRS interval 
(the J-point) from the Marquette-GE program.  Cornell-voltage (R wave amplitude in 
lead aVL + Q or QS wave amplitude in lead V3) (9), Cornell product (Cornell voltage x 
QRS duration) (10), and LVM predicted by a multivariate model (11) were used as 
measures of left ventricular hypertrophy (LVH).  The LVM model adjusted for Cornell 
voltage and body weight.  Age, race/ethnicity and sex were self-reported and BMI was 
calculated as weight (kg) divided by height (m) squared.  A summary of demographic 
characteristics and ECG variables are presented in Table 6. 
Table 6. Summary of variables for the short-term repeatability analysis, the ECG 
Repeatability Study (N = 63) 
Variable Name Variable Description Coding 
N (%) or mean 
(standard deviation) 
BMI Body mass index (kg/m2) Continuous 26.9 (5.3) 
AGE Age at Visit 1 (years) Continuous 52.0 (5.0) 
RACE Race/ethnicity 
1 = White 
2 = Black 
4 = Asian Indian 
43 (68.3%) 
19 (30.2%) 
1 (1.6%) 
RACE2 Race/ethnicity 
0 = White 
1 = Nonwhite 
43 (68.3%) 
20 (31.8%) 
SEX Sex 
1 = Male 
0 = Female 
32 (50.8%) 
31 (49.2%) 
HR Mean heart rate (beats/min) Continuous 59.6 (8.7) 
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QRST 
QRS/T angle using QRSnet 
amplitudes from leads V6, aVF 
and V2 and Tnet amplitudes from 
leads V5, aVF and V2 (°) Continuous 78.4 (26.0) 
QTRR 
Heart rate- and sex-adjusted QT 
as a linear function of the RR 
interval (ms) Continuous 415.8 (17.6) 
CV 
Cornell voltage (μV) (RaVL + 
SV3) Continuous 1213.8 (501.2) 
CP 
Cornell product (µV.s) (Cornell 
voltage (µV) x QRS(s)) Continuous 115.6 (50.3) 
ECGLVM 
Left ventricular mass as 
measured by ECG (g) Continuous 154.1 (27.3) 
TAMP_V5 T amplitude in lead V5 (µV) Continuous 408.6 (213.7) 
TAMP_V1 T amplitude in lead V1 (µV) Continuous 90.3 (154) 
ST60V5 
ST segment amplitude at time 
point 60 ms past end of QRS in 
lead V5 (µV) Continuous 50.5 (31.6) 
*The study sample included 63 healthy participants, aged 45 to 64 years, with no reported use of class Ia 
antiarrhythmics, or conditions such as heart failure, pregnancy or diabetes mellitus. 
 
3.4 ARIC Study variables 
3.4.1 Exposure assessment  
The following ECG measures were generated at the EPICARE Center using 
methods previously described (7): spatial QRS/T angle, QT interval, Cornell voltage, 
Cornell product, LVM, T net amplitudes in leads V5 and V1, and ST depression.  The 
QRS/T angle was defined as the angle between the net QRS and T wave vectors (8).  
QRS/T angle was calculated using a simplified method from the net QRS amplitudes (R – 
absolute value of S or QS, whichever was larger, in leads V6, aVF and V2) and the net T 
wave amplitudes (signed T +signed T prime) in leads V5, aVF and V2.  QTrr, used to 
evaluate QT prolongation, was the sex- and race/ethnicity-specific QT adjusted for heart 
rate as a linear function of the RR interval (2).  Cornell voltage (R wave amplitude in lead 
aVL + Q or QS wave amplitude in lead V3) (9), Cornell product (Cornell voltage x QRS 
duration) (10), and LVM predicted by a multivariate model (11) were used as measures 
of LVH.  The LVM model adjusted for Cornell voltage and body weight.  T waves were 
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obtained by calculating mean and peak T wave values in lead V5, whereas for T wave 
amplitude in lead V1, only the mean value was used.  ST depression was evaluated using 
ST amplitude in lead V5 at 60 ms past the end of the QRS interval (the J-point) from the 
Marquette-GE program.   
The coding schemes for ECG abnormalities in the ARIC Study are presented in 
Table 7. 
Table 7. Summary of ECG variables, the Atherosclerosis Risk in Communities (ARIC) 
Study  
Variable Name Variable Description Coding 
QRST 
QRS/T angle using QRSnet amplitudes from leads V6, aVF and V2 and Tnet 
amplitudes from leads V5, aVF and V2 (°) Continuous 
QTRR Heart rate- and sex-adjusted QT as a linear function of the RR interval (ms) Continuous 
CV Cornell voltage (μV) (RaVL + SV3) Continuous 
CP Cornell product (µV.s) (Cornell voltage (µV) x QRS (s)) Continuous 
ECGLVM Left ventricular mass (g) Continuous 
TAMP_V5 T amplitude in lead V5 (µV) Continuous 
TAMP_V1 T amplitude in lead V1 (µV) Continuous 
ST60V5 ST segment amplitude at time point 60 ms past end of QRS in lead V5 (µV) Continuous 
 
Construction of continuous ECG change variables used to address Aims 2 and 3  
The following linear regression model was used to derive the continuous exposure 
variable, long-term change of the ECG measure (Bi), for each participant: yij= Ai + Bi tij + 
εijk, where y = the predicted ECG abnormality value, i = 1, 2, 3…n participants, j = 1, 
2…4 visits, k = 1 to 2 ECG measures, t was the time between ARIC Visit 1 and 
subsequent visits and ε was the error term.  In the regression model used to derive Bi, yij = 
Ai + Bi tij + εijk, the random variability in y, σ2, was assumed to be the same for all 
participants and at all visits: Var (yijk | tij) = Var (εijk | tij) = σ2.   
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Construction of the categorical ECG change variables used to address Aims 2 and 3  
We additionally constructed categorical change ECG variables.  To provide 
comparability with an earlier analysis in the ARIC Study, we used cut points for ECG 
variables shown to be associated with incident heart failure used by Rautaharju and 
colleagues (7).  ECG variables were defined using the following cut points for men (M) 
and women (W):  QRS/T angle (°): M ≥ 107, W ≥ 89; QT interval (ms): M ≥ 436, W ≥ 
442; Cornell voltage (μV): M ≥ 2650, W ≥ 1673; Cornell product (μV.s): M ≥ 207, W ≥ 
152; LVM (g): M ≥ 204, W ≥ 162; TnetV5 amplitude (μV): M ≤ 122, W ≤ 107; TnetV1 
amplitude (μV): M ≥ 307, W ≥ 151; and ST60V5 (μV): M ≤ 5, W ≤ -7.  For each ECG 
variable, categorical change was defined as ever exceeding the cut point (“1”) over ARIC 
visits, or else “0”.   
 
3.4.2 Outcome assessment  
Incident heart failure  
Incident heart failure was defined as the first hospital discharge associated with a 
diagnosis of heart failure (International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM code 428 or 518.4) or death certificates with an underlying 
cause of death coded as heart failure (ICD-9-CM code 428 or ICD-10 code I50).  All 
cohort hospitalizations that occurred before January 1, 2005 were included.  The ICD-9 
codes and descriptions used in these analyses are reported in Table 8.  
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Prevalent heart failure at baseline 
Table 8. Hospital discharge diagnoses of International Classification of Diseases (ICD),  
9th Revision, Clinical Modification codes used to define heart failure by the  
Atherosclerosis Risk in Communities (ARIC) Study investigators 
ICD-9 Code Description 
428 Heart failure 
428.0 Congestive heart failure, unspecified 
428.1 Left heart failure 
428.2 Systolic heart failure 
428.3 Diastolic heart failure 
428.4 Combined systolic and diastolic heart failure 
428.9 Heart failure, unspecified 
518.4 Acute edema of the lung, unspecified 
 
If the participant reported s/he had taken any medication for heart failure or 
qualified for stage 3 of the Gothenburg Criteria (Table 10) for heart failure which 
requires specific cardiac, pulmonary and heart failure indicators to be present (12, 13) 
then the participant had prevalent heart failure (PREVHF01 = 1) at Visit 1, and they 
were excluded (see Table 9).   
Table 9. Prevalent heart failure (PREVHF01), derived from the heart failure medication 
(HFMEDS) and Gothenburg (GOTHENBURG) variables utilized by Atherosclerosis Risk 
in Communities (ARIC) Study investigators 
PREVPREVHF01 HFMEDHFMEDS GOTGOTHENBURG UR 
1 
1 Any 
Any 1 
0 0 0 
Missing 
Missing 0 or missing 
0 or missing Missing 
Table adapted from the ARIC Manual of Procedures 
The heart failure medication variable (HFMEDS) takes on a value of 1 (yes) 
or 0 (no).  The value for heart failure medication was 1 if the participant reported s/he 
had taken heart failure medication in the last two weeks.   
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The Gothenburg Score (GOTHENBURG) can take on the values of 0, 1, 2, 3 
or missing.  The Gothenburg score consists of cardio, pulmonary and heart failure 
therapy binary variables, with missing variables excluded.  A value of 1 was given for 
CARDIAC if the participant had any of the following variables: edema (swelling in 
the feet or ankles during the day), paroxysmal nocturnal dyspnea, coronary heart 
disease (CHD), angina, rales, or atrial fibrillation.  A value of 1 was given for 
PULMONARY if the participants had any of the following variables: history of 
bronchitis, history of asthma, rhonchi or chronic cough.  A value of 1 was given for 
heart failure therapy if the participant received either digitalis or diuretic therapy. 
Table 10. Gothenburg criteria score for heart failure utilized by the Atherosclerosis Risk  
in Communities (ARIC) Study investigators 
Score Cardiac Pulmonary 
Heart Failure 
Therapy 
3 1 1 1 
2 
1 1 0 or missing 
1 0 or missing 1 
1 1 0 or missing 0 or missing 
0 0 . . 
Missing Missing . . 
Table adapted from the ARIC Manual of Procedures 
 
3.4.3 Covariate assessment  
Covariates used to address Aim 2  
Variables of interest included: age, race/ethnicity, sex, hypertension, diabetes, and 
CHD.  These variables were considered because they are biologically or clinically 
relevant to the occurrence of heart failure (14, 15), or they were determined to be relevant 
based on a review of the literature.  A detailed description of the ARIC Study 
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demographic and clinical measures and the processing have been published elsewhere 
(16).  ARIC Study Visit 1 covariates are briefly described below.   
The covariates selected for the analysis were age (years), sex (male or female), 
self-reported race/ethnicity (black or white).  A race/center variable was created by 
combining each participant’s race/ethnicity with their respective study center.  Additional 
covariates selected for the analysis include CHD (yes or no), diabetes (yes or no) and 
hypertension (yes or no).  Each participant was asked to indicate whether they were 
white, black/African American, American Indian or Asian.  CHD at baseline was defined 
from a reported history of physician-diagnosed myocardial infarction (MI), coronary 
artery bypass surgery, coronary angioplasty, or evidence of a previous MI on an ECG.  
Blood pressure, lipids and glucose were measured according to standard ARIC 
procedures (4).  Participants were asked to fast twelve hours before blood draw and 
actual fasting times were recorded.  Blood was drawn from an antecubital vein of seated 
participants, serum was centrifuged, and frozen samples were shipped to central 
laboratories for analysis (16).  The mean of the last two of three systolic and diastolic 
sitting blood pressure measurements obtained from a random-zero sphygmomanometer 
was used for measures of blood pressure.  Hypertension was defined as a systolic blood 
pressure value equal to or greater than 140 mmHg, a diastolic blood pressure value equal 
to or greater than 90 mmHg, or use of blood pressure lowering medications in the past 
two weeks.  Pre-hypertension was defined as a systolic blood pressure value equal to or 
greater than 120 mm Hg but less than 140 mm Hg or a diastolic blood pressure value 
equal to or greater than 80 mm Hg but less than 90 mm Hg (17).  Type II diabetes 
mellitus was defined as a fasting serum glucose level of 7.0 mmol/L or more (126 
67 
 
mg/dL), nonfasting glucose level of 11.1 mmol/L or more (200 mg/dL), participant report 
of a physician diagnosis of diabetes, or current use of diabetes medication (18).  Pre-
diabetes was defined as a fasting serum glucose level of 6.1 mmol/L (110 mg/dL) or 
more but less than 7.0 mmol/L (126 mg/dL) (18). 
Table 11. Summary of clinical and demographic variables used to address Aim 2, the 
Atherosclerosis Risk in Communities (ARIC) Study 
Variable Name Variable Description Coding 
V1AGE01 Age at Visit 1 in years Continuous 
PRVCHD05 
Coronary heart disease: history of myocardial 
infarction, coronary artery bypass surgery or 
coronary angioplasty  
1 = CHD 
0 = No CHD 
RACECTR Combination of race/ethnicity and study center 
0 = White/Minneapolis, MN 
1 = White/Washington County,MD 
2 = Black/Jackson, MS 
3 = White/Foryth County, NC 
4 = Black/Forsyth County, NC 
GENDER Sex  
1 = Male 
0 = Female 
HTN 
Hypertension was defined as physician-
diagnosed or use of anti-hypertension 
medications.  Pre-hypertension was defined as 
a systolic blood pressure ≥ 120 mm Hg but < 
140 mm Hg or a diastolic blood pressure ≥ 80 
mm Hg but less than 90 mm Hg. 
2= Hypertension 
1= Pre-hypertension 
0= No hypertension 
DIAB 
Diabetes was defined as self-reported physician 
diagnosed or use of hypoglycemic medications.  
Pre-diabetes was defined as a fasting glucose 
level ≥ 110 mg/dL but < 126 mg/dL. 
2= Diabetes 
1= Prediabetes 
0= No diabetes 
*All data were derived from the ARIC Study at Visit 1 (1987-1989).   
 
Covariates used to address Aim 3  
The covariates selected for the analysis were age (years), sex (male or female), 
self-reported race/ethnicity (black or white).  Additional covariates selected for the 
analysis include CHD (yes or no), diabetes (yes or no), hypertension (yes or no), smoking 
status (current or not current), use of cholesterol-lowering medication (yes or no), and 
BMI (continuous) at the Visit 4 examination and physical activity (continuous) at the 
Visit 3 examination.  These variables were considered because they are biologically or 
68 
 
clinically relevant to the occurrence of heart failure (14, 15), or they were determined to 
be relevant based on a review of the literature.  ARIC Study Visit 4 covariates, with the 
exception of physical activity (physical activity was obtained at ARIC Visit 3), were used 
for this analysis.  However, if participants were missing covariate information for Visit 4, 
then Visit 3 covariates were used.  Likewise, if participants were missing Visit 3 
covariates, then covariate information for Visit 2 was used.   
A detailed description of the ARIC Study demographic and clinical measures and 
the processing have been published elsewhere (16).  Each participant was asked to 
indicate whether they were white, black/African American, American Indian or Asian.  
CHD at baseline was defined from a reported history of physician-diagnosed MI, 
coronary artery bypass surgery, coronary angioplasty, or evidence of a previous MI on an 
ECG.  Blood pressure, lipids and glucose were measured according to standard ARIC 
procedures (4).  Participants were asked to fast twelve hours before blood draw and 
actual fasting times were recorded.  Blood was drawn from an antecubital vein of seated 
participants, serum was centrifuged, and frozen samples were shipped to central 
laboratories for analysis (16).  The mean of the last two of three systolic and diastolic 
sitting blood pressure measurements obtained from a random-zero sphygmomanometer 
was used for measures of blood pressure.  Hypertension was defined as a systolic blood 
pressure value equal to or greater than 140 mmHg, a diastolic blood pressure value equal 
to or greater than 90 mmHg, or use of blood pressure lowering medications in the past 
two weeks.  Use of cholesterol-lowering medications was self-reported.  Type II diabetes 
mellitus was defined as a fasting serum glucose level of 7.0 mmol/L or more (126 mg/dL) 
(19), nonfasting glucose level of 11.1 mmol/L or more (200 mg/dL), participant report of 
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a physician diagnosis of diabetes, or current use of diabetes medication.  BMI was 
calculated as measured weight (kg) divided by height (m2).  Physical activity was 
measured using the sport during leisure time activity index (range 1-5) of Baecke's 
questionnaire (20).  The appropriateness of coding schemes was confirmed in univariate 
analyses.  The coding schemes for covariates at ARIC Visit 4 (and Visit 3 for physical 
activity) are presented in Table 12. 
Table 12. Summary of clinical and demographic variables used to address Aim 3, the 
Atherosclerosis Risk in Communities (ARIC) Study  
Variable Name Variable Description Coding 
BMI41 Body mass index (kg/m2) Continuous 
V4AGE41 Age in years Continuous 
PRVCHD43 
Coronary heart disease: history of myocardial 
infarction, coronary artery bypass surgery or 
coronary angioplasty  
1 = CHD 
0 = No CHD 
RACEGRP Race/ethnicity 
1 = Black 
0 = White 
GENDER Sex  
1 = Male 
0 = Female 
HYPERT45 
Physician-diagnosed hypertension or use of anti-
hypertension medications 
1 = Hypertension 
0 = No hypertension 
DIABTS42 
Self-reported physician diagnosed diabetes or use of 
hypoglycemic medications 
1 = Diabetes 
0 = No diabetes 
CURSMK41 Current cigarette smoking status 
1 = Current smoker 
0 = Not smoking 
SPRT_I31 
Sport during leisure time activity: 5 ordinal 
variables (low=1, high=5) derived from Baecke’s 
survey Continuous 
CHOLMD41 Cholesterol-lowering medications 
1 = Yes 
0 = No 
*All data were derived from the ARIC Study at Visit 4 (1996-1998), with the exception of SPRT_I31  
at Visit 3.  However, if participants were missing covariate information for Visit 4, then Visit 3  
covariates were used.  Likewise, if participants were missing Visit 3 covariates, then covariate  
information for Visit 2 was used.   
 
3.5 Statistical analysis 
3.5.1 Analytic plan for Aim 1 
Nested random effects models were used to partition the total variance into 
between-participant, between-visit and within-visit components of variance: yijk = μ + pi + 
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vj(i) + εk(ij), where y = ECG abnormality, i = 1, 2, 3…63 participants, j = 1, 2 visits and k = 
1, 2 ECG recordings.  pi was the effect of the ith participant.  vj(i) was the effect of the jth 
visit nested within the ith participant.  εk(ij) was the error term and was the effect of the kth 
ECG recording nested within the ith participant on the jth visit.  The total variance in the 
data was: σ2Τ = σ2p + σ2v+ σ2ε, where σ2p was the between-participant component of 
variation, σ2v was the between-visit component of variation, σ2ε was the within-visit 
component of variation and σ2Τ  was the total variance.  The within-visit component of 
variation represents methodological variability.  The within-participant component of 
variation, the summation of the between-visit and within-visit components of variance, 
represents a combination of temporal biological and methodological variability.   
The intra-class correlation (ICC) coefficient is the between-participant component 
of variation over the total variance (sum of between-participant, between-visit and 
within-visit variance) and can be interpreted as the correlation between ECG measures at 
different visits.  The ICC coefficient can also be calculated by subtracting the within-
person variance over the total variance from 1.  In these analyses, we assumed that: 1) the 
ECG measures were normally distributed; 2) the between-participant variation followed a 
normal distribution (pi ~ N(0, σ2s)); 3) the between-visit variation was normally 
distributed (vj(i) ~ N(0, σ2v)); 4) the residual variation followed a univariate normal 
distribution (εk(ij) ~ N(0,σ2ε)); and 5) pi, vj(i) and εk(ij) were independent of each other.  If 
the normality assumptions were not met, then we planned to log-transform ECG 
variables.  However, all ECG measures met the normality assumption.  The ICC 
coefficient was calculated for each of the ECG measures and 95% confidence intervals 
were derived using the Delta method (21).  The following criteria were used to 
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characterize short-term repeatability: poor, 0-0.40; moderate, 0.41-0.60; good, 0.61-0.80; 
and excellent, 0.81-1.0.   
When we calculated sex-specific ICC coefficients for each of the ECG measures, 
we found that the normality assumptions were not met.  It is recognized that a logarithmic 
transformation could diminish the skewness of the distribution of the data and even 
achieve a normal distribution.  This would permit the construction of confidence intervals 
for the sex-specific ICC coefficients, since they were limited by small numbers.  
However, logarithmically-transformed sex-specific ICC coefficients were non-normal, 
and as a result, we used the measured values of sex-specific ECG variables rather than 
their logarithmic transformation and bootstrapping methods to construct their confidence 
intervals.  A bootstrapping procedure was used to construct 95% confidence intervals 
using 2000 samples with replacement (22).  Lastly, the square roots of the between-
participant, between-visit and within visit variances were calculated and the coefficient of 
variation for each component was calculated as the ratio of its square root to its grand 
mean, multiplied by 100.   
 
3.5.2 Analytic plan for Aim 2 
Logistic and linear regression were used to compare adjusted categorical and 
continuous changes in the ECG measures over ARIC visits 1 through 4, stratified by 
CHD, diabetes and hypertension status at baseline.  QRS/T angle, Cornell voltage, 
Cornell product, T net amplitudes in leads V5 and V1, and ST depression were adjusted 
for age, race/center-, sex- and baseline ECG measure, while QT interval and LVM were 
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adjusted for age and baseline ECG measure only.  A two-tailed p-value<0.05 was 
required for statistical significance.   
 
3.5.3 Analytic plan for Aim 3 
We employed Cox proportional hazard regression modeling to assess the 
association between change, continuous (per one standard deviation change) and 
categorical, in ECG measures and incident heart failure.  For all survival analyses of time 
to heart failure the follow-up time was defined as the period from the third re-
examination (Visit 4) to the first hospitalization for heart failure, heart failure death, 
December 31, 2004, or the last date of contact if lost-to-follow-up.  The assumption of 
proportional hazard over time was verified by Cox tests and visual inspection of log(-log) 
plots.  
 
Assessing effect measure modification 
For assessment of effect measure modification on the multiplicative scale, Cox 
proportional hazard models of the association between each ECG abnormality change 
variable and incident heart failure with and without interaction terms between potential 
effect measure modifiers were compared using the likelihood ratio test.  An α of 0.15 was 
used for the likelihood ratio test when comparing models with and without interaction 
term(s).  When the likelihood ratio test was significant, the interaction terms were 
deemed significant to the association between the ECG change variable and incident 
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heart failure, and thus the interaction term remained in the model.  However, if the 
likelihood ratio test was not significant, then the covariate did not modify the relation 
between the ECG change variable and incident heart failure, and the interaction term was 
removed from the model.  The backward elimination method was used to examine the 
interaction terms one at a time in order to eliminate insignificant variables from the 
model.  Any covariates found to be effect measure modifiers were not assessed for 
confounding. 
 
Assessing confounding 
To assess for confounding by the covariates that were not effect measure 
modifiers, the crude and adjusted hazard ratios were compared.  Each of the covariates 
was removed from the model, one at a time and the likelihood ratio test was used to 
determine if the potential confounder can be removed from the model.  An α of 0.05 was 
used for the likelihood ratio test when comparing models with and without potential 
confounder(s).  If the likelihood ratio test was significant, then the covariate was deemed 
to be a significant confounder of the ECG change variable and incident heart failure 
association, and thus the confounder remained in the model.  However, if the likelihood 
ratio test was not significant, then the covariate did not confound the relation between the 
ECG change variable and incident heart failure, and the covariate was removed from the 
model.  The backward elimination method was used to examine potential confounders 
one at a time in order to eliminate insignificant variables from the model.   
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Correction for measurement error in continuous ECG change variables 
We incorporated variance estimates derived from the ECG Repeatability Study in 
Aim 1 to adjust for intra-individual variation (measurement error) in continuous ECG 
change variables using regression calibration methods (23).   
As mentioned in Section 3.4, the following linear regression model was used to 
derive the exposure variable, long-term change in the ECG measure (Bi), for each 
participant: yij= Ai + Bi tij + εijk, where y = the ECG measure value, i = 1, 2, 3…n 
participants, j = 1, 2…4 visits, and t was the time between ARIC Visit 1 and subsequent 
visits.  We included participants in the study who had 2 or more ECG measures for any of 
the ARIC Visits 1 through 4, for each ECG variable.  In the regression model used to 
derive Bi, yij = Ai + Bi tij, the random variability in y, σ2, was assumed to be the same for 
all participants and at all visits: Var (yijk | tij) = Var (εijk | tij) = σ2.  It was also assumed that 
εijk were independent, and were independent of Ai and Bi.  Furthermore, the regression 
estimator of Bi, our measure of long-term continuous change in ECG variable, for some 
given yi1k, yi2k, yi3k, yi4k was m,i kB  = 
1
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However, in contrast with the usual regression assumption, the within-participants 
error variance of the continuous ECG change variable, 2σ , was not constant across 
participants.  The within-participant component of variance of the change in ECG 
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exposure variable, depends on the number of ECG measurements (ni) and on the spread 
of the tij, , and hence, the following calculations were implemented to account for 
participant-dependent variability: 
2
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In order to derive, , the variance of the random within-participant component 
of variance in y, we estimated R from the ECG Repeatability Study in fulfillment of Aim 
1 and assumed that it applied to the ARIC Study data using the following calculation: 
2σ
2 2 2
, (1 )y e R= = −σ σ σ
2
,
y T
 ,where R was the ICC calculated for an ECG measure 
and 
y Tσ  was the total variance of the ECG measure in the ARIC Study.   
We replaced the observed continuous ECG change exposure variable, Bi,obs, in the 
regression model with a Stein estimator (transformed ECG measure) of the true 
continuous ECG change exposure variable; *iB  = liB (z)(1-iiR ) + i,i obs iB R , where liB (z) w
the predicted value of the regression of Bi,obs on z .  The other covariates in the mode
were assumed to have no intra-individual variation.  
as 
l, z, 
i
iR  was 1 –  the product of the mean 
squared error (MSE)-1 and the average within-participant error variance, 2 , ,B e iσ , in 
study population, where the MSE was derived from the regression of Bi,obs on z.  Lastly,
the transformed ECG measure and its corresponding baseline ECG measure were jointly 
corrected for intra-individual variation. 
the 
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CHAPTER 4 
 
Manuscript I: Short-term repeatability of ECG variables predictive of 
cardiovascular morbidity and mortality 
 
4.1 Abstract 
 Background: Various electrocardiogram (ECG) abnormalities and their changes 
over time are associated with excess risk of cardiovascular mortality and morbidity.  
Knowledge of the short-term repeatability of these ECG measures, which have not been 
characterized for many ECG parameters, can allow for its correction in prediction 
analysis.   
 Methods: We measured the two-minute and one-week repeatability of seven 
ECG variables measured by a computer-ECG software (spatial QRS/T angle, Cornell 
voltage, Cornell product, left ventricular mass, T net amplitudes in leads V5 and V1, and 
ST depression) in 63 middle-aged, white and black men and women in a ECG 
repeatability study and we assessed the contribution of between-participant, between-visit 
and within-visit components of variance.  
 
 Results: Short-term repeatability of the ECG measures was excellent.  Intra-class 
correlation (ICC) coefficients ranged from 0.86 to 0.99.   
 Conclusions: Our results suggest that select ECG measures employed for 
prediction in clinical and epidemiologic settings were highly reliable in the short-term.  
Estimation of their predicted effect on cardiovascular outcomes may not be subject to 
substantial bias due to short-term variability if measurements are obtained under 
standardized conditions.  Under such circumstances, analytic adjustment for short-term 
measurement variability may not be essential.   
 
4.2 Introduction 
 Many epidemiologic studies have demonstrated that abnormalities in various 
resting, standard twelve-lead electrocardiogram (ECG) measures and their changes over 
time are associated with subsequent cardiovascular morbidity and mortality (1-8).  
However, the short-term repeatability of the ECG measures is often not well documented 
in those studies.  Sources of error in measurements of ECG variables within a person 
include within-person biological and methodological variability, which includes 
variability in placement of electrodes and the precision of the ECG record readings (9).  
If measurement variability is high (low repeatability), then the ECG variable is likely to 
have bias associated with its estimate of effect on cardiovascular outcomes (10).  Past and 
future studies can benefit from the estimation of short-term repeatability of ECG 
measures, since this would enable consideration in measurement protocols and statistical 
adjustment for variability (11). 
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The ECG Repeatability Study was conducted in 2001 to estimate the two-minute 
and one-week repeatability of ECG measures in 63 participants, ages 45-64 years (12, 
13).  Two previous reports (12, 13) from the ECG Repeatability Study quantified the 
short-term repeatability of T wave axis, QT interval, heart rate and heart rate variability 
using the standard twelve-lead ECG.  Vaidean and colleagues (13) investigated spatial T 
wave axis and QT interval.  The intra-class correlation (ICC) coefficients for the T wave 
axis and heart rate were 0.87 (95% confidence interval: 0.81, 0.93) and 0.82 (95% 
confidence interval: 0.75, 0.90), respectively, and for QT interval-based indices ICC 
coefficients were greater than 0.60.  Schroeder and colleagues (12) found that for ten-
second recordings, ICC coefficients for mean heart rate and RR interval were greater than 
0.80, whereas ICC coefficients for standard deviation of all RR intervals (SDNN) and 
root mean square of differences in RR intervals (rMSSD), ranged from 0.41 to 0.57. 
Our aim of the study was to quantify the short-term measurement variability of 
spatial QRS/T angle, Cornell voltage, Cornell product, left ventricular mass (LVM), T net 
amplitudes in leads V5 and V1, and ST depression, in middle-aged, white and black men 
and women in the ECG Repeatability Study.  The ECG measures were chosen based on 
demonstrated relevance as cardiovascular risk predictors (3, 6).  To the authors’ 
knowledge, this is the first study to quantify the short-term repeatability of these ECG 
measures. 
 
4.3 Material and methods  
4.3.1 Study population  
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This ECG Repeatability Study included 63 volunteers, aged 45 to 64 years, 
recruited from the Chapel Hill, North Carolina area between July and October, 2001.  
Participants were invited to attend two examination visits, separated on average by ten 
days, with a standard deviation of four days.  At each visit, participants had two ECG 
recordings.  Recruitment was limited to those without reported use of type Ia anti-
arrhythmics (quinidine, procainamide, disopyramide or moricizine), an artificial 
pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or 
pregnancy.  Furthermore, participants were excluded if they smoked, ate or drank 
anything but water less than ten hours prior to the visit(s).  Age, race/ethnicity and sex 
were self-reported and body mass index (BMI) was calculated as weight (kg) divided by 
height (m) squared.  Detailed descriptions of the ECG Repeatability Study have been 
published (12, 13).  The Institutional Review Board of the University of North Carolina 
at Chapel Hill approved the study, and all participants gave informed, written consent.   
 
4.3.2 ECG methods 
The ECG Repeatability Study followed the standardized protocol used in the 
Atherosclerosis Risk in Communities (ARIC) Study for placing electrodes, room 
condition and data collection (14).  All ECG recordings were carried out in a quiet, 
temperature-controlled room.  Participants reported for the visits between 7:30 and 11:30 
am.  After participants rested in the supine position for fifteen minutes, one of four 
trained and certified ECG technicians recorded ten-second, twelve-lead ECGs using 
Kendall Q-Trace 5400 Ag/AgCl electrodes (Ludlow Co, Chicopee, MA).  The E-V6 
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Halfpoint method (15) was used when recording the first of two ECGs using a MAC 
Personal Cardiographer (Marquette Electronics, Inc, Milwaukee, WI).  The E-V6 
Halfpoint method improves the precision and the repeatability of chest electrode 
positioning by placing the V4 electrode at the horizontal level of the fifth intercostal space 
at the half-way point between the midsternal line and the left midaxillary line (V6 
location).  Without removal of the electrodes, the recording was repeated after one to two 
minutes.  ECGs were digitized and sent via modem after each recording session to the 
Epidemiological Cardiology Research (EPICARE) Center (Wake Forest University, 
Winston-Salem, NC).  The EPICARE Center, blinded to participant identity and previous 
ECG readings, processed the ECGs using the most recent version of the Marquette GE 
program, version 12SL.  Following an identical protocol, a second set of ECGs from the 
same participants were obtained on the second visit.   
The following ECG measures were generated at the EPICARE Center using 
methods previously described (6): QRS/T angle, Cornell voltage, Cornell product, LVM, 
net T wave amplitude in leads V5 and V1, and ST depression.  The QRS/T angle was 
defined as the angle between the mean QRS and T wave vectors (16).  QRS/T angle was 
calculated using a simplified method from the net QRS amplitudes (R – absolute value of 
S or QS, whichever is larger, in leads V6, aVF and V2) and the net T wave amplitudes 
(signed T +signed T prime) in leads V5, aVF and V2.  Cornell-voltage (R wave amplitude 
in lead aVL + Q or QS wave amplitude in lead V3) (17), Cornell product (Cornell voltage 
x QRS duration) (18), and LVM predicted by a multivariate model (19) were used as 
measures of left ventricular hypertrophy (LVH).  The LVM model adjusted for Cornell 
voltage and body weight.  T waves were obtained by calculating mean and peak T wave 
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values in lead V5, whereas for T wave amplitude in lead V1, only the mean value was 
used.  ST depression was evaluated using ST amplitude in lead V5 at 60 ms past the end 
of the QRS interval (the J-point) from the Marquette-GE program.   
 
4.3.3 Statistical analysis 
All analyses were performed with SAS 9.1 (SAS Institute, Inc., Cary, NC).  
Nested random effects models were used to partition the total variance into between-
participant, between-visit and within-visit components of variance.  The within-visit 
component of variation represents methodological variability.  The within-participant 
component of variation, the summation of the between-visit and within-visit components 
of variance, represents a combination of temporal biological and methodological 
variability.  In addition, the square roots of the between-participant, between-visit and 
within visit variances were calculated.  The coefficient of variation for each component 
was calculated as the ratio of the square root of its variance to its grand mean, multiplied 
by 100.  The ICC coefficient was calculated for each of the ECG measures and 95% 
confidence intervals were derived using the Delta method (20).  The ICC coefficient is 
the between-participant variance over the total variance (sum of between-participants, 
between-visits and within-visit variance) and can be interpreted as the correlation 
between ECG measures at different visits.  Furthermore, the sex-specific ICC coefficient 
was calculated for each of the ECG measures and 2000 samples were used to calculate 
confidence intervals using bootstrapping methods (21).  The following criteria were used 
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to characterize short-term repeatability: poor, 0-0.40; moderate, 0.41-0.60; good, 0.61-
0.80; and excellent, 0.81-1.0.   
 
4.4 Results 
 Age in years, race/ethnicity, sex and BMI of the population were described as 
means or proportions (Table 1).  Table 2 presents mean values and standard deviations 
calculated by visit (1 or 2) and measurement of ECG (1 – 4) for each ECG measure.  The 
mean values for the ECG measures were fairly stable across ECG recording sessions 
(Table 2).  Most of the total variation of ECG variables was due to between-participant 
variation (Table 3), with coefficients of variation ranging from 31.07 to 159.06.  The ICC 
coefficients were greater than 0.86, and thus indicate excellent short-term repeatability 
(Table 4).  The LVM measure had the highest short-term repeatability value (ICC 
coefficient = 0.99).  The sex-specific ICC coefficients were greater than 0.73, and thus 
indicate good to excellent short-term repeatability.   
 
4.5 Discussion 
 The data from this study indicate excellent short-term repeatability of spatial 
QRS/T angle, Cornell voltage, Cornell product, LVM, T net amplitudes in leads V5 and 
V1, ST depression measured from a twelve-lead ECG.   
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 Previous studies (12, 13) have examined the short-term repeatability of T wave 
axis, QT interval, heart rate and heart rate variability in the ECG Repeatability Study 
using a standard ten-second, twelve-lead ECG.  In general, they found that the between-
participant component represented most of the total variability compared to between-visit 
and within-visit components of variance, with the exception being SDNN and rMSSD, 
measures of heart rate variability.  The high between-participant component of variance 
has been attributed to the highly standardized procedures for collection and reading of 
ECGs which maximizes between-participant biological variability (13).  Similar to 
Schroeder and colleagues (12), who evaluated mean heart rate and RR interval, our ICC 
coefficients for ECG measures represent excellent short-term repeatability.  Vaidean and 
colleagues (13) observed a range ICC coefficients (0.61 to 0.92) for measures of the QT 
interval, whereas, comparable to our study, both T wave axis and heart rate had excellent 
short term repeatability, 0.87 and 0.82, respectively. 
 Within-participant variability can be explained by a combination of temporal 
biological and methodological variation.  In order to minimize the influence of 
methodological variation, the ECG Repeatability Study applied strict quality control 
approaches that were comparable to standardized protocol used in the ARIC Study (22).  
Despite adherence to a standardized measurement protocol for data acquisition and 
processing by trained and certified technicians, operator-related, procedure-related and 
biological sources of variability may exist.  Electrode misplacement can occur and in a 
systematic fashion even when staff are trained and aware that they are being evaluated 
(23).  The electrodes in our study remained in place within visits, but electrode placement 
between visits may have contributed to variability (24).  As a weakness of this study, we 
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were unable to compare between-technician and within-technician differences, because 
many ECG recordings had to be performed by the same technician in the same visit.  
Various within-participant sources of variability in ECG measures are known to exist that 
are subject to change between visits (9).  However, our study indicates that most of the 
total variation in ECG measurements was due to the between-participant rather than to 
the between-visit component of variance. 
 When Vaidean and colleagues (13) evaluated the sex-specific short-term 
repeatability of QT interval, calculated as a linear function of the RR interval, higher ICC 
coefficient values were observed for men (0.92; 95% confidence interval: 0.88, 0.97) than 
women (0.62; 95% confidence interval:0.41, 0.83).  Although, in our study, there were no 
sex-specific differences in ICC coefficients for Cornell voltage, Cornell product, LVM, 
and net T wave amplitude in leads V5, and V1, there were notable differences for QRS/T 
angle, and ST depression, with women having lower values than men.  Replication 
studies using larger numbers of participants may be informative for the extent of 
variability of spatial QRS/T angle, Cornell voltage, Cornell product, LVM, T net 
amplitudes in leads V1 and V5, and ST depression, by important demographic factors, 
such as age, race/ethnicity and BMI.  
 We found that women had lower ICC coefficients for QRS/T angle and ST 
depression than men.  BMI has been known to impact short-term repeatability of ECG 
measures (9) and may have influenced the ICC coefficient estimates in our study.  In 
support of this hypothesis, we found higher mean BMI values for women than men (data 
not shown).  However, despite sex-specific differences in BMI in our analysis, ICC 
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coefficients for net T wave amplitude in leads V5 and V1, and ECG measures of LVH 
(LVM, Cornell voltage, and Cornell product) were identical by sex. 
 Adding new information to the published literature, we estimated the short-term 
repeatability of spatial QRS/T angle, Cornell voltage, Cornell product, LVM, T net 
amplitudes in leads V1 and V5, and ST depression.  Complementing this, we presented 
the proportion of total variance due to between-participant, between-visit and within-visit 
components of variance.  We additionally presented our short-term repeatability results 
by sex.  Lastly, our study employed the data collecting and processing protocols used by 
the ARIC Study (22), which is comparable to that used by several other large-scale 
population-based studies.  Generalizability of our estimates to other comparable 
populations is aided by this. 
 In conclusion, high short-term repeatability results for select ECG measures in the 
present study indicate that they can be reliably measured in epidemiologic studies when 
carefully standardized protocols for ECG acquisition and processing are employed.  The 
high short-term repeatability supports analyses of their effects on cardiovascular disease 
outcomes.   
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 Table 13. (MS I: Table 1) Characteristics of participants, the ECG Repeatability Study(N=63) 
Characteristic Mean (standard deviation) or N (percent) 
Age (years) 52 (5) 
Black ethnicity 20 (32%) 
Female sex 31 (49%) 
Body mass index (kg/m2) 27 (5) 
* The study population included 63 healthy participants, ages 45 to 64 years, with no reported use of class Ia  
antiarrhythmics, no artificial pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or pregnancy.  
† Abbreviations: ECG, electrocardiogram; kg, kilogram; m, meter. 
 
Table 14. (MS I: Table 2) Means (standard deviations) for ECG measures, the ECG  
Repeatability Study (N=63) 
ECG Measure First Visit  Second Visit 
 ECG1 ECG2  ECG3 ECG4 
QRS/T angle (°) 79 (26) 80 (26)  78 (26) 77 (27) 
Cornell voltage (μV) 1213 (509) 1224 (517)  1214 (496) 1204 (494) 
Cornell product (μV.s) 114 (51) 116 (53)  114 (49) 114 (49) 
Left ventricular mass (g) 154 (28) 154 (28)  154 (27) 154 (27) 
TnetV5 amplitude (μV) 404 (211) 398 (207)  418 (224) 415 (218) 
TnetV1 amplitude (μV) 84 (155) 88 (149)  92 (160) 98 (155) 
ST60V5 (μV) 49 (31) 50 (31)  52 (33) 51 (33) 
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* The study sample included 63 healthy participants, ages 45 to 64 years, with no reported use of class Ia antiarrhythmics,  
no artificial pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or pregnancy. 
† Abbreviations: ECG, electrocardiogram; °, degree; µV, micro-volts; g, gram; s, seconds.  
‡ Definitions: ECG1, ECG parameter estimate at visit 1; ECG2, ECG parameter estimate at visit 1, approximately 1 minute  
after ECG1; ECG3, ECG parameter estimate at visit 2; ECG4; ECG parameter estimate at visit 2, approximately 1 minute  
after ECG3; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, 
 aVF and V2; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass,  
estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;  
ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
 
    
 
 Table 15. (MS I: Table 3) Square root of variance components and coefficients of variation  
of ECG measures, the ECG Repeatability Study (N=63) 
ECG Measure Square Root Coefficient of Variation 
QRS/T angle (°) 
  Between-participant 
  Between-visit 
  Within-visit 
 
24.36 
9.28 
2.21 
 
31.07 
11.84 
2.82 
ST60V5 (μV) 
  Between-participant 
  Between-visit 
  Within-visit 
 
29.57 
10.79 
4.61 
 
58.61 
21.39 
9.14 
TnetV5 amplitude (μV) 
  Between-participant 
  Between-visit 
  Within-visit 
 
203.70 
65.96 
18.59 
 
49.85 
16.14 
4.55 
TnetV1 amplitude (μV) 
  Between-participant 
  Between-visit 
  Within-visit 
 
143.55 
52.68 
24.40 
 
159.06 
58.37 
27.04 
Left ventricular mass (g) 
  Between-participant 
  Between-visit 
  Within-visit 
 
27.32 
2.55 
1.19 
 
17.73 
1.65 
0.77 
Cornell voltage (μV) 
  Between-participant 
  Between-visit 
  Within-visit 
 
496.722 
73.58 
45.17 
 
40.92 
6.06 
3.72 
Cornell product (μV.s) 
  Between-participant 
  Between-visit 
  Within-visit 
 
49.67 
8.04 
5.10 
 
43.35 
7.02 
4.45 
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* The study sample included 63 healthy participants, ages 45 to 64 years, with no reported use of class Ia  
antiarrhythmics, no artificial pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or pregnancy.  
The coefficient of variation is the product of 100 and the square root of its variance/grand mean.   
† Abbreviations: ECG, electrocardiogram; °, degree; µV, micro-volts; g, gram; s, seconds. 
‡ Definitions: QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads  
V5, aVF and V2; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass,  
estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;  
ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
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Table 16. (MS I: Table 4) Reliability coefficients for ECG measures, the ECG Repeatability  
Study (N=63) 
ECG Measure Reliability Coefficient
 Female and Male Female Male 
QRS/T angle (°) 0.87 (0.81, 0.93) 0.75 (0.73, 0.78) 0.93 (0.92, 0.95) 
Cornell voltage (μV) 0.97 (0.96, 0.98) 0.97 (0.97, 1.00) 0.97 (0.00, 1.00) 
Cornell product (μV.s) 0.96 (0.95, 0.98) 0.97 (0.75, 0.98) 0.96 (0.97, 1.00) 
Left ventricular mass (g) 0.99 (0.98, 0.99) 0.99 (0.99, 0.99) 0.97 (0.97, 0.98) 
TnetV5 amplitude (μV) 0.90 (0.85, 0.95) 0.85 (0.83, 1.00) 0.91 (0.81, 1.00) 
TnetV1 amplitude (μV) 0.86 (0.85, 0.86) 0.74 (0.70, 1.00) 0.86 (0.00, 1.00) 
ST60V5 (μV) 0.86 (0.80, 0.92) 0.73 (0.70, 0.75) 0.84 (0.82, 0.85) 
* The study sample included 63 healthy participants, ages 45 to 64 years, with no reported use of class Ia antiarrhythmics,  
no artificial pacemaker or conditions such as renal failure, heart failure, diabetes mellitus or pregnancy. The reliability  
coefficient is the between-participant variance/total variance of the ECG measure. 
† Abbreviations: ECG, electrocardiogram; °, degree; µV, micro-volts; g, gram; s, seconds. 
‡ Definitions: QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads  
V5, aVF and V2; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass,  
estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;  
ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
CHAPTER 5 
 
Results Manuscript II: Long-term changes of ECG predictor variables.  The 
Atherosclerosis Risk in Communities (ARIC) Study 
 
5.1 Abstract 
 Background: Few have described the long-term changes in electrocardiogram 
(ECG) variables in population samples, or in individuals with coronary heart disease 
(CHD), diabetes or hypertension status.  Since a number of ECG measurements are 
predictive of downstream cardiovascular and cerebrovascular diseases, their changes over 
time are of clinical and public health interest. 
 Methods: We evaluated the changes over an average of 9 years (range = 7 – 12 
years) in selected ECG measures (spatial QRS/T angle, QT interval, Cornell voltage, 
Cornell product, left ventricular mass (LVM), T net amplitudes in leads V5 and V1, and 
ST depression) in the population-based cohort of the Atherosclerosis Risk in 
Communities (ARIC) Study.  These changes were characterized by diabetes, 
hypertension and CHD status at intake.  Linear and logistic regression modeling was used 
to evaluate the long-term changes of ECG measures, as continuous (n = 13901) and 
 categorical variables (n range = 10239 – 12870), adjusting for age, race/center, sex and 
baseline ECG measure.    
 Results: In general, higher mean annual rates of change in QRS/T angle, QT 
interval, Cornell voltage, Cornell product, LVM, and T net amplitude in lead V1, and 
lower mean annual rates of change in T net amplitude in lead V5 and ST depression, were 
observed in persons with CHD, diabetes and hypertension compared to those without; 
and thus, a higher proportion of ECG change was present in persons with these 
conditions; the exception being with LVM, where lower values, rather than the expected 
higher values, of mean rates of change per year were observed in diabetics and 
hypertensives.   
 Conclusions: Our results suggest that long-term changes in ECG measures are of 
small magnitude in mostly healthy adults sampled from the population.  Long-term 
changes of ECG measures associated with cardiovascular risk are of greater magnitude in 
persons with CHD, diabetes or hypertension, compared with persons without these 
conditions.   
 
5.2 Introduction 
Epidemiologic studies have demonstrated that the changes of abnormalities in 
various resting, standard twelve-lead electrocardiogram (ECG) measures are associated 
with subsequent cardiovascular morbidity and mortality (1-4).  However, little is known 
about the long-term changes in ECG measures in groups defined by demographic 
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 characteristics, cardiovascular risk or morbidity.  This information may aid risk 
stratification in clinical encounters and assist researchers in characterizing the role of 
ECG measurements on incident cardiovascular morbidity and mortality.  There is a 
paucity of information describing the changes of ECG variables over the long term.  
Research has focused on the long-term changes of ECG variables in the course of disease 
(2, 5-7) and in response to treatments (5-7), but only two studies to our knowledge 
evaluated the long-term changes of ECG measures, specifically heart rate and heart rate 
variability, in relatively healthy persons (8, 9).   
To our knowledge, no work has focused on the descriptive epidemiology of the 
long-term changes of various ECG variables in relatively healthy middle-aged 
populations, taking into account clinical risk factors for cardiovascular disease morbidity 
and mortality.  Therefore, we examined the changes of several continuous and categorical 
ECG measurements over the course of an average of nine years of follow-up in the 
Atherosclerosis Risk in Communities (ARIC) Study.  Because of their demonstrated 
relevance as cardiovascular risk predictors we focused on spatial QRS/T angle, QT 
interval, Cornell voltage, Cornell product, left ventricular mass (LVM), T net amplitudes 
in leads V5 and V1, and ST depression, and examined whether temporal changes in these 
measures differed by coronary heart disease (CHD), diabetes and hypertension status at 
cohort intake.  We stratified by CHD, diabetes and hypertension status, since the majority 
of heart failure cases are attributable to these conditions (10), all of which are treatable or 
preventable (11).   
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 5.3 Material and methods  
5.3.1 Study population  
The ARIC Study combines epidemiologic surveillance of four communities and a 
community-based prospective cohort designed to investigate the etiology and natural 
history of atherosclerosis and its sequelae.  From 1987 to 1989, the ARIC Study cohort of 
15,792 black and white participants aged 45 to 64 years was drawn from four 
communities in North Carolina (NC), Mississippi (MS), Minnesota (MN), and Maryland 
(MD).  Two of the population samples (Washington County, MD and Minneapolis, MN 
suburbs) were mostly white.  Blacks were over-sampled in Forsyth County, NC (12% 
black) and were exclusively sampled in Jackson, MS to provide statistical power to 
investigate findings by race/ethnicity.  Following an extensive baseline examination 
participants were followed via annual telephone interviews, clinical examinations 
approximately every three years from 1987 to 1999, and ongoing medical record 
abstraction for hospitalized events and deaths.  Each clinical examination consisted of 
standardized interviews, anthropometric and blood pressure measurements, venipuncture 
for blood samples and a twelve-lead standard ECG.  A comparison of study participants 
to non-respondents has been described (12).  The Institutional Review Boards at each of 
the institutions involved approved the study, and all participants gave informed, written 
consent.   
 
5.3.2 ECG methods 
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 The ARIC Study used a standardized protocol for the acquisition of and 
processing of ECGs (13).  All ECG recordings were carried out in a quiet, temperature-
controlled room.  After participants rested in the supine position for fifteen minutes, 
trained and certified ECG technicians recorded ten-second, twelve-lead ECGs using 
Kendall Q-Trace 5400 Ag/AgCl electrodes (Ludlow Co, Chicopee, Mass).  The E-V6 
Halfpoint method (14) was used when recording ECGs using a MAC Personal 
Cardiographer (Marquette Electronics, Inc, Milwaukee, WI).  The E-V6 Halfpoint 
method improves the precision and the repeatability of chest electrode positioning by 
placing the V4 electrode at the horizontal level of the fifth intercostal space at the half-
way point between the midsternal line and the left midaxillary line (V6 location).  ECGs 
were digitized and sent via modem after each recording session to the Epidemiological 
Cardiology Research (EPICARE) Center (Wake Forest University, Winston-Salem, NC).  
The EPICARE Center, blinded to participant identity processed the ECGs using the 12SL 
version of the Marquette GE program.   
The following ECG measures were generated at the EPICARE Center using 
methods previously described (15): spatial QRS/T angle, QT interval, Cornell voltage, 
Cornell product, LVM, T net amplitudes in leads V5 and V1, and ST depression.  The 
QRS/T angle was defined as the angle between the mean QRS and T wave vectors (16).  
The QRS/T angle was defined as the angle between the mean QRS and T-wave vectors 
(16).  QRS/T angle was calculated using a simplified method from the net QRS 
amplitudes (R – absolute value of S or QS, whichever is larger, in leads V6, aVF and V2) 
and the net T wave amplitudes (signed T +signed T prime) in leads V5, aVF and V2.  QT 
interval, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted for 
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 heart rate as a linear function of the RR interval (17).  Cornell voltage (R wave amplitude 
in lead aVL + Q or QS wave amplitude in lead V3) (18), Cornell product (Cornell voltage 
x QRS duration) (19), and LVM predicted by a multivariate model (20) were used as 
measures of left ventricular hypertrophy.  The LVM model adjusted for Cornell voltage 
and body weight.  T waves were obtained by calculating mean and peak T wave values in 
lead V5, whereas for T wave amplitude in lead V1, only the mean value was used.  ST 
depression was evaluated using ST amplitude in lead V5 at 60 ms past the end of the QRS 
interval (the J-point) from the Marquette-GE program.   
The following participant-specific linear regression model was used to derive the 
exposure variable, continuous change of the ECG measure (Bi): yij = Ai + Bi tij, where y = 
the ECG variable value, i = 1, 2, 3…n participants, j = 1, 2, 3 or 4 visits, and t was the 
time between ARIC Visit 1 and subsequent visits.  The continuous change ECG variable 
is the average rate of change per year and summarizes the longitudinal information for 
each participant. 
We additionally constructed categorical change ECG variables.  To provide 
comparability with an earlier analysis in the ARIC Study, we used cut points for ECG 
variables shown to be associated with incident heart failure used by Rautaharju and 
colleagues (15).  ECG variables were defined using the following cut points for men (M) 
and women (W):  QRS/T angle (°): M ≥ 107, W ≥ 89; QT interval (ms): M ≥ 436, W ≥ 
442; Cornell voltage (μV):  M ≥ 2650, W ≥ 1673; Cornell product (μV.s): M ≥ 207, W ≥ 
152; LVM (g): M ≥ 204, W ≥ 162; TnetV5 amplitude (μV): M ≤ 122, W ≤ 107; TnetV1 
amplitude (μV): M ≥ 307, W ≥ 151; and ST60V5 (μV): M ≤ 5, W ≤ -7.  For each ECG 
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 variable, categorical change was defined as ever exceeding the cut point (“1”) over ARIC 
visits, or else “0”.   
 
5.3.4 Covariates 
The covariates selected for the analysis were age (years) and sex (male or female).  
A race/center variable was created by combining each participant’s self-reported 
race/ethnicity (black or white) with their respective study center (Forsyth County, NC, 
Jackson, MS, Minneapolis, MN and Washington County, MD).  Additional covariates 
selected for the analysis include hypertension (yes or no), diabetes (yes or no) and CHD 
(yes or no) at the baseline examination.  Blood pressure, lipids and glucose were 
measured according to standard ARIC procedures (13).  Participants were asked to fast 
twelve hours before blood draw and actual fasting times were recorded.  Blood was 
drawn from an antecubital vein of seated participants, serum was centrifuged, and frozen 
samples were shipped to central laboratories for analysis.  The mean of the last two of 
three systolic and diastolic sitting blood pressure measurements obtained from a random-
zero sphygmomanometer was used for measures of blood pressure.   
Hypertension was defined as a systolic blood pressure value equal to or greater 
than 140 mmHg, a diastolic blood pressure value equal to or greater than 90 mmHg, or 
use of blood pressure lowering medications in the past two weeks (21).  Pre-hypertension 
was defined as a systolic blood pressure value equal to or greater than 120 mm Hg but 
less than 140 mm Hg or a diastolic blood pressure value equal to or greater than 80 mm 
Hg but less than 90 mm Hg (21).  Type II diabetes mellitus was defined as a fasting 
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 serum glucose level of 7.0 mmol/L or more (126 mg/dL), nonfasting glucose level of 
11.1 mmol/L or more (200 mg/dL), participant report of a physician diagnosis of 
diabetes, or current use of diabetes medication (22).  Pre-diabetes was defined as a fasting 
serum glucose level of 6.1 mmol/L (110 mg/dL) or more but less than 7.0 mmol/L (126 
mg/dL) (22).  CHD at baseline was defined from a reported history of physician-
diagnosed myocardial infarction, coronary artery bypass surgery, coronary angioplasty, 
or evidence of a previous myocardial infarction on an ECG.   
 
5.3.5 Statistical analysis 
We excluded participants with fewer than two ECGs (n = 1340), with a QRS 
interval greater than or equal to 120 ms (n = 574), with a race/ethnicity other than black 
or white (n = 48), and black participants in Minneapolis, MN or Washington County, MD 
(n = 55).  The final sample size for a cohort so defined (“cohort 1”) was 13,901.  
Analyses evaluating the continuous change of ECG variables utilized cohort 1 data, 
whereas analyses evaluating categorical ECG change variables required the exclusion of 
participants with missing ECGs at baseline (n range = 228 – 287) and whose 
measurements parameters at baseline exceeded the established cut points mentioned 
above (n range = 1287 – 4148; cohorts 2 – 9).  Cohorts 2 through 9 excluded those whose 
ECG measures at baseline exceeded the established cut point because they already had a 
higher risk for incident heart failure at baseline.  The final sample sizes for cohorts 2, 3, 
4, 5, 6, 7, 8 and 9 were 10239, 12870, 12735, 12230, 12142, 12033, 12126 and 12004, 
respectively.   
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 Baseline characteristics and ECG measures were described as means and 
proportions in the full cohort and cohort 1.  Logistic and linear regression were used to 
compare adjusted categorical and continuous changes of the ECG measures over ARIC 
visits 1 through 4, stratified by CHD, diabetes and hypertension status at baseline.  
QRS/T angle, Cornell voltage, Cornell product, T net amplitudes in leads V5 and V1, and 
ST depression were adjusted for age, race/center-, sex- and baseline ECG measure, while 
QT interval and LVM were adjusted for age and baseline ECG measure only since by 
definition these ECG measures were already adjusted for race/ethnicity and sex.  A two-
tailed p-value <0.05 was required for statistical significance.  All analyses were 
performed with SAS 9.1 (SAS Institute, Inc., Cary, NC).   
 
5.4 Results 
Selected baseline characteristics of the full ARIC cohort and cohort 1 (see 
Methods), are presented in Table 1.  Participants in cohort 1 and cohorts 2 – 9 (data not 
shown) were comparable to the full ARIC cohort in terms of age and sex, were more 
likely to be white and female and were less likely to have CHD, diabetes and 
hypertension.   
Table 2 presents an overview of the ECG measures at baseline for the full cohort 
and cohort 1.  It is important to note that only 13725 participants have ECGs information 
for the baseline visit; however these same participants still have two or more ECGs and 
thus qualify for inclusion into cohort 1.  Compared to the full cohort, participants in 
cohort 1 had lower mean values for Cornell voltage, Cornell product, T net amplitude in 
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 lead V1, had a higher mean value for T net amplitude in lead V5, had similar values for 
QRS/T angle, QT interval, LVM, and ST depression, and were less likely to cross the 
threshold cut points established for categorical ECG variables.   
The age-, race/center-, sex and baseline ECG-adjusted changes of ECG variables 
over the average length of follow-up (9 years) are presented in Table 3, stratified by CHD 
status at baseline.  Participants with a CHD manifestation at cohort intake had higher 
mean rates of change per year for QRST/T angle, QT interval, Cornell voltage, Cornell 
product, LVM, T net amplitude in lead V1, and lower mean rates of change per year for T 
net amplitude in lead V5 and ST depression.  Participants with CHD were more likely to 
cross pre-specified cut points over ARIC visits for QRS/T angle, QT interval, Cornell 
voltage, Cornell product, T net amplitudes in leads V5 and V1 and ST depression, 
compared to participants without CHD; no differences were observed by CHD status for 
LVM.   
The age-, race/center-, sex and baseline ECG-adjusted mean changes of ECG 
variables per year, stratified by diabetes and hypertension status are presented in Tables 4 
and 5, respectively.  The mean changes per year of continuous ECG variables differed by 
diabetes status, with greater values observed for the temporal change in QRS/T angle and 
T net amplitude in leads V5 and V1 in pre-diabetics compared to non-diabetics.  Lower 
values were observed for continuous annual change in Cornell voltage, Cornell product, 
and LVM when pre-diabetics were compared to non-diabetics, while mean annual change 
values were comparable for QT interval and ST depression.  Participants with diabetes at 
baseline had higher mean rates of change per year for QRST/T angle, QT interval, 
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 Cornell voltage, Cornell product and T net amplitude in lead V1, and lower mean rates of 
change per year for LVM, T net amplitude in lead V5 and ST depression compared with 
non-diabetics.  When comparing the changes in categorical ECG variables, minimal 
changes were observed among pre-diabetics compared with non-diabetics, although 
statistically significant differences were observed for QRS/T angle, QT interval, Cornell 
voltage, Cornell product and ST depression.  Whereas, larger proportions of participants 
with diabetes crossed pre-specified cut points during follow-up for all ECG measures 
(QRS/T angle, QT interval, Cornell voltage, Cornell product, LVM, T net amplitudes in 
leads V1 and V5 and ST depression) compared with non-diabetics.  
As shown in Table 5, all continuous measures of annualized change differed 
significantly by hypertension status for all ECG variables when pre-hypertensives and 
hypertensives were compared with normotensives; the only exception being LVM when 
pre-hypertensives were compared with normotensives.  Greater mean values of rate of 
change per year were observed for QRS/T angle, QT interval, Cornell voltage, Cornell 
product and T net amplitude in lead V1 and lower values were observed for T net 
amplitude in lead V5 and ST depression when pre-hypertensives or hypertensives were 
compared with normotensives.  A lower mean value of rate of change per year was 
observed for LVM when hypertensives were compared with normotensives.  Furthermore, 
changes in categorical ECG variables statistically significantly differed by hypertension 
status for all ECG measures, where larger proportions of pre-hypertensive and 
hypertensive participants crossed the pre-specified ECG measure cut points compared 
with normotensives.   
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 5.5 Discussion 
 Our results indicate that the long-term changes in ECG measures in mostly 
healthy, middle-aged adults sampled from the population are of small magnitude.  Our 
analyses also show that such long-term changes of ECG measures are generally greater in 
magnitude in persons with CHD, diabetes or hypertension, compared to their peers in this 
cohort without these conditions.   
 Long-term changes of small magnitude in QRS/T angle, QT interval, Cornell 
voltage, Cornell product, LVM, T net amplitude in leads V5 and V1, and ST depression 
were observed during a follow-up ranging from 7 to 12 years (average 9 years), but often 
statistically significant changes were observed by CHD, diabetes and hypertension status, 
adjusting for age, race/center, sex and baseline ECG measure.   
Higher values of QRS/T angle, QT interval, Cornell voltage, Cornell product, 
LVM and T net amplitude in lead V1, and lower values for T net amplitude in lead V5 and 
ST depression have been shown to be associated with increased risk for heart failure in 
the ARIC Study, the Women’s Health Initiative and the Strong Heart Study (15, 23, 24).  
The mechanisms linking these ECG variables with incident heart failure are unclear.  It 
has been posited that the ECG measures studied may be markers of ventricular 
remodeling and evolving CHD (15, 23-25).  In our study and as expected, the observed 
temporal change in ECG measures tended to be in the direction of increasing risk among 
those with CHD, diabetes, or hypertension manifest at the baseline examination.  
Exceptions include LVM in diabetics and in hypertensives, where mean rates of change 
per year were lower in diseased participants compared with non-diseased.   
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 Despite the important role of the temporal evolution in ECG variables in the 
context of clinical and demographic risk factors for predictions of cardiovascular 
morbidity and mortality, little prospective research has described the long-term changes 
of ECG measures in relatively healthy populations.  A previous study conducted by Levy 
and colleagues presented categorical changes of R wave and S wave voltages and 
repolarization abnormalities by sex in participants with left ventricular hypertrophy in the 
Framingham Heart Study (2).  Although it would appear that there were no sex-
differences in ECG voltages and repolarization abnormalities, no statistical test was 
performed.  Okin and colleagues showed in hypertensive patients with ECG left 
ventricular hypertrophy receiving antihypertensive treatment, that Cornell product and 
Sokolow-Lyon voltage decreased to a greater degree in men than in women (6, 7), in 
non-diabetics than in diabetics (5, 6), and in participants < 65 years compared to those ≥ 
65 years of age (6).  However, patients in this study were selected based on moderate-to-
severe hypertension and elevated Cornell product and Sokolow-Lyon voltages, and thus 
results cannot be generalized to healthier populations.  Lastly, Schroeder and colleagues 
evaluated measures of heart rate variability by diabetes (8) and hypertension (9) status in 
the ARIC Study over a mean of 9 years of follow-up and concluded that there were no 
differences in the rate of change in heart rate variability by these conditions. 
 In contrast to previous studies of the long-term changes of ECG measures, our 
study is the first to quantify the long-term changes of a wide array of ECG measures, 
inclusive of categorical and continuous measures, and to examine their temporal change 
by CHD, diabetes and hypertension status while adjusting for baseline ECG, age, 
race/ethnicity and sex.  Our study was based on an extended follow-up of a large cohort, 
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 with standardized risk factor assessment of men and women from diverse communities in 
the US population.  Lastly, an important strength of this study is its reliance on a strict 
and standardized protocol for data collection and processing of ECGs throughout the 
study. 
 There are limitations to this study for the readers to consider.  The yearly rates of 
change were estimated from triennial re-examination points.  Considering the small 
magnitude of the average change in ECG measures seen in individuals without manifest 
morbidity at baseline our inability to measure change in intervals smaller than three years 
does not represent a significant shortcoming, although estimated from middle-aged 
persons who survived from one ARIC visit to the next.  As another limitation, mean 
annual changes in ECG measures were assessed in populations (cohort 1 and cohorts 2-9 
[data not shown]) that tended to be healthier than the original cohort.  As a result, the 
long-term changes in ECG measures by CHD, diabetes and hypertension status were 
probably underestimated.  Lastly, fixed sex-specific cut point values were used to classify 
the ECG measures in our analysis.  It is possible that the appropriateness of these cut 
points may not generalize to other population groups.  It should also be mentioned that 
other risk factors such as low physical activity, body mass index, and smoking status 
deserve attention in future analyses of the long-term changes of ECG variables. 
 To our knowledge, ours is the most extensive study of the long-term changes of 
select ECG measures to date.  Our results suggest that mean long-term changes in most 
ECG measures known to predict cardiovascular events are of small magnitude in mostly 
healthy, middle-aged adults sampled from the population and followed for an average of 
9 years.  Our results also suggest that CHD, diabetes and hypertension can modify the 
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 rate of long-term change in these ECG measures: the magnitude of the changes observed 
in the latter groups was greater than that seen in the cohort members without these 
morbid conditions.  Replication of these analyses in different populations and with 
consideration of other conditions associated with cardiovascular risk will improve our 
understanding of the contribution of ECG measures and their change on the risk of 
cardiovascular outcomes. 
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 Table 17. (MS II: Table 1) Means (standard deviations) and proportions of participants’ characteristics at the baseline examination (1987-
1989), the Atherosclerosis Risk in Communities (ARIC) Study 
Covariate Mean (Standard deviation) or n (percent) 
 
Full cohort 
(n=15792) 
 Cohort 1*  
(n=13901) 
Age (years) 
  < 50 
  50-54 
  55-59 
   60 
  Mean  
 
4235 (26.8%) 
4097 (25.9%) 
3852 (24.4%) 
3608 (22.9%) 
54.2 (5.8) 
 
 
3827 (27.5%) 
3681 (26.5%) 
3372 (24.3%) 
3021 (21.7%) 
54.0 (5.7) 
Sex 
  Women  
  Men 
 
8710 (55.2%) 
7082 (44.9%) 
 
7829 (56.3%) 
6072 (43.7%) 
Race/ethnicity 
  White 
  Black 
 
11478 (72.7%) 
4266 (27.0%) 
 
10420 (75.0%) 
3481 (25.0%) 
Race/Center 
  White/Minneapolis, MN 
  White/Washington County, MD 
  Black/Jackson, MS 
  White/Foryth County, NC 
  Black/Forsyth County, NC 
 
4009 (25.4%) 
4020 (25.5%) 
3728 (23.6%) 
3531 (22.4%) 
483 (3.1%) 
 
3662 (26.3%) 
3581 (25.8%) 
3103 (22.3%) 
3177 (22.9%) 
378 (2.7%) 
Coronary heart disease 
  No 
  Yes 
 
14682 (95.0%) 
766 (5.0%) 
 
13072 (96.0%) 
551 (4.0%) 
Non-diabetic 
Prediabetic 
Diabetic 
12051 (77.0%) 
1723 (11.0%) 
1870 (12.0%) 
10871 (78.7%) 
1452 (10.5%) 
1486 (10.8%) 
Normotensive 
Pre-hypertensive 
Hypertensive 
6441 (41.0%) 
3767 (24.0%) 
5504 (35.0%) 
5880 (42.5%) 
3349 (24.2%) 
4605 (33.3%) 
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Definitions: *Cohort 1, black or white participants with at least two electrocardiograms (ECGs) between visits 1-4, with a QRS interval < 120 ms; coronary heart disease, history 
of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood glucose < 110 mg/dL; pre-diabetics, fasting blood glucose 110-125 
mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; 
normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-140 mm Hg or diastolic blood 
pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti-hypertension medications. 
 
 
 
  
 Table 18. (MS II: Table 2) Means (standard deviations) of ECG measures and proportion exceeding thresholds for risk of heart failure at 
the baseline examination (1987-1989), the Atherosclerosis Risk in Communities (ARIC) Study 
ECG Measure Mean (Standard deviation) or n (percent) 
 
Full cohort*  
(n=15564) 
 Cohort 1† 
(n=13725) 
QRS/T angle (°) 
  Male ≥ 107, female ≥ 89 
78.1 (31.5) 
4148 (26.7%)  
77.0 (30.2) 
3480 (25.4%) 
QT interval (ms) 
  Male ≥ 436, female ≥ 442 
416.4 (17.4) 
1287 (8.3%) 
415.2 (15.7) 
866 (6.3%) 
Cornell voltage (μV)   
  Male ≥ 2650, female ≥ 1673 
1248.7 (562.8) 
1307 (8.4%) 
1220.6 (524.6) 
1003 (7.3%) 
Cornell product (μV.s) 
  Male ≥ 207, female ≥ 152 
117.8 (64.5) 
2023 (13.0%) 
112.7 (54.8) 
1508 (11.0%) 
Left ventricular mass (g) 
  Male ≥ 204, female ≥ 162 
153.9 (30.3) 
1979 (12.8%) 
152.8 (29.6) 
1584 (11.5%) 
TnetV5 amplitude (μV) 
  Male ≤ 122, female ≤ 107 
281.3 (186.6) 
2116 (13.6%) 
287.5 (178.3) 
1702 (12.4%) 
TnetV1 amplitude (μV)   
  Male ≥ 307, female ≥ 151 
71.1 (159.0) 
2003 (12.9%) 
67.4 (146.6) 
1614 (11.8%) 
ST60V5 (μV) 
  Male ≤ 5, female ≤ -7 
33.7 (38.6) 
2106 (13.5%) 
33.9 (35.9) 
1734 (12.6%) 
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Abbreviation: ECG. Electrocardiograph 
Definitions: *Full cohort with ECGs at Visit 1, approximately 15564 depending on the ECG measure; † Cohort 1, black or white participants with at least two ECGs between visits 
1-4, with a QRS interval < 120 ms. It is important to note that approximately 13725 participants have ECGs information for the baseline visit; QRS/T angle, calculated using 
QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QTrr, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted for 
heart rate as a linear function of the RR-interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a 
multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in 
lead V5. 
 
 
 
 
 
 
 
 
 
 
 
  
 Table 19. (MS II: Table 3) Race/center-, sex-, age- and baseline ECG-adjusted* means (standard deviations) of change in ECG measures 
and proportions of participants that exceed thresholds for risk of heart failure over mean follow-up of 9 years, by CHD status at baseline, 
the Atherosclerosis Risk in Communities (ARIC) Study   
Measures of ECG change Mean (95% confidence interval) or percent (95% confidence interval) 
 No CHD (n=13072)†  CHD (n=551)† 
QRS/T angle (°) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0014 (0.0013, 0.0014) 
22% (22%, 23%) 
 
 
0.0056 (0.0052, 0.0060)‡ 
41% (37%, 45%)‡ 
QT interval (ms)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0020 (0.0019, 0.0020) 
17% (17%, 18%) 
 
 
0.0026 (0.0023, 0.0029)‡ 
21% (19%, 23%)‡ 
Cornell voltage (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0394 (0.0382, 0.0406) 
8% (7%, 9%) 
 
0.0709 (0.0650, 0.0767)‡ 
14% (12%, 17%)‡ 
Cornell product (μV.s) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0046 (0.0044, 0.0047) 
11% (10%, 12%) 
 
0.0099 (0.0092, 0.0106)‡ 
21% (18%, 24%)‡ 
Left ventricular mass (g)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0017 (0.0017, 0.0018) 
11% (11%, 11%) 
 
0.0026 (0.0024, 0.0028)‡ 
10% (9%, 12%) 
TnetV5 amplitude (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0078 (-0.0083, -0.0073) 
16% (16%, 17%) 
 
-0.0282 (-0.0307, -0.0258)‡ 
24% (21%, 27%)‡ 
TnetV1 amplitude (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0021 (0.0017, 0.0025) 
13% (13%, 14%) 
 
0.0113 (0.0094, 0.0132)‡ 
22% (20%, 25%)‡ 
ST60V5 (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0029 (-0.0030, -0.0028) 
16% (16%, 17%) 
 
-0.0055 (-0.0060, -0.0051)‡ 
25% (22%, 28%)‡ 
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Abbreviations: ECG, electrocardiograph; CHD, coronary heart disease 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; CHD, history of myocardial 
infarction, coronary artery bypass surgery or coronary angioplasty; ‡p< 0.05 compared with no CHD; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 
and Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, 
(RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, 
net T wave amplitude in lead V1;ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more ECG measures 
over visits 1-4 and time from baseline; + change across threshold of risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure. 
 
 
 
  
 Table 20. (MS II: Table 4) Race/center-, sex-, age- and baseline ECG-adjusted* means (standard deviations) of change in ECG and 
proportions of participants that exceed thresholds for risk of heart failure over a mean follow-up of 9 years, by diabetes status at  
baseline, the Atherosclerosis Risk in Communities (ARIC) Study 
Measures of ECG change Mean (95% confidence interval) or percent (95% confidence interval) 
 Non-diabetics (n=10871)†  Pre-diabetics (n=1452)†  Diabetics (n=1486)† 
QRS/T angle (°) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0010 (0.0010, 0.0011) 
21% (21%, 22%) 
 
 
0.0021 (0.0018, 0.0023)‡ 
25% (23%, 26%)‡ 
 
 
0.0045 (0.0043, 0.0048)‡ 
36% (34%, 38%)‡ 
QT interval (ms)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0019 (0.0019, 0.0020) 
17% (16%, 17%) 
 
 
0.0019 (0.0017, 0.0021) 
19% (18%, 20%)‡ 
 
 
0.0026 (0.0024, 0.0028)‡ 
20% (19%, 21%)‡ 
Cornell voltage (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0401 (0.0.0388, 0.0414) 
8% (7%, 9%) 
 
0.0320 (0.0290, 0.0361)‡ 
7% (6%, 8%)‡ 
 
0.0503 (0.0468, 0.0539)‡ 
10% (9%, 12%)‡ 
Cornell product (μV.s) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0046 (0.0045, 0.0048) 
11% (11%, 12%) 
 
0.0040 (0.0036, 0.0048)‡ 
10% (9%, 11%)‡ 
 
0.0065 (0.0061, 0.0070)‡ 
13% (11%, 14%)‡ 
Left ventricular mass (g)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0019 (0.0018, 0.0019) 
10% (10%, 11%) 
 
0.0014 (0.0013, 0.0015)‡ 
11% (10%, 12%) 
 
0.0011 (0.0009, 0.0012)‡ 
15% (14%, 16%)‡ 
TnetV5 amplitude (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0066 (-0.0071, -0.0060) 
16% (15%, 17%) 
 
-0.0110 (-0.0125, -0.0095)‡ 
17% (16%, 18%) 
 
-0.0215 (-0.0230, -0.0200)‡ 
21% (19%, 22%)‡ 
TnetV1 amplitude (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0011 (0.0006, 0.0015) 
13% (13%, 14%) 
 
0.0032 (0.0020, 0.0043)‡ 
12% (11%, 13%) 
 
0.0111 (0.0100, 0.0123)‡ 
19% (17%, 20%)‡ 
ST60V5 (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0028 (-0.0029, -0.0027) 
16% (16%, 17%) 
 
-0.0029 (-0.0032, -0.0026) 
15% (13%, 16%)‡ 
 
-0.0047 (-0.0050, -0.0044)‡ 
21% (19%, 23%)‡ 
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Abbreviation: ECG, electrocardiograph 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; non-diabetics, fasting blood  
glucose < 110 mg/dL;  
pre-diabetics, fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic 
medications, or self-reported physician diagnosis; ‡p < 0.05 compared with non-diabetics; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and  
Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, 
(RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5;  
TnetV1, net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more  
ECG measures over visits 1-4 and time from baseline; + change across threshold of risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart 
failure. 
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Table 21. (MS II: Table 5) Race/center-, sex-, age- and baseline ECG-adjusted* means (standard deviations) of change in ECG measures 
and proportions of participants that exceed thresholds for risk of heart failure over a mean follow-up of 9 years, by hypertension status at 
baseline, the Atherosclerosis Risk in Communities (ARIC) Study 
Measures of ECG change Mean (95% confidence interval) or percent (95 % confidence interval) 
 Normotensives (n=5880)†  Pre-hypertensive (n=3349)†  Hypertensivess (n=4605)† 
QRS/T angle (°) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0007 (0.0006, 0.0008) 
18% (18%, 19%) 
 0.0013 (0.0012, 0.0015)‡ 
22% (21%, 23%)‡ 
 
 
0.0028 (0.0026, 0.0029)‡ 
30% (29%, 32%)‡ 
QT interval (ms)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0016 (0.0015, 0.0016) 
14% (14%, 15%) 
 0.0020 (0.0018, 0.0021)‡ 
17% (16%, 18%)‡ 
 
 
0.0026 (0.0024, 0.0027)‡ 
22% (21%, 23%)‡ 
Cornell voltage (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0338 (0.0320, 0.0356) 
7% (6%, 7%) 
0.0422 (0.0398, 0.0445)‡ 
9% (8%, 10%)‡ 
 
0.0473 (0.0452, 0.0494)‡ 
10% (9%, 11%)‡ 
Cornell product (μV.s) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0039 (0.0037, 0.0042) 
10% (9%, 10%) 
0.0049 (0.0046, 0.0052)‡ 
12% (11%, 13%)‡ 
 
0.0057 (0.0055, 0.0060)‡ 
13% (13%, 14%)‡ 
Left ventricular mass (g)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0018 (0.0017, 0.0019) 
8% (8%, 9%) 
0.0017 (0.0016, 0.0018) 
10% (10%, 11%)‡ 
 
0.0017 (0.0016, 0.0017)‡ 
15% (15%, 16%)‡ 
TnetV5 amplitude (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0044 (-0.0051, -0.0036) 
14% (13%, 14%) 
-0.0070 (-0.0079, -0.0060)‡ 
16% (16%, 17%)‡ 
 
-0.0152 (-0.0160, -0.0143)‡ 
21% (20%, 22%)‡ 
TnetV1 amplitude (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0006 (-0.0012, -0.0000) 
12% (11%, 13%) 
0.0023 (0.0015, 0.0030)‡ 
14% (13%, 15%)‡ 
 
0.0061 (0.0054, 0.0068)‡ 
16% (15%, 17%)‡ 
ST60V5 (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0025 (-0.0027, -0.0024) 
13% (12%, 14%) 
-0.0029 (-0.0031, -0.0028)‡ 
17% (16%, 18%)‡ 
 
-0.0037 (-0.0039, -0.0035)‡ 
21% (20%, 22%)‡ 
Abbreviation: ECG, electrocardiograph 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; normotensives, systolic blood 
pressure (SBP) <  
120 mm Hg or diastolic blood pressure (DBP) < 80 mm Hg; pre-hypertensives, SBP 120-140 mm Hg or DBP 80-90 mm Hg; hypertensives, SBP >140 mm Hg, or DBP > 90 mm 
Hg, and/or use of anti-hypertension medications; ‡p < 0.05 compared with non-hypertensives; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and 
Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, 
(RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, 
net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more ECG 
measures over visits 1-4 and time from baseline; + change across threshold of risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure. 
CHAPTER 6 
 
Results Manuscript III: Temporal changes in ECG variables and incident heart 
failure. The Atherosclerosis Risk in Communities (ARIC) Study 
 
6.1 Abstract 
Background: It has been demonstrated in clinical trials of high risk populations 
that temporal changes in select electrocardiogram (ECG) variables are associated with 
incident heart failure.  However, their impact on heart failure incidence in a relatively 
healthy, population-based cohort has not been assessed.   
Methods: We examined the association between selected ECG measures (spatial 
QRS/T angle, QT interval, Cornell voltage, and Cornell product, left ventricular mass, T 
net amplitudes in leads V1 and V5, and ST depression) and incident heart failure 
hospitalization or death in the Atherosclerosis Risk in Communities (ARIC) Study.  The 
long-term ECG change variables were analyzed as categorical (n range = 9637 – 7812), 
based on sex-specific cut points, and continuous, based on a one standard deviation 
change (n = 10313).  Heart failure was defined using International Classification of 
Diseases codes, 9th Revision/10th Revision, 428/I50.  Cox proportional hazards regression 
modeling was used to control for clinical and demographic risk factors for heart failure.  
Results: During a mean follow-up of 7 years, 670 participants developed heart 
failure in cohort 1.  A 1 standard deviation increase in mean annual rate of change in 
QRS/T angle, Cornell voltage, Cornell product, left ventricular mass and T net amplitude 
in lead V5 were statistically significantly associated with incident heart failure and the 
most precise predictor of incident heart failure was mean rate of change in Cornell 
voltage (hazard ratio [HR] = 1.18; 95% confidence interval [CI] = 1.09, 1.27; confidence 
limit ratio [CLR] = 1.17).  All categorical ECG change variables were statistically 
significantly associated with new onset heart failure, with the exception of QT interval 
and Cornell voltage; the most precise predictors of incident heart failure were categorical 
changes in QRS/T angle (HR = 1.97; 95% CI = 1.57, 2.48; CLR: 1.58) and T net 
amplitude in lead V1 (HR = 1.33; 95% CI = 1.06, 1.68; CLR: 1.58).   
Conclusions: Our results suggest that longitudinal changes in ECG measures are 
predictive of incident heart failure, independent of clinical and demographic risk factors 
for heart failure.  Further studies aimed at identifying mechanisms which explain the 
variations in the impact of changes in ECG measures on heart failure incidence are 
warranted and may provide insight into avenues for the prevention of heart failure. 
 
6.2 Introduction 
The burden of heart failure has increased over the past decades.  From 1979 to 
2005, hospital discharges for heart failure increased 171% (1, 2).  In 2009, estimated 
heart failure healthcare costs are $37.2 billion, and in 2003 $4.4 billion was paid to 
Medicare beneficiaries for congestive heart failure (3).  As of 2006, there were 5.7 
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million adults diagnosed with heart failure, and 670,000 incident cases (3).  Although 
incidence remains relatively stable over the past decades (4-6), prevalence has been 
increasing (7).  Early identification and treatment of risk factors may be the most 
important step in eliminating the public health burden of heart failure (8).  It has been 
demonstrated in large-population based studies that certain electrocardiogram (ECG) 
variables, either measured at one point in time (9-11) or entered in a model as a time-
varying covariate (12), are predictive of incident heart failure.   
Although ECG variables have been known to vary over time due to biological and 
methodological variability (13), little work has focused on the changes in these 
parameters long-term and their relation to new-onset heart failure.  To our knowledge, no 
work has focused on the examination of the effect of the long-term changes of various 
ECG variables in relatively healthy middle-aged populations, on incident heart failure.  
Therefore, we examined the changes of several continuous and categorically defined 
ECG measurements over the course of an average of nine years of follow-up in the 
Atherosclerosis Risk in Communities (ARIC) Study.  Because of their demonstrated 
relevance as cardiovascular risk predictors we focused on spatial QRS/T angle, QT 
interval, Cornell voltage, Cornell product, left ventricular mass (LVM), T net amplitudes 
in leads V5 and V1, and ST depression, and examined the association between the long-
term changes of the ECG measures and incident heart failure.  We additionally corrected 
for short-term variability of continuous ECG change variables. 
 
6.3 Material and methods  
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6.3.1 Study population  
The ARIC Study combines epidemiologic surveillance of four communities and a 
community-based prospective cohort designed to investigate the etiology and natural 
history of atherosclerosis and its sequelae.  From 1987 to 1989, the ARIC Study cohort of 
15,792 black and white participants ages 45 to 64 years was drawn from four 
communities in North Carolina (NC), Mississippi (MS), Minnesota (MN), and Maryland 
(MD).  Two of the population samples (Washington County, MD and Minneapolis, MN 
suburbs) were mostly white.  Blacks were over-sampled in Forsyth County, NC (12% 
black) and were exclusively sampled in Jackson, MS to provide statistical power to 
investigate findings by ethnicity.  Following an extensive baseline examination 
participants were followed via annual telephone interviews, clinical examinations 
approximately every three years from 1987 to 1999, and ongoing medical record 
abstraction for hospitalized events and deaths.  Each clinical examination consisted of 
standardized interviews, anthropometric and blood pressure measurements, venipuncture 
for blood samples and a twelve-lead standard ECG.  A comparison of study participants 
to non-respondents has been described (14).  The Institutional Review Boards at each of 
the institutions involved approved the study, and all participants gave informed, written 
consent.   
 
6.3.2 ECG methods 
The ARIC Study used a standardized protocol for the acquisition of and 
processing of ECGs (15).  All ECG recordings were carried out in a quiet, temperature-
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controlled room.  After participants rested in the supine position for fifteen minutes, 
trained and certified ECG technicians recorded ten-second, twelve-lead ECGs using 
Kendall Q-Trace 5400 Ag/AgCl electrodes (Ludlow Co, Chicopee, Mass).  The E-V6 
Halfpoint method (16) was used when recording ECGs using a MAC Personal 
Cardiographer (Marquette Electronics, Inc, Milwaukee, WI).  The E-V6 Halfpoint 
method improves the precision and the repeatability of chest electrode positioning by 
placing the V4 electrode at the horizontal level of the fifth intercostal space at the half-
way point between the midsternal line and the left midaxillary line (V6 location).  ECGs 
were digitized and sent via modem after each recording session to the Epidemiological 
Cardiology Research (EPICARE) Center (Wake Forest University, Winston-Salem, 
North Carolina).  The EPICARE Center, blinded to participant identity processed the 
ECGs using the 12SL version of the Marquette GE program.   
The following ECG measures were generated at the EPICARE Center using 
methods previously described (11): spatial QRS/T angle, QT interval, Cornell voltage, 
Cornell product, LVM, T net amplitudes in leads V5 and V1, and ST depression.  The 
QRS/T angle was defined as the angle between the net QRS and T wave vectors (17).  
The QRS/T angle was defined as the angle between the net QRS and T wave vectors 
(17).  QRS/T angle was calculated using a simplified method from the net QRS 
amplitudes (R – absolute value of S or QS, whichever is larger, in leads V6, aVF and V2) 
and the net T wave amplitudes (signed T +signed T prime) in leads V5, aVF and V2.  The 
QT interval, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted 
for heart rate as a linear function of the RR interval (18).  Cornell voltage (R wave 
amplitude in lead aVL + Q or QS wave amplitude in lead V3) (19), Cornell product 
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(Cornell voltage x QRS duration) (20), and LVM predicted by a multivariate model (21) 
were used as measures of left ventricular hypertrophy.  The LVM model adjusted for 
Cornell voltage and body weight.  T waves were obtained by calculating mean and peak 
T wave values in lead V5, whereas for T wave amplitude in lead V1, only the mean value 
was used.  ST depression was evaluated using ST amplitude in lead V5 at 60 ms past the 
end of the QRS interval (the J-point) from the Marquette-GE program.   
The following participant-specific linear regression model was used to derive the 
exposure variable, continuous change in the ECG measure (Bi): yij = Ai + Bi tij, where y = 
the ECG variable value, i = 1, 2, 3…n participants, j = 1, 2, 3 or 4 visits, and t was the 
time between ARIC Visit 1 and subsequent visits.  The continuous change ECG variable 
is the average rate of change per year and summarizes the longitudinal information for 
each participant.  To account for intra-individual variation (measurement error) in the 
continuous ECG variables, regression calibration techniques were used (22). 
We additionally constructed categorical change ECG variables.  To provide 
comparability with an earlier analysis in the ARIC Study, we used cut points for ECG 
variables shown to be associated with incident heart failure used by Rautaharju and 
colleagues (11).  ECG variables were defined using the following cut points for men (M) 
and women (W):  QRS/T angle (°): M ≥ 107, W ≥ 89; QT interval (ms): M ≥ 436, W ≥ 
442; Cornell voltage (μV):  M ≥ 2650, W ≥ 1673; Cornell product (μV.s): M ≥ 207, W ≥ 
152; LVM (g): M ≥ 204, W ≥ 162; TnetV5 amplitude (μV): M ≤ 122, W ≤ 107; TnetV1 
amplitude (μV): M ≥ 307, W ≥ 151; and ST60V5 (μV): M ≤ 5, W ≤ -7.  For each ECG 
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variable, categorical change was defined as ever exceeding the cut point (“1”) over ARIC 
visits, or else “0”.   
 
6.3.3 Heart failure 
Documentation of heart failure at baseline was based on reported use of 
medication prescribed for heart failure, or stage 3 of the Gothenburg criteria for heart 
failure which requires specific cardiac, pulmonary and heart failure indicators to be 
present (23, 24).  Incident heart failure was defined as the first hospital discharge 
associated with a diagnosis of heart failure (International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM code 428 or 518.4) or death certificates with 
an underlying cause of death coded as heart failure (ICD-9-CM code 428 or ICD-10 code 
I50).  All cohort hospitalizations that occurred before January 1, 2005 were included.   
 
6.3.4 Covariates 
The covariates selected for the analysis were age (years), sex (male or female), 
self-reported race/ethnicity (black or white).  Additional covariates selected for the 
analysis include coronary heart disease (yes or no), diabetes (yes or no), hypertension 
(yes or no), smoking status (current or not current), use of cholesterol-lowering 
medication (yes or no), and body mass index (continuous) at the Visit 4 examination and 
physical activity (continuous) at the Visit 3 examination.  If participants were missing 
covariate information for Visit 4, then Visit 3 covariates were used.  Likewise, if 
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participants were missing Visit 3 covariates, then covariate information for Visit 2 was 
used.  Each participant was asked to indicate whether they were white, black/African 
American, American Indian or Asian.  Coronary heart disease at baseline was defined 
from a reported history of physician-diagnosed myocardial infarction, coronary artery 
bypass surgery, coronary angioplasty, or evidence of a previous myocardial infarction on 
an ECG.  Blood pressure, lipids and glucose were measured according to standard ARIC 
procedures (15).  Participants were asked to fast twelve hours before blood draw and 
actual fasting times were recorded.  Blood was drawn from an antecubital vein of seated 
participants, serum was centrifuged, and frozen samples were shipped to central 
laboratories for analysis (16).  The mean of the last two of three systolic and diastolic 
sitting blood pressure measurements obtained from a random-zero sphygmomanometer 
was used for measures of blood pressure.  Hypertension was defined as a systolic blood 
pressure value equal to or greater than 140 mmHg, a diastolic blood pressure value equal 
to or greater than 90 mmHg, or use of blood pressure lowering medications in the past 
two weeks (25).  Use of cholesterol-lowering medications was self-reported.  Type II 
diabetes mellitus was defined as a fasting serum glucose level of 7.0 mmol/L or more 
(126 mg/dL) (26), nonfasting glucose level of 11.1 mmol/L or more (200 mg/dL), 
participant report of a physician diagnosis of diabetes, or current use of diabetes 
medication.  Body mass index was calculated as measured weight (kg) divided by height 
(m2).  Physical activity was measured using the sport during leisure time activity index 
(range 1-5) of Baecke's questionnaire (27).   
 
6.3.5 Statistical analysis 
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We excluded participants with fewer than two ECGs (n = 1340), with a QRS 
interval greater than or equal to 120 ms (n = 574), with a race/ethnicity other than black 
or white (n = 48), black participants in Minneapolis, MN or Washington County, MD (n 
= 55), those with prevalent heart failure at baseline (n = 752), with missing information 
on heart failure at the baseline examination (n = 287) and those who were censored prior 
to ARIC Visit 4 (n = 4486).  The final sample size for a cohort so defined (“cohort 1”) 
was 10313.  Analyses evaluating the continuous change of ECG variables utilized cohort 
1 data, whereas analyses evaluating categorical ECG change variables required the 
exclusion of participants with missing ECGs at baseline (n range = 228 – 287) and whose 
measurements parameters at baseline exceeded the established cut points mentioned 
above (cohorts 2 – 9; n range = 1287 – 4148).  Cohorts 2 through 9 excluded those whose 
ECG measures at baseline exceeded the established cut point because they already had a 
higher risk for incident heart failure at baseline.  The final sample sizes for cohorts 2, 3, 
4, 5, 6, 7, 8 and 9 were 7812, 9637, 9554, 9205, 9152, 9110, 9086 and 9044, respectively. 
Baseline characteristics and ECG measures were described as means and 
proportions in cohort 1, by incident heart failure status.  For all survival analyses of time 
to heart failure the follow-up time was defined as the period from the third re-
examination (Visit 4) to the first hospitalization for heart failure, heart failure death, 
December 31, 2004, or the last date of contact if lost-to-follow-up.  In order to assess the 
associations between ECG change variables and incident heart failure, Cox proportional 
hazards regression modeling was used and confidence limit ratios were used to assess the 
precision of these estimates.  We incorporated variance estimates derived from the ECG 
Repeatability Study(18, 28) to adjust for intra-individual variation (measurement error) in 
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continuous ECG change variables using regression calibration methods (22).  The 
transformed ECG measure and its corresponding baseline ECG measure were jointly 
corrected for intra-individual variation.  To minimize confounding, covariates were 
included based on clinical and demographic measures shown to be associated with both 
ECG abnormalities and incident heart failure.  Effect measure modification by 
race/ethnicity, sex, hypertension, diabetes, coronary heart disease and baseline ECG 
measure was assessed by constructing ECG change variable-covariate interaction terms 
and were retained in the model if the p-value was < 0.15.  A two-tailed p-value <0.05 was 
required for all other tests for statistical significance.  The assumption of proportional 
hazard over time was verified by Cox tests and visual inspection of log(-log) plots.  All 
analyses were performed with SAS 9.1 (SAS Institute, Inc., Cary, NC).   
 
6.4 Results  
During a mean follow-up of 7 years, 670 participants developed heart failure in 
cohort 1.  Table 1 presents selected characteristics of cohort 1 at Visit 4 by incident heart 
failure status.  When compared with participants without heart failure, persons with heart 
failure in cohort 1 were more likely to be older, men, black, smokers, less physically 
active, were more likely to have coronary heart disease, diabetes, hypertension, and a 
higher body mass index, and were more likely to use cholesterol-lowering medications.  
As expected, the mean rate of change in spatial QRS/T angle, QT interval, Cornell 
voltage, Cornell product, LVM, and T net amplitude in lead V1 were higher and mean 
rates of change in T net amplitude in leads V5 and ST depression were lower in 
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participants with incident heart failure, compared to participants without heart failure in 
cohort 1 (Table 2).  Furthermore, a higher proportion of ECG change was present in 
participants with incident heart failure in cohort 1 as shown in Table 3.  
Covariate and baseline-ECG adjusted Cox proportional hazards regression models 
for the associations between longitudinal change in continuous and categorical ECG 
variables and incident heart failure are presented in Table 4.  Mean rates of annual change 
in QRS/T angle, Cornell voltage, Cornell product, LVM, and T net amplitude in lead V5 
were statistically significantly associated with new onset heart failure.  The most precise 
predictor of incident heart failure was mean rate of annual in Cornell voltage (hazard 
ratio [HR] = 1.18; 95% confidence interval [CI] = 1.09, 1.27; confidence limit ratio 
[CLR] = 1.17), suggesting that a 1 standard deviation increase in mean rate of annual 
change in Cornell voltage was associated with 1.18 times the average hazard for heart 
failure over time.  The strongest predictor of incident heart failure was mean rate of 
annual change in Cornell product (HR = 1.26; 95% CI = 1.13, 1.43; CLR = 1.27). 
All covariate and baseline-ECG-adjusted hazard ratios for longitudinal change in 
categorical ECG variables were well above 1 (HR range = 1.32 – 2.86) (See Table 4).  
All categorical ECG change variables were statistically significantly associated with new 
onset heart failure, with the exception of QT interval and Cornell voltage.  The most 
precise predictors of incident heart failure were categorical changes in QRS/T angle (HR 
= 1.97; 95% CI = 1.57, 2.48; CLR: 1.58) and T net amplitude in lead V1 (HR = 1.33; 95% 
CI = 1.06, 1.68; CLR: 1.58).  Although the least precise predictor of new onset heart 
failure, LVM had the greatest impact on incident heart failure (HR = 2.86; 95% CI = 
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1.89, 4.33; CLR: 2.29), and our results suggest that participants with LVM values ≥ 204g 
for men or ≥ 162g for women at any ARIC Visit (2, 3 or 4) had 2.86 times the average 
hazard for heart failure over time compared to participants with lower values.   
 
6.5 Discussion 
Mean rates of annual change of spatial QRS/T angle, Cornell voltage, Cornell 
product, LVM, and T net amplitude in lead V5, and categorical changes in spatial QRS/T 
angle, Cornell product, LVM, T net amplitude in leads V5 and V1 and ST depression were 
associated with new onset heart failure, independently of covariates and the baseline 
value of the pertinent ECG measurement.  In contrast, mean annual rates of change in QT 
interval, T net amplitude in lead V1 and ST depression and categorical changes in QT 
interval and Cornell voltage were not associated with incident heart failure.  This is the 
first study, to our knowledge, to examine the associations between continuous and 
categorical longitudinal changes in a wide variety of ECG measures and incident heart 
failure in a relatively healthy, population-based cohort.  
Based on a single measurement, higher values of QRS/T angle, QT interval, 
Cornell voltage, Cornell product, LVM and T net amplitude in lead V1, and lower values 
for T net amplitude in lead V5 and ST depression have been shown to be associated with 
increased risk for heart failure in the ARIC Study, the Women’s Health Initiative and the 
Strong Heart Study (9-11).  The mechanisms linking these ECG variables with incident 
heart failure are unclear.  It has been posited that the ECG measures studied may be 
markers of ventricular remodeling and evolving coronary heart disease (9-12), an 
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interpretation that would benefit from consideration of repeat measures of these ECG 
parameters.  ECG variables are known to vary over time due to both biologic and 
methodologic variability (13).  Furthermore, the short-term variability or measurement 
error in such ECG measures was not accounted for in previous analyses.  Biased 
regression coefficients may result from modeling the association between ECG variables 
and the onset of heart failure if short-term repeatability is not accounted for in the 
analyses (29).  
Two studies have reported on the effect of QRS interval, measured at one point in 
time, on heart failure incidence and found conflicting results.  While Dhingra and 
colleagues found that both continuous and categorical measures of QRS interval were 
associated with incident heart failure in the Framingham Heart Study (12), Rautaharju 
and colleagues did not find the QRS interval to be a statistically significant predictor of 
heart failure (11).  When we conducted additional analyses using the longitudinal change 
in QRS interval (< 120 ms), both continuous and categorical, as an additional exposure of 
interest, we found that a 1 standard deviation increase in mean rate of change in QRS 
interval was associated with 1.18 (95% CI = 1.12, 1.24; CLR = 1.11) times the average 
hazard for heart failure over time.  However, this finding should be interpreted with 
caution since the short-term reliability of the QRS interval is not known, and thus was not 
adjusted for in this analysis.  The association of its categorical counterpart with incident 
heart failure was weaker and less precise.  Participants with a QRS interval ≥ 108 for men 
and ≥ 100 for women at any ARIC Visit (2, 3 or 4) had 3.6 (95% CI = 2.44, 5.32; CLR = 
2.18) times the average hazard for heart failure over time compared to participants below 
these values.   
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To the best of our knowledge, there are only two studies that have examined the 
association between changes in ECG variables and new-onset heart failure, and the 
results are conflicting (30, 31).  In the Losartan Intervention For Endpoint reduction in 
hypertension (LIFE) study, Okin and colleagues found that both categorical and 
continuous measures of a temporal reduction in ECG-defined left ventricular hypertrophy 
were associated with lower likelihood of new-onset heart failure over an average of 4.7 
years of follow-up (31).  Categorical and continuous measures of reduction in LVH were 
defined as a Cornell product LVH reduction ≥ 236 mm per ms compared with lesser 
reductions, and as an 817 mm per ms (1 standard deviation of the mean) lower Cornell 
product, respectively.  In contrast, Fagard and colleagues  found that change, defined as a 
continuous time-varying measure of LVM (sum of 3 voltages, RaVL, SV1 and RV5), 
updated yearly during an average of 6.1 years, was not associated with incident heart 
failure in 4507 elderly patients (30).  These two studies were limited to hypertensive 
patients receiving anti-hypertensive medications in clinical trials.   
In contrast to previous studies of the long-term changes in ECG measures and 
incident heart failure, our study is the first to quantify the long-term changes in a wide 
array of ECG measures, inclusive of categorical and continuous measures, in a relatively 
healthy, population-based cohort.  The repeat visits in the ARIC Study allowed us to 
construct measures of long-term ECG change variables over a mean of nine years.  Over 
the course of this extended follow-up of this cohort, standardization was maintained in 
the acquisition and quantification of the ECG measures, as well as in risk factor 
assessment of men and women from four communities in the U.S.  Further, we were able 
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to correct for the measurement error in the continuous ECG change measures using 
regression calibration methods (22).   
There are limitations to this study for the readers to consider.  The yearly rates of 
change were estimated from triennial re-examination points.  However, the magnitude of 
average change was small (data not shown), and our inability to measure change in 
intervals smaller than three years does not represent a significant shortcoming, although 
estimated from middle-aged persons who survived from one ARIC visit to the next.  As 
another limitation, changes in ECG measures were assessed in populations that tended to 
be healthier than the original cohort.  As a result, the long-term changes in ECG measures 
were probably underestimated.  Also, classification of incident heart failure depended on 
ICD-9 and ICD-10 diagnostic codes, which were not corroborated by a physician review 
and were obtained from death certificate data.  Both ICD codes (32) and death certificate 
data (33) have been known to vary in validity.  It is also possible that participants’ ECG 
changes occurred post-ARIC Visit 4, but before their development of heart failure.  
Lastly, fixed sex-specific cut point values were used to classify the ECG measures in our 
analysis, while it is possible that the appropriateness of these cut points may not 
generalize to other population groups.   
 In conclusion, longitudinal changes in ECG measures are associated with incident 
heart failure in a relatively healthy, population-based cohort of middle-aged adults.  The 
long-term changes of specific ECG measures might be especially useful for continuous 
monitoring of heart failure in the clinical setting, and based upon our results, these select 
ECG measures show promise.  Further research to ascertain whether these select ECGs 
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predict incident heart failure above and beyond traditional risk factors for heart failure is 
warranted and may provide insight into avenues for the prevention of heart failure.   
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 Table 22. (MS III: Table 1) Means (standard deviations) and proportions of participants’ characteristics at Visit 4 (1996-1998), the 
Atherosclerosis Risk in Communities (ARIC) Study (n=10313) 
Characteristic Cohort 1 
 N(%) or mean (standard deviation) p value 
 
No heart failure 
(n=9643) 
Incident heart failure  
(n=670)  
Age (years) 62.5 (5.6) 65.5 (5.3) <0.0001 
Women  5542 (57.5%) 324 (48.4%) <0.0001 
Black 2115 (21.9%) 190 (28.4%) 0.0001 
Coronary heart disease 411 (4.3%) 111 (16.8%) <0.0001 
Diabetes 1360 (14.3%) 239 (36.3%) <0.0001 
Hypertension  4269 (44.4%) 452 (68.0%) <0.0001 
Current smoker of cigarettes 1383 (14.5%) 138 (20.9%) <0.0001 
Current user of cholesterol-lowering medications 1191 (12.4%) 138 (20.9%) <0.0001 
Body mass index (kg/m2) 28.5 (5.4) 30.6 (6.5) <0.0001 
Physical activity 2.5 (0.8) 2.4 (0.8) <0.0001 
Definitions: Cohort 1, participants with no missing ECG data at baseline, with more than one ECG, with a QRS interval < 120 ms, with a black or white race and without  138 administrative censoring before Visit 4; heart failure, hospitalized heart failure using international classification codes 9
th/10th Revision 428/I50; coronary heart disease,  
history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; diabetes, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose  
level ≥ 200 mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; hypertension, systolic blood pressure >140 mm Hg, or diastolic blood pressure  
> 90 mm Hg, and/or use of anti-hypertension medications; physical activity, sport during leisure time index used. 
 
 
 
 
 
 
 
 Table 23. (MS III: Table 2) Mean rate of change per year in ECG measures over a mean follow-up of 9 years, the Atherosclerosis Risk in 
Communities (ARIC) Study (n=10313)* 
Characteristic Cohort 1 
 Mean (standard deviation) p value 
 
No heart failure 
(n=9643) 
Incident heart failure  
(n=670)  
QRS/T angle (°): 
  Mean rate of change per year 
 
0.0010 (0.0032) 
 
0.0025 (0.0044) 
 
<0.0001 
QTrr interval (ms): 
  Mean rate of change per year 
 
0.0020 (0.0019) 
 
0.0022 (0.0027) 
 
0.0030 
Cornell voltage (μV): 
  Mean rate of change per year 
 
0.0401 (0.0786) 
 
0.0658 (0.1576) 
 
<0.0001 
Cornell product (μV.s): 
  Mean rate of change per year 
 
0.0043 (0.0092) 
 
0.0097 (0.0243) 
 
<0.0001 
Left ventricular mass (g): 
  Mean rate of change per year 
 
0.0018 (0.0031) 
 
0.0022 (0.0050) 
 
0.0031 
TnetV5 amplitude (μV): 
  Mean rate of change per year 
 
-0.0027 (0.0280) 
 
-0.0154 (0.0423) 
 
<0.0001 
TnetV1 amplitude (μV): 
  Mean rate of change per year 
 
0.0007 (0.0172) 
 
0.0036 (0.0240) 
 
<0.0001 
ST60V5 (μV): 
  Mean rate of change per year 
 
-0.0023 (0.0040) 
 
-0.0044 (0.0065) 
 
<0.0001 
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Abbreviation: ECG, electrocardiograph. 
Definitions: *N presented is derived from Cohort 1; failure, hospitalized heart failure using international classification codes 9th/10th Revision 428/I50; QRS/T angle, calculated 
using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as  
a linear function of the RR interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG 
model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5; mean rate 
of change per year, function of 2 or more ECG measures over visits 1-4 and time from baseline. 
 
 
 
 
 
 
 
 
 
 Table 24. (MS III: Table 3) Categorical change in ECG measures as proportions of participants that exceed thresholds for risk of heart 
failure over a mean follow-up of 9 years, the Atherosclerosis Risk in Communities (ARIC) Study 
Characteristic Mean (standard deviation) p value 
 
No heart failure 
(n=9643)* 
Incident heart failure  
(n=670)*  
QRS/T angle (°): 
  Male ≥ 107, female ≥ 89 over any ARIC visit (2-4) 
 
864 (17.3%) 
 
75 (33.5%) 
 
<0.0001 
QTrr interval (ms): 
  Male ≥ 436, female ≥ 442 over any ARIC visit (2-4) 
 
659 (13.2%) 
 
63 (28.1%) 
 
<0.0001 
Cornell voltage (μV): 
  Male ≥ 2650, female ≥ 1673 over any ARIC visit (2-4) 
 
248 (5.0%) 
 
27 (12.1%) 
 
<0.0001 
Cornell product (μV.s): 
  Male ≥ 207, female ≥ 152 over any ARIC visit (2-4) 
 
352 (7.0%) 
 
33 (14.7%) 
 
<0.0001 
Left ventricular mass (g): 
  Male ≥ 204, female ≥ 162 over any ARIC visit (2-4) 
 
404 (8.1%) 
 
44 (19.6%) 
 
<0.0001 
TnetV5 amplitude (μV): 
  Male ≤ 122, female ≤ 107 over any ARIC visit (2-4) 
 
490 (9.8%) 
 
52 (23.2%) 
 
<0.0001 
TnetV1 amplitude (μV): 
  Male ≥ 307, female ≥ 151 over any ARIC visit (2-4) 
 
597 (11.9%) 
 
44 (19.6%) 
 
0.0006 
ST60V5 (μV): 
  Male ≤ 5, female ≤ -7 over any ARIC visit (2-4) 
 
634 (12.7%) 
 
61 (27.2%) 
 
<0.0001 
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Abbreviation: ECG, electrocardiograph. 
Definitions: *N presented is derived from cohort 1, however cohorts 2-9 were used for calculations per each ECG measure; failure, hospitalized heart failure using international 
classification codes 9th/10th Revision 428/I50; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QT 
interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage 
(µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;ST60V5,ST 
segment amplitude at time point 60 ms past end of QRS in lead V5; categorical change, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart  
failure. 
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Table 25. (MS III: Table 4) The adjusted hazard ratios for the associations between change in ECG variables, categorical and continuous, 
and incident heart failure over a mean of 7 years of follow-up, the Atherosclerosis Risk in Communities (ARIC) Study 
ECG measure Mean rate of change per year  Categorical change
 HR 95% CI CLR  HR 95% CI CLR 
QRS/T angle (°) 0.88† (0.81, 0.96) 1.19  1.97* (1.57, 2.48) 1.58 
QT interval (ms) 0.68‡ (0.41, 1.13) 2.76  1.32† (1.00, 1.74) 1.74 
Cornell voltage (µV) 1.18§ (1.09, 1.27) 1.17  1.45§ (0.99, 2.12) 2.14 
Cornell product (µV/s) 1.26# (1.13, 1.43) 1.27  1.87† (1.37, 2.55) 1.86 
Left ventricular mass (g) 1.18** (1.07, 1.31) 1.22  2.86** (1.89, 4.33) 2.29 
TnetV5 amplitude (µV) 0.69†† (0.61, 0.79) 1.30  1.87§§ (1.47, 2.37) 1.61 
TnetV1 amplitude (µV) 1.10‡ (1.00, 1.21) 1.21  1.33* (1.06, 1.68) 1.58 
ST60V5 (µV) 1.02‡‡ (0.94, 1.10) 1.17  2.15‡‡ (1.63, 2.85) 1.75 
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; CI, confidence interval; CLR, confidence limit ratio. 
Definitions: ECGxSEX, ECG change variable and sex interaction; ECGxRACE, ECG change variable and race; ECGxCHD, ECG change variable and coronary heart disease 
interaction; ECGxDIAB, ECG change variable and diabetes interaction; ECGxHTN, ECG change variable and hypertension interaction; ECGxBASE, ECG change variable and 
baseline ECG measure interaction. 
*Model 1: Adjusted for age, body mass index, coronary heart disease, hypertension, diabetes, smoking status, physical activity, cholesterol-lowering medication and baseline ECG. 
†Model 1 + ECGxSEX 
‡Model 1 + ECGxCHD and ECGxBASE 
§Model 1 + ECGxDIAB and ECGxSEX 
#Model 1 + ECGxHTN, ECGxSEX and ECGxBASE 
** Model 1 + ECGxHTN 
††Model 1 + ECGxSEX and ECGxRACE 
‡‡Model 1 + ECGxDIAB and ECGxBASE 
§§Model 1 + ECGxBASE 
 
 
 
 
 
 
 
 
 
CHAPTER 7: DISCUSSION 
 
7.1 Overview and findings 
This dissertation aimed to answer the question of whether electrocardiogram 
(ECG) variables are highly repeatable in the short-term, whether the magnitude of the 
long-term changes of ECG variables is associated with characteristics predictive of heart 
failure and whether the long-term changes of ECG variables are associated with incident 
heart failure, while considering their short-term repeatability when appropriate.   
 
7.1.1 The ECG variables were highly repeatable in the short-term 
Nested random effects models were employed to partition the total variance of 
each selected ECG variable into between-participant, between-visit and within-visit 
components of variance.  Our measure of short-term repeatability, the intra-class 
correlation (ICC) coefficient represents the between-participant component of variation 
over the total variance (sum of between-participant, between-visit and within-visit 
variance) and can be interpreted as the correlation between ECG measures at different 
visits.  Our results indicate that ECG-left ventricular mass (LVM) had the highest value 
of short-term repeatability (ICC coefficient = 0.99), and thus was highly repeatable 
between ECG Repeatability Study visits (mean of two weeks).  In fact, all measures of 
    
left ventricular hypertrophy were comparable with respect to short-term repeatability; 
Cornell voltage (ICC  coefficient = 0.97) and Cornell product (ICC  coefficient = 0.96).  
Although the short-term repeatability estimates were lower in the remaining ECG 
variables, spatial QRS/T angle, T net amplitudes in leads V1 and V5 and ST depression, 
short-term repeatability was excellent (ICC coefficients ≥ 0.86).  
 The greatest strength of this study is the quantification of the short-term 
repeatability of several ECG variables that have been show to be associated with 
subsequent cardiovascular morbidity and mortality (1-3).  To the authors’ knowledge, 
this is the first study to quantify the short-term repeatability of these ECG measures.  
Another strength of this study includes the application of strict quality control approaches 
and adherence to a standardized measurement protocol for data acquisition and 
processing of ECGs by trained and certified technicians.  Based on our results in this 
study, we can conclude that estimation of their predicted effect on cardiovascular 
outcomes may not be subject to substantial bias due to short-term variability if 
measurements are obtained under standardized conditions.  Under such circumstances, 
analytic adjustment for short-term measurement variability may not be essential.  Since 
several other population-based studies have employed the data collecting and processing 
protocols used by the ARIC Study (4), generalizability of our estimates to other 
comparable populations is maximized.   
 
7.1.2 The magnitude of the long-term changes of ECG variables is associated with 
coronary heart disease, diabetes and hypertension status 
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  Linear and logistic regression modeling was used to evaluate the long-term 
changes of ECG measures, as continuous and categorical variables, over a mean of 9 
years, adjusting for age, race/center, sex and baseline ECG.  We found that higher mean 
values of the annual rate of change in QRS/T angle, QT interval, Cornell voltage, Cornell 
product, LVM, and T net amplitude in lead V1, and lower mean values of the annual rate 
of change in T net amplitude in lead V5 and ST depression, were observed in persons 
with coronary heart disease, diabetes and hypertension compared to participants without 
these conditions.  As a result, a higher proportion of ECG change was present in persons 
with these conditions compared to those without.   
Since few have described the long-term changes in ECG variables in population 
samples, or in individuals with coronary heart disease, diabetes or hypertension status, 
our study contributes to the literature.  Furthermore, the ARIC Study is well suited to 
describe the long-term changes of ECG variables, and to examine these changes by 
clinical characteristics.  Our study was based on an extended follow-up of a large cohort, 
with standardized risk factor assessment of men and women from diverse communities in 
the US population.  Another important strength of this study is its reliance on a strict and 
standardized protocol for data collection and processing of ECGs throughout the study.   
 
7.1.3 the long-term changes of ECG variables were associated with incident heart failure 
We employed Cox proportional hazards regression modeling to assess the 
association between ECG change variables, continuous and categorical, and incident 
heart failure, while adjusting for covariates, pertinent baseline ECG and considering 
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 measurement error in the continuous ECG change variable.  Our findings show that over 
a mean of 7 years, mean rates of annual change of spatial QRS/T angle, Cornell voltage, 
Cornell product, LVM, and T net amplitude in lead V5, and categorical changes in spatial 
QRS/T angle, Cornell product, LVM, T net amplitude in leads V5 and V1 and ST 
depression were associated with new onset heart failure, independently of covariates and 
the baseline value of the pertinent ECG measurement.  The most precise predictor of 
incident heart failure was mean rate of annual in Cornell voltage (hazard ratio [HR] = 
1.18; 95% confidence interval [CI] = 1.09, 1.27; confidence limit ratio [CLR] = 1.17), 
whereas the most precise predictors of incident heart failure were categorical changes in 
QRS/T angle (HR = 1.97; 95% CI = 1.57, 2.48; CLR: 1.58) and T net amplitude in lead 
V1 (HR = 1.33; 95% CI = 1.06, 1.68; CLR: 1.58).   
To the authors’ knowledge, this is the first study to examine the effect of the 
changes of multiple ECGs, both continuous and categorical, on incident heart failure in a 
relatively healthy, population-based study.  Moreover, we examined the effect of long-
term changes in continuous ECG variables on incident heart failure, while considering its 
short-term reliability.  However, the indirect calibration of ECG variables using data from 
the ECG Repeatability Study may have resulted in some inaccuracy in the regression 
calibration methods.  Given that the ECG Repeatability Study followed the standardized 
protocol used in the ARIC Study for placing electrodes, room condition and data 
collection (5) and was similar to the ARIC cohort with respect to demographic factors 
(See Table 5), an inappropriate incorporation of the short-term repeatability estimates 
obtained from ECG measures in the ECG Repeatability Study into our analyses in the 
ARIC Study seems unlikely.   
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 A major strength of this study is the construction of the long-term continuous 
ECG change variable since it maximizes the use of available information for each 
participant.  Participant-specific linear regression modeling was used to derive the mean 
rate of annual change in ECG variable by summarizing longitudinal information, 
specifically the number of ECG measures per person and its corresponding time from 
baseline.  However, the benefits of the long-term continuous ECG change variable did 
come with some costs; mean rate of change per year cannot be directly estimated in 
clinical settings nor is it easily interpretable.  In order to address these limitations, we 
constructed a categorical change variable using clinically meaningful cut points for ECG 
variables shown to be associated with incident heart failure (3).  However, it is possible 
that the appropriateness of the sex-specific cut point values chosen may not generalize to 
other population groups.   
 
7.2 Overall discussion 
Although ECG variables, either measured at one point in time (1, 3, 6) or entered 
in a model as a time-varying covariate (7), have been shown to be predictive of incident 
heart failure, little work has focused on the changes in these parameters long-term and 
their relation to new-onset heart failure.  We hypothesized that changes in ECG variables 
over time may predict incident heart failure in a relatively healthy population-based 
cohort.  However, without understanding the short-term variability in the measurement of 
ECG change variables, interpretation of change in ECG variables longer-term is limited.  
Our results suggest that select ECG variables, measured at one point in time and 
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 employed for prediction in clinical and epidemiologic settings were highly reliable in the 
short-term.  Since by design the participants in the ECG Repeatability Study were 
comparable to persons in the ARIC Study cohort (See Table 5), we were able to validly 
incorporate the short-term repeatability estimates obtained from ECG measures in the 
ECG Repeatability Study into our analyses in the ARIC Study.  We extended regression 
calibration techniques that typically correct for measurement error in a variable at one 
point in time, to the case where an exposure variable, specifically continuous ECG 
change, incorporates repeat measures of ECG variables and several time points.  As 
demonstrated in Table 40, the reliability coefficients for mean rate of change in ECG 
variables in the ARIC Study tended to be lower (range = 0.26 – 0.86) than the original 
reliability coefficients (range = 0.66 – 0.99) for ECG measures estimated in the ECG 
Repeatability Study.  These results suggest that analytic adjustment for short-term 
measurement variability in ECG variables measured at one point in time may not be 
indicated.  However, analytic adjustment for continuous ECG change measures may be 
desirable, since the ECG variable is likely to have bias associated with its estimate of 
effect on incident heart failure due to its low short-term repeatability (8).   
Since a number of ECG measurements are predictive of downstream 
cardiovascular and cerebrovascular diseases, their change over time is of clinical and 
public health interest.  We found that the long-term changes of ECG measures associated 
with cardiovascular risk were greater in magnitude in persons with coronary heart 
disease, diabetes or hypertension, compared with persons without these conditions.  
Taking into account these findings, we would expect that coronary heart disease, diabetes 
and hypertension status would modify the associations between the long term ECG 
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 changes and incident heart failure.  In support of this hypothesis, we found that coronary 
heart disease, diabetes or hypertension modified the association between several 
continuous and categorical measures of longitudinal changes in ECG measures and 
incident heart failure (See Table 25).  It is important to note that Rautaharju and 
colleagues (3) observed modification of ECG abnormality-incident heart failure 
associations by sex in the ARIC Study when assessing ECG variables measured at one 
point in time.  Our results indicate that sex modified the association between mean rates 
of annual change in QRS/Tangle, Cornell voltage, Cornell product and T net amplitude in 
lead V5 or categorical measures of change in QT interval, Cornell voltage, Cornell 
product and ST depression and new-onset heart failure.  Although Rautaharju and 
colleagues (3) did not observe effect measure modification of the associations between 
ECG variables measured at one point in time and incident heart failure by race/ethnicity, 
we found that the association between mean rate of change in T net amplitude and new 
onset heart failure was modified by race/ethnicity. 
Taking results from Rautaharju and colleagues (3) into consideration, several 
conclusions about the effect of the long-term changes of ECG variables on incident heart 
failure can be drawn from this study.  The most persuasive conclusion, based on our 
findings, is that longitudinal changes in ECG measures are predictive of incident heart 
failure, independent of clinical and demographic risk factors for heart failure and baseline 
ECG.  On the other hand, the associations between baseline ECG abnormalities and 
incident heart failure presented by Rautaharju and colleagues (3) may suffice to capture 
the predictive association with heart failure, given the low degree of measurement error 
associated with the ECG variables and the minimal amount of change long-term.  
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However, our results tended to be more precise as indicated by the confidence limit ratios 
presented in Table 26.  It is important to note that direct comparison between the two 
studies is limited since the exposure variables were not conceptually similar, sample 
populations of the ARIC cohort were not the same, covariate and effect measure modifier 
adjustment varied between the studies, and start of follow-up were at different ARIC 
visits.   
 Table 26. The adjusted hazard ratios for the effect of ECG variables, measured at one point and time or long-term ECG  
change variables, on incident heart failure, the Atherosclerosis Risk in Communities (ARIC) Study 
 Rautaharju and colleagues(3)  Chichlowska and colleagues 
 Men Women  Mean rate of change + Categorical change 
ECG measure HR (95% CI) CLR HR (95% CI) CLR  HR (95% CI) CLR HR (95% CI) CLR 
QRS/T angle (°) 2.04 (1.53, 2.72) 1.78 2.33 (1.63, 2.78) 1.71  0.88 (0.81, 0.96) 1.19 1.97 (1.57, 2.48) 1.58 
QTrr interval (ms) 2.08 (1.55, 2.78) 1.79 1.08 (0.80, 1.46) 1.83  0.68 (0.41, 1.13) 2.76 1.32 (1.00, 1.74) 1.74 
Cornell voltage 
(μV) 1.57 (1.11, 2.22) 2.00 
1.50 (1.13, 2.01) 1.78  1.18 (1.09, 1.27) 1.17 1.45 (0.99, 2.12) 2.14 
Cornell product 
(μV.s) 1.68 (1.21, 2.33) 1.93 
1.62 (1.22, 2.15) 1.76  1.26 (1.13, 1.43) 1.27 1.87 (1.37, 2.55) 1.86 
Left ventricular 
mass (g) 2.35 (1.66, 3.33) 2.01 
1.34 (0.95, 1.90) 2.00  1.18 (1.07, 1.31) 1.22 2.86 (1.89, 4.33) 2.29 
TnetV5 amplitude 
(μV) 
1.78 (1.32, 2.39) 1.81 1.32 (0.99, 1.77) 1.79  0.69 (0.61, 0.79) 1.30 1.87 (1.47, 2.37) 1.61 
TnetV1 amplitude 
(μV) 
1.77 (1.28, 2.44) 1.90 1.59 (1.19, 2.12) 1.78  1.10 (1.00, 1.21) 1.21 1.33 (1.06, 1.68) 1.58 
ST60V5 (μV) 2.11 (1.58, 2.82 1.78 1.38 (1.01, 1.88) 1.83  1.02 (0.94, 1.10) 1.17 2.15 (1.63, 2.85) 1.75 
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; CI, confidence interval; CLR, confidence limit ratio. 150 
   
 7.3 Conclusions 
Because the long-term changes of specific ECG measures might be especially 
useful for continuous monitoring of heart failure in the clinical setting, it is important that 
physiological and methodological variations in ECG measures be readily distinguishable 
from variations that are likely to be pathological.  Our results suggest that the short-term 
repeatability of ECG measures was excellent, and thus, intra-individual variation 
(measurement error) was minimal.  Therefore, we have confidence in our ability to 
ascertain the long-term changes of ECG measures, representing physiological changes, 
and to assess their impact on new-onset heart failure.  We also observed that the 
longitudinal changes in ECG measures were higher in magnitude in persons with 
coronary heart disease, diabetes and hypertension.  Moreover, longitudinal changes in 
ECG measures were predictive of incident heart failure, independent of clinical and 
demographic risk factors for heart failure, pertinent baseline ECG measure and while 
considering their short-term variability, and thus these ECG measures show promise to be 
useful in the identification of persons at increased risk for heart failure in clinical settings.  
ECGs are relatively inexpensive and easy to obtain.  On the other hand, these ECG 
measures were measured by a computer-ECG software, which can measure ECG 
variables with a greater degree of precision than visual coding methods used in clinical 
settings (9).  Nonetheless, ascertainment of whether these select ECGs predict incident 
heart failure above and beyond traditional risk factors for heart failure is warranted before 
suggesting their use in clinical settings for the prevention of heart failure.  
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APPENDIX A: SUPPLEMENTAL RESULTS FOR MANUSCRIPT II 
 
Construction of the cohort sample used to address Aim 2, Tables 27 – 33  
We excluded participants in the Atherosclerosis Risk in Communities (ARIC) 
Study with fewer than two electrocardiograms (ECGs) (n = 1340), with a QRS interval 
greater than or equal to 120 ms (n = 574), with a race/ethnicity other than black or white 
(n = 48), and black participants in Minneapolis, Minnesota (MN) or Washington County, 
Maryland (MD) (n = 55).  The final sample size for a cohort so defined (cohort 1) was 
13,901.  Analyses evaluating the continuous change of ECG variables utilized cohort 1 
data, whereas analyses evaluating categorical ECG change variables required the 
exclusion of participants with missing ECGs at baseline (n range = 228 – 287) and whose 
measurements parameters at baseline exceeded the established cut points for heart failure 
detailed in Chapter 3, Section 4 (n range = 1287 – 4148; cohorts 2 – 9).  The final sample 
sizes for cohorts 2, 3, 4, 5, 6, 7, 8 and 9 were 10239, 12870, 10239, 12230, 12142, 12033, 
12126 and 12004, respectively.   Cohorts 1 through 9 were used to address Aim 2. 
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 Table 27. (MS II supplemental results) Means (standard deviations) and proportions of participants’ characteristics at the baseline 
examination (1987-1989) by number of ECGs, the Atherosclerosis Risk in Communities (ARIC) Study 
Covariate Mean (Standard deviation) or n (percent) 
 
Full cohort 
(n=15792) Participants with 1 ECG 
Participants with 2 or more ECGs 
(n=13901)* 
Age (years) 
  < 50 
  50-54 
  55-59 
   60 
  Mean  
 
4235 (26.8%) 
4097 (25.9%) 
3852 (24.4%) 
3608 (22.9%) 
54.2 (5.8) 
 
279 (22.5%) 
265 (21.3%) 
300 (24.1%) 
399 (32.1%) 
55.4 (6.1%) 
 
3827 (27.5%) 
3681 (26.5%) 
3372 (24.3%) 
3021 (21.7%) 
54.0 (5.7) 
Sex 
  Women  
  Men 
 
8710 (55.2%) 
7082 (44.9%) 
 
631 (50.8%) 
612 (49.2%) 
 
7829 (56.3%) 
6072 (43.7%) 
Race/ethnicity 
  White 
  Black 
 
11478 (72.7%) 
4266 (27.0%) 
 
600 (53.1%) 
583 (46.9%) 
 
10420 (75.0%) 
3481 (25.0%) 
Race/Center 
  White/Minneapolis, MN 
  White/Washington County, MD 
  Black/Jackson, MS 
  White/Foryth County, NC 
  Black/Forsyth County, NC 
 
4009 (25.4%) 
4020 (25.5%) 
3728 (23.6%) 
3531 (22.4%) 
483 (3.1%) 
 
159 (12.8%) 
250 (20.1%) 
495 (39.8%) 
251 (20.2%) 
88 (7.1%) 
 
3662 (26.3%) 
3581 (25.8%) 
3103 (22.3%) 
3177 (22.9%) 
378 (2.7%) 
Coronary heart disease 
  No 
  Yes 
 
14682 (95.0%) 
766 (5.0%) 
 
1092 (90.0%) 
121 (10.0%) 
 
13072 (96.0%) 
551 (4.0%) 
Diabetes 
  No 
  Yes 
 
13774 (88.1%) 
1870 (12.0%) 
 
929 (76.3%) 
289 (23.7%) 
 
12302 (89.2%) 
1486 (10.8%) 
Hypertension  
  No  
  Yes 
 
10208 (65.0%) 
5504 (35.0%) 
 
613 (49.5%) 
625 (50.5%) 
 
9229 (66.7%) 
4605 (33.3%) 
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Definitions: *Cohort 1, black or white participants with at least two electrocardiograms (ECGs) between visits 1-4, with a QRS interval < 120 ms; coronary heart disease,  
history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; diabetes, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose 
level ≥ 200 mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood  
pressure > 90 mm Hg, and/or use of anti-hypertension medications. 
 
 
 
 
 Table 28. (MS II supplemental results) Means (standard deviations) and proportions of participants’ characteristics for cohorts 2-5 at the  
baseline examination (1987-1989), the Atherosclerosis Risk in Communities (ARIC) Study 
Covariate Mean (Standard deviation) or n (percent) 
 
Cohort 2* 
(n=10239) 
Cohort 3† 
(n=12870) 
Cohort 4‡ 
(n=12735) 
Cohort 5§ 
(n=12230) 
Age (years) 53.9 (5.7) 53.9 (5.7) 53.9 (5.7) 53.9 (5.7) 
Sex 
  Women  
  Men 
 
5686 (55.5%) 
4553 (44.5%) 
 
7274 (56.5%) 
5596 (43.5%) 
 
6872 (54.0%) 
5863 (46.0%) 
 
6874 (56.2%) 
5356 (43.8%) 
Race/ethnicity 
  White 
  Black 
 
7865 (76.8%) 
2374 (23.2%) 
 
9701 (75.4%) 
3169 (24.6%) 
 
9919 (77.9%) 
2816 (22.1%) 
 
9577 (78.3%) 
2653 (21.7%) 
Race/Center 
  White/Minneapolis, MN 
  White/Washington County, MD 
  Black/Jackson, MS 
  White/Foryth County, NC 
  Black/Forsyth County, NC 
 
2790 (27.3%) 
2741 (26.8%) 
2116 (20.7%) 
2334 (22.8%) 
258 (2.5%) 
 
3408 (26.5%) 
3329 (25.9%) 
2824 (21.9%) 
2964 (23.0%) 
345 (2.7%) 
 
3492 (27.4%) 
3391 (26.6%) 
2494 (19.6%) 
3036 (23.8%) 
322 (2.5%) 
 
3368 (27.5%) 
3260 (26.7%) 
2346 (19.2%) 
2949 (24.1%) 
307 (2.5%) 
Coronary heart disease 
  No 
  Yes 
 
9770 (97.0%) 
306 (3.0%) 
 
12190 (96.3%) 
475 (3.8%) 
 
12034 (96.0%) 
501 (4.0%) 
 
11595 (96.3%) 
445 (3.7%) 
Non-diabetic 
Prediabetic 
Diabetic 
8105 (79.8%) 
1100 (10.8%) 
947 (9.3%) 
10073 (78.9%) 
1379 (10.8%) 
1323 (10.4%) 
10043 (79.4%) 
1352 (10.7%) 
1248 (9.9%) 
9679 (79.7%) 
1287 (10.6%) 
1174 (9.7%) 
Normotensive 
Pre-hypertensive 
Hypertensive 
4556 (44.7%) 
2519 (24.7%) 
3117 (30.6%) 
5601 (43.7%) 
3108 (24.3%) 
4100 (32.0%) 
5678 (44.8%) 
3103 (24.5%) 
3893 (30.7%) 
5547 (45.6%) 
2975 (24.5%) 
3648 (30.0%) 
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Definitions: *Cohort 2, participants excluded if exceeding cut point for QRS/T angle at baseline; †cohort 3, participants excluded if exceeding cut point for QT interval at baseline; 
‡cohort4, participants excluded if exceeding cut point for Cornell voltage at baseline; §cohort 5, participants excluded if exceeding cut point for Cornell product at baseline; 
coronary heart disease, history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood glucose < 110 mg/dL; pre-diabetics, 
fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic medications, or 
self-reported physician diagnosis; normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-
140 mm Hg or diastolic blood pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti 
hypertension medications. 
 
 
 
 
 
 Table 29. (MS II supplemental results) Means (standard deviations) and proportions of participants’ characteristics for cohorts 6-9 at the  
baseline examination (1987-1989), the Atherosclerosis Risk in Communities (ARIC) Study 
Covariate Mean (Standard deviation) or n (percent) 
 
Cohort 6* 
(n=12142) 
Cohort 7† 
(n=12033) 
Cohort 8‡ 
(n=12126) 
Cohort 9§ 
(n=12004) 
Age (years) 54.0 (5.7) 53.8 (5.7) 54.0 (5.7) 53.6 (5.7) 
Sex 
  Women  
  Men 
 
6808 (56.1%) 
5334 (43.9%) 
 
6817 (56.7%) 
5216 (43.4%) 
 
6803 (56.1%) 
5323 (43.9%) 
 
6820 (56.8%) 
5184 (43.2%) 
Race/ethnicity 
  White 
  Black 
 
9256 (76.2%) 
2886 (23.8%) 
 
9213 (76.6%) 
2820 (23.4%) 
 
9283 (76.6%) 
2843 (23.5%) 
 
8815 (73.4%) 
3189 (26.6%) 
Race/Center 
  White/Minneapolis, MN 
  White/Washington County, MD 
  Black/Jackson, MS 
  White/Foryth County, NC 
  Black/Forsyth County, NC 
 
3252 (26.8%) 
3092 (25.5%) 
2550 (21.0%) 
2912 (24.0%) 
336 (2.8%) 
 
3219 (26.8%) 
3176 (26.4%) 
2526 (21.0%) 
2818 (23.4%) 
294 (2.4%) 
 
3256 (26.9%) 
3114 (25.7%) 
2500 (20.6%) 
2913 (24.0%) 
343 (2.8%) 
 
3054 (25.4%) 
3104 (25.9%) 
2844 (23.7%) 
2657 (22.1%) 
345 (2.9%) 
Coronary heart disease 
  No 
  Yes 
 
11504 (96.2%) 
454 (3.8%) 
 
11510 (97.2%) 
334 (2.8%) 
 
11514 (96.3%) 
438 (3.7%) 
 
11473 (97.1%) 
347 (2.9%) 
Non-diabetic 
Prediabetic 
Diabetic 
9740 (80.8%) 
1227 (10.2%) 
1087 (9.0%) 
9543 (80.4%) 
1240 (10.4%) 
1158 (9.7%) 
9505 (79.0%) 
1300 (10.8%) 
1230 (10.2%) 
9456 (79.4%) 
1243 (10.4%) 
1211 (10.2%) 
Normotensive 
Pre-hypertensive 
Hypertensive 
5552 (45.9%) 
2937 (24.3%) 
3596 (29.8%) 
5385 (45.0%) 
2900 (24.2%) 
3690 (30.8%) 
5251 (43.5%) 
2941 (24.4%) 
3878 (32.1%) 
5318 (44.5%) 
2910 (24.4%) 
3723 (31.2%) 
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Definitions: *Cohort 6, participants excluded if exceeding cut point for left ventricular mass at baseline; †cohort 7, participants excluded if exceeding cut point for TV5 at baseline; 
‡cohort 8, participants excluded if exceeding cut point for TV1 at baseline; §cohort 9, participants excluded if exceeding cut point for ST depression at baseline; coronary heart 
disease, history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood glucose < 110 mg/dL; pre-diabetics, fasting blood 
glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic medications, or self-reported 
physician diagnosis; normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-140 mm Hg or 
diastolic blood pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti-hypertension medications. 
 
 
 
 
 
 Table 30. (MS II supplemental results) Proportion of participants with specific patterns of ECGs available by visit over a mean follow-up 
of 9 years, by ECG measure, the Atherosclerosis Risk on Communities (ARIC) Study (n=13901)* 
 ARIC Visit, n (percent) 
 1 & 2 1 & 3 1 &4 2 & 3 2 &4 3 & 4 1,2 &3 1,2 &4 1,3 &4 2,3 &4 1,2,3 &4 
QRS/T angle (°) 1195 (8.6%) 154 (1.1%) 110 (7.9%) 19 (0.1%) 11 (0.0%) 8 (0.0%) 1397 (10.0%) 360 (2.6%) 278 (20.0%) 152 (1.1%) 10217 (73.5%) 
QTrr interval (ms) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
Cornell voltage (μV) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
Cornell product (μV.s) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
Left ventricular mass (g) 1197 (8.6%) 154 (1.1%) 108 (7.8%) 17 (0.1%) 11 (0.0%) 8 (0.0%) 1404 (10.1%) 348 (2.5%) 273 (19.6%) 143 (1.0%) 10238 (73.8%) 
TnetV5 amplitude (μV) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
TnetV1 amplitude (μV) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
ST60V5 (μV) 1190 (8.6%) 152 (1.1%) 107 (7.7%) 17 (0.1%) 11 (0.0%) 6 (0.0%) 1397 (10.0%) 350 (2.5%) 272 (19.6%) 142 (1.0%) 10257 (73.8%) 
* Cohort 1, black or white participants with at least one electrocardiogram (ECG) beyond baseline, with a QRS interval < 120 ms; QRS/T angle, calculated using QRSnet 
amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QTrr, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted for heart 
rate as a linear function of the RR-interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate 
ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
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the Atherosclerosis Risk in Communities (ARIC) Study (n=13901)* 
 ARIC Visit, n (percent) 
 2 3 4 
QRS/T angle (°) 1497 (10.8%) 2187 (15.7%) 10217 (73.5%) 
QTrr interval (ms) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
Cornell voltage (μV) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
Cornell product (μV.s) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
Left ventricular mass (g) 1495 (10.8%) 2168 (15.6%) 10238 (73.6%) 
TnetV5 amplitude (μV) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
TnetV1 amplitude (μV) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
ST60V5 (μV) 1483 (10.7%) 2161 (15.5%) 10257 (73.8%) 
 
* Cohort 1, black or white participants with at least one electrocardiogram (ECG) beyond baseline, with a QRS interval < 120 ms; QRS/T angle, calculated using QRSnet 
amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QTrr, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted for heart 
rate as a linear function of the RR-interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate 
ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
 
 
 
 
 
 Table 32. (MS II supplemental results) Means (standard deviations) for ECG measures per visit, the Atherosclerosis Risk in Communities  
(ARIC) Study (n=13901)* 
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* Cohort 1, black or white participants with at least one electrocardiogram (ECG) beyond e, with a QRS interval ; QRS/T angle, calculated using QRSnet 
amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QTrr, used to evaluate QT prolongation, is the sex- and race-specific QT adjusted for heart 
rate as a linear function of the RR-interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate 
ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1; ST60V5, ST segment amplitude at time point 60 ms past end of QRS in lead V5. 
 baselin < 120 ms
ECG Measure Mean (Standard deviation) 
 Visit 1 
(n = 13725) 
Visit 2 
(n = 13364) 
Visit 3 
(n = 12243) 
Visit 4 
(n = 11145) 
QRS duration (ms) 
Missing 
90.8 (9.6) 
176 
91.3 (10.4) 
537 
92.1 (11.8) 
1676 
92.6 (13.2) 
2765 
QRS/T angle (°) 
Missing 
77.0 (30.2) 
190 
78.2 (31.6) 
550 
80.3 (33.1) 
1658 
79.7 (33.1) 
2756 
QTrr interval (ms) 
Mising 
415.2 (15.7) 
176 
416.6 (16.5) 
537 
419.4 (19.1) 
1658 
421.3 (19.1) 
2756 
Cornell voltage (μV) 
Missing 
1220.6 (524.6) 
176 
1253.0 (537.7) 
537 
1260.6 (544.2) 
1658 
1353.4 (561.0) 
2756 
Cornell product (μV.s) 
Missing 
112.7 (54.8) 
176 
116.4 (577.2) 
537 
118.3 (61.5) 
1658 
128.0 (67.0) 
2756 
Left ventricular mass (g) 
Missing 
152.8 (29.6) 
179 
154.4 (29.6) 
543 
155.9 (29.9) 
1664 
158.5 (30.5) 
2772 
TnetV5 amplitude (μV) 
Missing 
287.5 (178.3) 
176 
272.1 (181.7) 
537 
241.0 (181.0) 
1658 
287.6 (196.7) 
2756 
TnetV1 amplitude (μV) 
Missing 
67.4 (146.6) 
176 
82.3 (147.5) 
537 
65.4 (143.8) 
1858 
74.3 (151.9) 
2756 
ST60V5 (μV) 
Missing 
33.9 (35.9) 
176 
30.8 (36.3) 
537 
26.1 (36.6) 
1658 
26.3 (37.0) 
2756 
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Table 33. (MS II supplemental results) Mean rate of change per year for ECG measures, the Atherosclerosis Risk in Communities (ARIC) 
Study (n=13901)* 
ECG Measure Mean    
 Minimum Quartile 1 Median Quartile 3 Maximum  Mean rate of change per 
year 
(standard deviation) 
QRS duration (ms) -0.02064 -0.00093 0.00009 0.00138 0.06186 0.00062 (0.00363) 
QRS/T angle (°) -0.09930 -0.00300 0.00097 0.00542 0.11925 0.00155 (0.00971) 
QTrr interval (ms) -0.10263 -0.00113 0.00175 0.00475 0.11173 0.00200 (0.00775) 
Cornell voltage (μV) -1.52300 -0.01896 0.03687 0.09408 2.36022 0.04040 (0.14135) 
Cornell product (μV.s) -0.12856 -0.00181 0.00354 0.00919 0.37982 0.00478 (0.01689) 
Left ventricular mass (g) -0.06551 -0.00066 0.00170 0.00402 0.04729 0.00174 (0.00500) 
TnetV5 amplitude (μV) -0.73810 -0.03191 -0.00403 0.02141 0.54277 -0.00863 (0.06013) 
TnetV1 amplitude (μV) -0.59814 -0.01857 0.00152 0.02165 0.44881 0.00236 (0.04817) 
ST60V5 (μV) -0.27867 -0.00718 -0.00192 0.00247 0.15794 -0.00301 (0.01176) 
* Cohort 1, black or white participants with at least one ECG beyond baseline, with a QRS interval < 120 ms. 
† Abbreviations: ECG, electrocardiogram; °, degree; µV, micro-volts; g, gram; s, seconds.  
‡ Definitions: QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QTrr, used to evaluate QT 
prolongation, is the sex- and race-specific QT adjusted for heart rate as a linear function of the RR interval; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude 
in lead V1; left ventricular mass, estimated by a multivariate ECG model; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell Voltage (µV) x QRS (s)); ST60V5, ST segment 
amplitude at time point 60 ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more ECG measures over visits 1-4 and time from baseline. 
 
 
 
 
 Construction of the cohort sample used to assess QRS duration  
We described the long-term changes of QRS interval over ARIC Study visits 
(Table 34).  Categorical change for the QRS interval was defined as ever exceeding the 
cut point (“1”) over ARIC visits, or else “0”.  The categorical QRS interval variable was 
defined using the following cut point for men and women:  men ≥ 112 ms, women ≥ 100 
ms.  Analyses evaluating the continuous change of the QRS interval variable utilized 
cohort 1 data, whereas analyses evaluating the categorical change of the QRS interval 
variable required the exclusion of participants with a missing ECG at baseline (n = 228) 
and whose QRS interval exceeded the cut points mentioned above at baseline (n = 1596).  
The final sample size was 12751.   
 
160 
 
 Table 34. (MS II supplemental results) Race/center-, sex-, age and baseline ECG-adjusted means (standard deviations) of  
change in QRS interval and proportions of participants that exceed threshold for risk of heart failure over a mean follow-up of 9  
years, by CHD, diabetes and hypertension status at baseline, the Atherosclerosis Risk in Communities (ARIC) Study (n=13901)* 
 Mean (Standard deviation) or percent (95% confidence interval) 
QRS Interval (ms) 
No CHD 
(n=13072) 
CHD 
(n=551)  
  Mean rate of change per year 
  + change across threshold of risk 
0.0006 (0.0005, 0.0006) 
9% (8%, 9%) 
0.0019 (0.0017, 0.0021)† 
20% (18%, 23%)†  
 
Non-diabetics 
(n=10871) 
Pre-diabetics 
(n=1452) 
Diabetics 
(n=1486) 
  Mean rate of change per year 
  + change across threshold of risk 
0.0006 (0.0005, 0.0006) 
9% (9%, 9%) 
0.0006 (0.0005, 0.0007) 
11% (10%, 12%)† 
0.0011 (0.0010, 0.0012)† 
13% (11%, 14%)† 
 
Normotensives 
(n=5880) 
Pre-hypertensives 
(n=3349) 
Hypertensives 
(n=4605) 
  Mean rate of change per year 
  + change across threshold of risk 
0.0004 (0.0004, 0.0005) 
7% (7%, 8%) 
0.0006 (0.0006, 0.0007)† 
10% (9%, 11%)† 
0.0008 (0.0008, 0.0009)† 
12% (11%, 13%)† 
* Cohort 1, black or white participants with at least one ECG beyond baseline, with a QRS interval < 120 ms. 
Definitions: Observations that exceeded the threshold (“1”) for categorical QRS interval were determined using the following cut points for men and women: men ≥ 112,  
women ≥ 100; CHD, coronary heart disease; CHD, history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood  
161 glucose < 110 mg/dL; pre-diabetics, fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200  
mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80  
mm Hg; pre-hypertensives, systolic blood pressure 120-140 mm Hg or diastolic blood pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or  
diastolic blood pressure > 90 mm Hg, and/or use of anti-hypertension medications; †p < 0.05 compared with no CHD, non-diabetics or normotensives. 
 
  
 
 
 
 
 We described observations that exceeded the threshold (“1”) for categorical ECG variables and remained in that category 
versus those that went back to “0” status over ARIC visits (Tables 35 – 37).   
Table 35. (MS II supplemental results) Race/center-, sex-, age- and baseline ECG variable-adjusted* proportions of participants that 
exceed thresholds for risk of heart failure and stay, over a mean follow-up of 9 years, by CHD status at baseline, the  
Atherosclerosis Risk in Communities (ARIC) Study (n=13901)† 
Measures of ECG change Percent (95% confidence interval) 
 No CHD (n=13072)  CHD (n=551) 
QRS/T angle (°) 
  + change across threshold of risk 
 
15% (15%, 16%)  
 
30% (27%, 33%)‡ 
QT interval (ms)  
  + change across threshold of risk 
 
11% (11%, 12%)  
 
14% (13%, 16%)‡ 
Cornell voltage (μV)   
  + change across threshold of risk 
 
8% (7%, 9%) 
 
14% (12%, 17%)‡ 
Cornell product (μV.s) 
  + change across threshold of risk 
 
8% (8%, 9%) 
 
17% (15%, 19%)‡ 
Left ventricular mass (g)  
  + change across threshold of risk 
 
8% (8%, 9%) 
 
9% (8%, 11%) 
TnetV5 amplitude (μV) 
  + change across threshold of risk 
 
9% (9%, 9%) 
 
20% (17%, 22%)‡ 
TnetV1 amplitude (μV)   
  + change across threshold of risk 
 
8% (8%, 9%) 
 
17% (15%, 20%)‡ 
ST60V5 (μV) 
  + change across threshold of risk 11% (11%, 12%) 
 
20% (17%, 22%)‡ 
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Abbreviations: ECG, electrocardiograph; CHD, coronary heart disease  
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; CHD, history of myocardial 
infarction, coronary artery bypass surgery or coronary angioplasty; ‡p < 0.05 compared with no CHD; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF  
and V2 and Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval;  
Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave  
amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5; + change across threshold of  
risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure. 
 
 
 
 
 Table 36. (MS II supplemental results) Race/center-, sex-, age- and baseline ECG variable-adjusted* proportions of participants that 
exceed thresholds for risk of heart failure and stay, over a mean follow-up of 9 years, by diabetes status at baseline, the  
Atherosclerosis Risk in Communities (ARIC) Study (n=13901)† 
Measures of ECG change Percent (95 % confidence interval) 
 Non-diabetics (n=10871)  Pre-diabetics (n=1452)  Diabetics (n=1486) 
QRS/T angle (°) 
  + change across threshold of risk 
 
14% (14%, 15%)  
 
19% (17%, 20%)‡  
 
28% (26%, 30%)‡ 
QT interval (ms)  
  + change across threshold of risk 
 
11% (11%, 11%)  
 
13% (12%, 14%)‡  
 
12% (11%, 13%)‡ 
Cornell voltage (μV)   
  + change across threshold of risk 
 
6% (6%, 7%) 
 
6% (5%, 7%) 
 
8% (7%, 9%)‡ 
Cornell product (μV.s) 
  + change across threshold of risk 
 
9% (9%, 10%) 
 
8% (7%, 8%)‡ 
 
10% (9%, 12%)‡ 
Left ventricular mass (g)  
  + change across threshold of risk 
 
9% (8%, 9%) 
 
9% (8%, 10%) 
 
13% (12%, 14%)‡ 
TnetV5 amplitude (μV) 
  + change across threshold of risk 
 
8% (8%, 9%) 
 
10% (9%, 11%)‡ 
 
16% (14%, 17%)‡ 
TnetV1 amplitude (μV)   
  + change across threshold of risk 
 
8% (7%, 8%) 9% (8%, 10%) 
 
13% (12%, 14%)‡ 
ST60V5 (μV) 
  + change across threshold of risk 
 
11% (10%, 11%) 
 
10% (9%, 11%) 
 
17% (16%, 19%)‡ 
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Abbreviation: ECG, electrocardiograph. 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; non-diabetics, fasting blood  
glucose < 110 mg/dL; pre-diabetics, fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL,  
use of hypoglycemic medications, or self-reported physician diagnosis; ‡p < 0.05 compared with non-diabetics; QRS/T angle, calculated using QRSnet amplitudes from leads  
V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR  
interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave 
amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5; + change across threshold of risk, 
crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure.  
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Table 37. (MS II supplemental results) Race/center-, sex-, age- and baseline ECG-adjusted* proportions of participants that exceed 
thresholds for risk of heart failure and stay, over a mean follow-up of 9 years, by hypertension status at baseline, the Atherosclerosis  
Risk in Communities (ARIC) Study (n=13901)† 
Measures of ECG change Percent (95 % confidence interval) 
 Normotensives (n=5880)  Pre-hypertensive (n=3349)  Hypertensivess (n=4605) 
QRS/T angle (°) 
  + change across threshold of risk 
 
13% (12%, 13%)  16% (15%, 17%)‡  21% (20%, 22%)‡ 
QT interval (ms)  
  + change across threshold of risk 
 
13% (12%, 13%)  15% (15%, 16%)‡  
 
19% (19%, 20%)‡ 
Cornell voltage (μV)   
  + change across threshold of risk 
 
7% (6%, 7%) 9% (8%,10%)‡ 
 
10% (9%, 11%)‡ 
Cornell product (μV.s) 
  + change across threshold of risk 
 
7% (7%, 8%) 9% (9%, 10%)‡ 
 
10% (9%, 11%)‡ 
Left ventricular mass (g)  
  + change across threshold of risk 
 
7% (7%, 7%) 8% (7%, 8%)‡ 12% (11%, 12%)‡ 
TnetV5 amplitude (μV) 
  + change across threshold of risk 
 
7% (7%, 8%) 10% (9%, 10%)‡ 
 
12% (12%, 13%)‡ 
TnetV1 amplitude (μV)   
  + change across threshold of risk 7% (6%, 7%) 9% (8%, 9%)‡ 
 
10% (10%, 11%)‡ 
ST60V5 (μV) 
  + change across threshold of risk 
 
9% (8%, 9%) 11% (11%, 12%)‡ 
 
15% (14%, 16%)‡ 
Abbreviation: ECG, electrocardiograph 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; normotensives, systolic blood 
pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-140 mm Hg or diastolic blood pressure 80-90 mm Hg; 
hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti-hypertension medications; ‡p < 0.05 compared with non-
hypertensives; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and V2; QT interval is the sex- and race-
specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left 
ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1;ST60V5,ST segment amplitude at  
time point 60 ms past end of QRS in lead V5; + change across threshold of risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure. 
 
 
 
 
 
 
 
 
 We described the long-term changes in ECG measures over ARIC visits in participants with coronary heart disease, diabetes 
and hypertension status compared to participants without these conditions (Table 38).   
Table 38. (MS II supplemental results) Race/center-, sex-, age- and baseline ECG-adjusted* mean rate of change per year (standard 
deviations) in ECG measures and proportions of participants that exceed thresholds for risk of heart failure over a mean follow-up of  
9 years, by CHD, diabetes and hypertension status at baseline, the Atherosclerosis Risk in Communities (ARIC) Study (n=13901)† 
Measures of ECG change Mean (95% confidence interval) or percent (95 % confidence interval) 
 No CHD, diabetes and hypertension (n=13819)  CHD, diabetes and hypertension (n=81) 
QRS/T angle (°) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0015 (0.0014, 0.0016) 
23% (22%, 24%) 
 
 
0.0080 (0.0070, 0.0090)‡ 
46% (37%, 57%)‡ 
QT interval (ms)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0020 (0.0019, 0.0020) 
17% (17%, 18%) 
 
 
0.0042 (0.0034, 0.0050)‡ 
19% (15%, 25%) 
Cornell voltage (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0403 (0.0392, 0.0415) 
8% (8%, 9%) 
 
0.0736 (0.0585, 0.0888)‡ 
22% (15%, 32%)‡ 
Cornell product (μV.s) 
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0047 (0.0046, 0.0049) 
11% (11%, 12%) 
 
0.0115 (0.0096, 0.0133)‡ 
19% (13%, 26%)‡ 
Left ventricular mass (g)  
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0017 (0.0017, 0.0018) 
11% (11%, 11%) 
 
0.0017 (0.0012, 0.0022) 
10% (7%, 14%) 
TnetV5 amplitude (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0085 (-0.0089, -0.0080) 
17% (16%, 17%) 
 
-0.0366 (-0.0429, -0.0303)‡ 
32% (24%, 42%)‡ 
TnetV1 amplitude (μV)   
  Mean rate of change per year 
  + change across threshold of risk 
 
0.0023 (0.0019, 0.0027) 
14% (13%, 14%) 
 
0.0149 (0.0099, 0.0198)‡ 
26% (20%, 33%)‡ 
ST60V5 (μV) 
  Mean rate of change per year 
  + change across threshold of risk 
 
-0.0030 (-0.0031, -0.0029) 
16% (16%, 17%) 
 
-0.0058 (-0.0070, -0.0046)‡ 
45% (34%, 59%)‡ 
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Abbreviations: ECG, electrocardiograph; CHD, coronary heart disease 
Definitions: *QT interval and left ventricular mass were adjusted for age and baseline ECG only; †the N presented is derived from Cohort 1; CHD, history of myocardial 
infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood glucose < 110 mg/dL; pre-diabetics, fasting blood glucose 100-125 mg/dL; 
 
 
 diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; 
normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-140 mm Hg or diastolic blood 
pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti-hypertension medications; ‡p < 0.05 
compared with no CHD, diabetes and hypertension; QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from leads V5, aVF and  
V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of the RR interval; Cornell voltage, (RaVL + SV3); Cornell product,  
(Cornell voltage (µV) x QRS (s)); left ventricular mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in lead V1; 
ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more ECG measures over visits 1-4 and time  
from baseline; + change across threshold of risk, crossing the threshold cut point at visits 2, 3 or 4, indicating increased risk for heart failure. 
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We additionally described the long-term changes of ST amplitude, above and below 0 µV, over ARIC visits in participants 
with coronary heart disease, diabetes or hypertension status compared to participants without these conditions (Table 39).   
Table 39. (MS II supplemental results) Race/center-, sex-, age- and baseline ECG-adjusted* mean rate of change per year (standard 
deviations) in ST amplitude over a mean follow-up of 9 years, by CHD, diabetes or hypertension status at baseline, the Atherosclerosis 
Risk in Communities (ARIC) Study (n=13901)* 
 Mean rate of change per year (Standard deviation) 
ST amplitude 
No CHD 
(n=13072) 
CHD 
(n=551)  
Above 0 µV 0.0058 (0.0057, 0.0059) 0.0076 (0.0070, 0.0081)‡  
Below 0 µV -0.0084 (-0.0085, -0.0083) -0.0124 (-0.0129, -0.0118)‡  
 
Non diabetics 
(n=10871) 
Pre-Diabetics 
(n=1452) 
Diabetics 
(n=1486) 
Above 0 µV 0.0056 (0.0055, 0.0057) 0.0058 (0.0055, 0.0061) 0.0078 (0.0075, 0.0081)‡ 
Below 0 µV -0.0081 (-0.0082, -0.0080) -0.0087 (-0.0091, -0.0084) ‡ -0.0117 (-0.0120, -0.0114)‡ 
 
Normotensives 
(n=5880) 
Pre-Hypertensives 
(n=3349) 
Hypertensives 
(n=4605) 
Above 0 µV 0.0055 (0.0054, 00057) 0.0054 (0.0052, 0.0057) 0.0065 (0.0064, 0.0067)‡ 
Bwlow 0 µV -0.0077 (-0.0079, -0.0075) -0.0082 (-0.0084, -0.0080)‡ -0.0101 (-0.0103, -0.0099)‡ 
Abbreviations: ECG, electrocardiograph; CHD, coronary heart disease 
Definitions: The N presented is derived from Cohort 1; CHD, history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting  
blood glucose < 110 mg/dL; pre-diabetics, fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 
mg/dL, use of hypoglycemic medications, or self-reported physician diagnosis; normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg;  
pre-hypertensives, systolic blood pressure 120-140 mm Hg or diastolic blood pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood 
pressure > 90 mm Hg, and/or use of anti-hypertension medications; ‡p < 0.05 compared with no CHD, diabetes or hypertension;ST60V5,ST segment amplitude at time point 60  
ms past end of QRS in lead V5; mean rate of change per year, function of 2 or more ECG measures over visits 1-4 and time from baseline. 
 
 
APPENDIX B: SUPPLEMENTAL RESULTS FOR MANUSCRIPT III 
 
Figure 1. The adjusted hazard ratios for the association between change in QRS interval, 
categorical (n=9847) and continuous (n=10313), and incident heart failure over a mean of 7 
years of follow-up, the Atherosclerosis Risk in Communities (ARIC) Study.   
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Definition: The QRS categorical variable was defined using the following cut points for men (M) and women (W): M ≥ 
108, W ≥ 100. Note: Hazard ratios for categorical change in QRS interval were adjusted for age, sex, race/ethnicity, 
body mass index, physical activity, hypertension, cholesterol-lowering medications, diabetes, smoking status, coronary 
heart disease, and interactions between the ECG change variable with baseline QRS interval, coronary heart disease, 
sex and hypertension.  Hazard ratios for continuous change in QRS interval were adjusted for age, sex,race/ethnicity, 
body mass index, physical activity, hypertension, cholesterol-lowering medications, diabetes, smoking status, coronary 
heart disease, and interactions between the ECG change variable with coronary heart disease and diabetes. 
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Table 40. (MS III supplemental results) Short-term reliability estimates (R) for the ECG 
measures in the ECG Repeatability Study and for the long-term continuous ECG change 
variable (mean rate of change per year) in the Atherosclerosis Risk in Communities (ARIC) 
Study 
 ECG Repeatability Study  The ARIC Study 
ECG measure R for ECG measure  
R for the mean rate of annual 
change in the ECG measure 
QRS/T angle (°) 0.87  0.47 
QT interval 0.66  0.34 
Cornell voltage (μV)   0.97  0.83 
Cornell product (μV.s) 0.96  0.83 
Left ventricular mass (g) 0.99  0.88 
TnetV5 amplitude (μV) 0.90  0.65 
TnetV1 amplitude (μV)   0.86  0.49 
ST60V5 (μV) 0.86  0.45 
Abbreviations: R, intra-class correlation coefficient; ECG, electrocardiogram 
Definitions: QRS/T angle, calculated using QRSnet amplitudes from leads V6, aVF and V2 and Tnet amplitudes from 
leads V5, aVF and V2; QT interval is the sex- and race-specific QT interval adjusted for heart rate as a linear function of 
the RR interval; Cornell voltage, (RaVL + SV3); Cornell product, (Cornell voltage (µV) x QRS (s)); left ventricular 
mass, estimated by a multivariate ECG model; TnetV5, net T wave amplitude in lead V5; TnetV1, net T wave amplitude in 
lead V1;ST60V5,ST segment amplitude at time point 60 ms past end of QRS in lead V5mean rate of change per year, 
function of 2 or more ECG measures over visits 1-4 and time from baseline. 
 
Construction of the cohort sample used to address Aim 3, Table 41   
We excluded participants with fewer than two electrocardiograms (ECGs) (n = 
1340), with a QRS interval greater than or equal to 120 ms (n = 574), with a 
race/ethnicity other than black or white (n = 48), black participants in Minneapolis, 
Minnesota (MN) or Washington County, Maryland (MD) (n = 55), those with prevalent 
heart failure at baseline (n = 752), with missing information on heart failure at the 
baseline examination (n = 287) and those who were censored prior to Atherosclerosis 
Risk in Communities (ARIC) Study Visit 4 (n = 4486).  The final sample size for a 
cohort so defined (cohort 1) was 10,313.   
 Table 41. (MS III supplemental results) Means (standard deviations) and proportions of participants’ characteristics at Visit 4 (1996-
1998)*, the Atherosclerosis Risk in Communities (ARIC) Study 
Covariate Mean (Standard deviation) or N (%) 
 
Full cohort 
(N=11656) 
 Cohort 1†  
(N=10313) 
Age (years) 62.8 (5.7)  62.7 (5.7) 
Women  6508 (55.8%) 5866 (56.9%) 
Black race/ethnicity 2664 (22.9%) 2305 (22.4%) 
Coronary heart disease 983 (8.6%) 522 (5.1%) 
Diabetes 1943 (16.9 %) 1599 (15.7%) 
Hypertension  5557 (47.9%) 4721 (46.0%) 
Current smoker of cigarettes 1716 (14.9%) 1521 (14.9%) 
Current user of cholesterol-lowering medications 1663 (14.3) 1329 (12.9%) 
Body mass index (kg/m2) 28.8 (5.6) 28.6 (5.5) 
Physical activity 2.5 (0.8) 2.5 (0.8) 
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Definitions: *If if participants were missing covariate information for Visit 4, then Visit 3 covariates were used.  Likewise, if participants were missing Visit 3 covariates, then 
covariate information for Visit 2 was used.  †Cohort 1, black or white participants with at least one electrocardiogram (ECG) beyond baseline, with a QRS interval < 120 ms; 
coronary heart disease, history of myocardial infarction, coronary artery bypass surgery or coronary angioplasty; non-diabetics, fasting blood glucose < 110 mg/dL; pre-diabetics, 
fasting blood glucose 110-125 mg/dL; diabetics, fasting blood glucose level ≥ 126 mg/dL, a nonfasting blood glucose level ≥ 200 mg/dL, use of hypoglycemic medications, or 
self-reported physician diagnosis; normotensives, systolic blood pressure < 120 mm Hg or diastolic blood pressure < 80 mm Hg; pre-hypertensives, systolic blood pressure 120-
140 mm Hg or diastolic blood pressure 80-90 mm Hg; hypertensives, systolic blood pressure >140 mm Hg, or diastolic blood pressure > 90 mm Hg, and/or use of anti 
hypertension medications. 
 
 
 
 
 
 
 
 
 
 Table 42. (MS III supplemental results) The adjusted hazard ratios for the association 
between mean rate of change per year in ST amplitude and incident heart failure over a 
mean of 7 years of follow-up, the Atherosclerosis Risk in Communities (ARIC) Study  
 HR 95% CI CLR 
ST elevation (≥0 µV), n=4019 1.13 (1.03, 1.24) 1.20 
ST depression (≤0 µV), n=6294 0.87 (0.85, 0.90) 1.06 
Abbreviations: HR, hazard ratio; CI, confidence interval; CLR, confidence limit ratio. 
*Adjusted for age, race/ethnicity, body mass index, coronary heart disease, hypertension, diabetes, smoking status, 
physical activity, cholesterol-lowering medication and interactions with coronary heart disease and baseline ECG. 
† Adjusted for age, race/ethnicity, body mass index, coronary heart disease, hypertension, diabetes, smoking status, 
physical activity, cholesterol-lowering medication and interactions with coronary heart disease and hypertension. 
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